var title_f38_38_39520="Triamcinolone: Drug information";
var content_f38_38_39520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triamcinolone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5637?source=see_link\">",
"       Triamcinolone (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/55/8052?source=see_link\">",
"       Triamcinolone (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31768?source=see_link\">",
"       Triamcinolone (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/30/32229?source=see_link\">",
"       Triamcinolone (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10015 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39520=[""].join("\n");
var outline_f38_38_39520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/32/5637?source=related_link\">",
"      Triamcinolone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/55/8052?source=related_link\">",
"      Triamcinolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31768?source=related_link\">",
"      Triamcinolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/30/32229?source=related_link\">",
"      Triamcinolone (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_38_39521="Postop prim close exstrophy";
var content_f38_38_39521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postoperative picture of a male infant after complete primary bladder exstrophy repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Laurence Baskin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39521=[""].join("\n");
var outline_f38_38_39521=null;
var title_f38_38_39522="Melioidosis liver abscess";
var content_f38_38_39522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56531&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography of melioidosis liver abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 266px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEKAX4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK6jSfBOq6hbxXG1Ibd8fMx5APTimouWxMpKO5y9WIbO5mx5VvK+fRCa9X0r4dWcLQ289y908j4d4gEBU8FO5BGK9M8L+HND066hhaISPHlVzySp/nit44dvcwliUtj55i8FazJHvMCqvAOSTjP0BrcHwzvmiQR3Ej3DLv8pbc9Prn+lfW3hzTIZIVmjijdBIR5e0AMMVJf2NtZ2S3NwiQBV5bb9wf3T71qqETF4ie58anwJe7XHnbJVHyo8RG78eaxpvDuox3q2qweZOwJ2qemPrivr3/hHbG8mVg/313IRwF+voTWlZ+CPD1zFuW2ljkD5WYtkkd6Tw66DjiZdT4lk0u/QEtZ3G0HBYRkjPpnpVVo3RyjqVYdQ3BFfZ+peCrW2miezxtkcqqqhBY9jmsG70TT901nfW9ncuq7WaWFXZfUZI6VP1W+zK+tW3R8l0uDjOOPWvpC68NeGrq+ihsLLSN7IeBb/eA747VK2leCrUyQz6XpME6fJiSHJb1OCfyqfq0u5X1qPY+aakSKRxlEdhnGQM19QjwxoE8phtdLshCy4SVIlXg9cHHHNdJo3wx0ma3865gWOWJugUHy1I+97mn9WfcPrS7HyXBoV/L/yxMZxkK4wT+FaCeDNWdFZUj57ZJ/pX0T4n0LTNMdLeRZHbfhSByB71q+CtLW/SdGa3ihgPzSHjOemKtYZdSHiZPY+Yx4K1XarEwKCcclhz/wB81malod/p0scc8JYuu5fL+b+Vfck3h3TzDI9vbxvGR96ReEwOv41w+v8AhO0QLKYhG0r4bcB8i45wabwy6CWKktz5AII6jFJXvWufD/SL4OxzHKuSZEOCB6Y6GuH1j4aX0aPPpMqTxE/JFJ8jnPYHof0rCVCcTeOIhLyPPaKtahYXWnXDQXsDwyj+Fh/I96q1jaxunfYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACipra3muplitonlkboqDJr1Pw38Fddugs+tQtZWrDcrFsFh+VVGDlsRKcYbnlCqWYKoJYnAA6k10Gi+ENX1Vx5duYY8gM83yhQT1x1r2uy8HaT4eYeRE0N2APLncZ+YdzXWeGtDj1O9afU51spZMRsE5V2PTn0rpjhv5jmniv5Tw+P4Xzwu3226Z0Xk/Zk3bh2wTW/p/wphncSIC1omFlLk+YRjrjsa9j1Cy/su8exaDzJY8xjYdvXufX1rBZ9VlMk7TJBGFEWUHzOP9r1PvWqowXQxdeb6mTpvwj0JJEV5YZEwGSRhhhjoDzW8miafYQoGZCCcja3ClegNWS/8AaSpbB/JnCgpN937vUMO/1qoqCJI1uiGVifufxe31rRQitkZucnuzn9ckv1R10jTYVuSSzCZsB8/3TWf4cu/ENsT/AGqtkZsboju+ZOeRwK7hVihinjaWTzEPmwLcLkrnsaW3is5UDNAftAG0sy8c0+V3DmVrHTeFdaAk2XdxBtlQY9GY9vp71t6vrOntaCEN9pjjO2Xdggr6Vw0CW+AsLQrLHEzDd2PSnRTPCiIsSGROWjK4Dgjnmnyk3Md7yS21h0spd+nTsGDDP7r0GT2xXqPh7XLWe3trM3ESFIiFWQDDH61we9YUaSKDfbKdzheoXuDVm6eBIEYBJIziRSox5eOcE+tK3cLnX65qkS2ctvG0M2SEKI2WUdcj+VeB/ErTvFV47XGmShtNA3tBbtiVSOpOeT+Br0SW7heaK5tUMQ2Hy5SvJz2zTbidi0TyeWXdMMRwpNEo3VrjjLld7HmPwpa/sLpLi7tXkeVmCmYEED6npyK67xhon/CXXds9pYwWt/GMiQtw2O1bgkMO6SVQZXb5QBwi+4qVpYnkEMLKfLHmEjIz2wKFDSzG53lzIqeELOayET3j+dHG4jZMYUMTXrVvLG6F3QZYkbInH71ccLXlqzC2LQrIBbsRukbs2astftJF+6lkX7wQ/dYt/hVWRLYnxFC3N6NrzCJB5s7Rr6YwAfU9Kb8PtTtPNea4gf7NIf3dvIOfq1RTl7iLy7lJBD9xnJ547+9VRbHO22lxKBklx8qJ6/WiwX0PUb/Ure6twjXUcTbfmdXDb1PQYrzHxp44020JtRgzRHZul5GfU1RGkmVf3l5MrKCSEOBtBzz9a5HxT4H/ALe1FL1dQaOKVQREoJGPX60pXS91FRSb95mlHr9vcq6W15aebnLAzLnnv1p1xFdTgfZLuPCYVVLZUdzk1xOofDOW2kkMHnS4UMqRgZUepP8ASuNvhqmiXE1u8k0S7sfM2Q3oaydRx+NG0aUZ6QZ6zrlusGnONX0qC8ClcrF8xPpx2rnJvCXh3XftBsobnT7kAEKFwM4/uk8Vz+geNNbt5Ut4BHKzkBnZctgV29p4o0afUmtLxHW5X/lsOd5I9R2oXJUVxSjUpux5nr3gfV9IQSiNbu3Jxvt/mI+q9RXMSI0blJFZWHUMMEV9Macba7gL6fE0zAlV5woOO9ZniDwppusgtq0RNxjCNAwUxt7+o+tZzwvWJcMXbSR870V1/iHwHq2lXW23j+1wEErJHj8j71yTKVYqwIYHBBGCK5JQcdGjsjOM9YsbRRRUlBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXf/Cf4V6/8SdQZNLRbbTYWC3GoTqfKj6ZVcfefBztHtkgHNdN8C/gpffEC7F/q4nsvDcZ+a4QgPMwODGmQfxboOnJ4H3BoOjadoGk2+maLZw2VhbrtjhhXaq+p9yTySeSSSeaAOL+G3wi8LeA7SH7BZrd6kq4kv7hcyOe+B0Uew/M1s/ES+tNL8PS3NwqvcDi3j/iZvQVf8U+JbHw3apJeF5biY7YLWHBlmI67QSBgZ5JOB+IB8B8Ta5faxqdze6rOGVXEf2QggQcfwj+Zzya6aFNt83Q5cRUily9Tnp7e91L7RfXYmEe8nAGCh9CKuw281rHKE80XLYcqXyjL/Snz3sQzDIkqxMMExnOPeo7aIxz+bE0tzEyn95jPl+x9q7ThuTi/uPt3mySMWdwGEowyj/ZbuKkkmcTGMOI3ZsQy/wAJHb61nrE0sjwCZlccqso6j2PpThPcRSNEtssyQD50k4dR1yKYFuZpnYRuvkzs2XkXlSPcdqlmvGV5Ve08xTjDQnKr7g+tU5DKoM9tExV/vAvuLp7ehqwt3HGM2zQ+TMuDE5KlSPUGgCTzHkT9080zx/eecAMB/dqaKZpVWTl5V4bI2HcP6VA4ihCO3mQmTIkLOGRx60jA3KCIvJNvIyBkBSDwB7UCJVlVTIjxoSzmNkPBGRk1PIy/ZComleKNsBOuCeOtVJLqFbpWuoLjz0ITeUx8o9fp6055bqO4ljtzazRSrvLZyDjtj8ePpQMubvLuBInmRmOPcY9uRN6j3qOGd4jHHFMyLcEs6kZA+vp9KrQTxNJHNMZ7hJAUEZOPLYVKH23JZTGomUEA8gevPagRK124nEMO3yYuHL9/90dzVMTKYntldmnZiyFv4V+lPkaKOcR+d9oljbdG8gwFOeme59KmeaATLdLGxkb5C7r84PoPagBGvY52laGQ7QFWYn5SPoO9RyG3jKSS7kCk+VJGC21fU+9DyRkD7SIluUJO6RMZX3Hc0yYkRtuCrayfOqohDBsc59KYySZ9saRbjJEjEovAZwe7e4p9yAux3w6xgNuLY59BVZLiCCJDIxNyDtUKnHNJ5luZiWMjN9xRKCeT14FAF55JbhxMzF1c5jVOg9c1GtxHK7LJ5i4OQMYGe3PpUNvHvgmZ5hE4IPluCFYDrx/nrTPNt7mBZJJBHb54hUckDn/Ipkl1bt8iYKrE4UrjhyeMU2OW4a3kMrCOISZ2IB8o9vaq88zM266AjjGAIVG1TnoeO9RReWSqlCwnbYmJMs+Op57CgC49vD5wfb5ZPy8NnCn1rN1jS9Pkga1ltreaNyFMkgzt+gqxEscaqgcvI5KAZ6Ec5PsBUX2qytpMMz3cjYYRBc5I9T6UNJjV7nDP4B0uK4aTT7mRwoIk3AhVz6ep9q43W/BGr2ExmsonmgbhXGd2PpXuU93cPC8dvDFtIyfNwI174WoLe6tzGonmkmkdTGqrwCe2PpWUqMWrI1jXnF33PAdO1nW/DdwwxKoHLRyqdufUV2vhz4gQ3lwItRgS2kY7928CJsdjnmu81KK3a1SC7SCScsoWNUyCvYMe9cjrngPRLuWVomS1YNtHkEkMT/skYqVGpDZ3RbqU5/ErPujr9OuvtdzE0zxJbS87iBnaem0d/rT/ABL8Bo/E8LzeH7qOHVgvmNFIuFYe56Z6AV5tbaR4g8PXVvN9oW9gHyKxckRIOADnt7Cvqj4L+LINUtjpd4oj1SNN6sUCeag44HXiiq+am3YmnG1RJM+GvFvhXWfCWqvp2v2Mtnchdy+YpAkXONyk/eH0rDr9MvG/g3Q/G2kNp3iGyS4iGTFKPllgb+9G/VT+h7gjiviD40fB3WPhzfrMn+naBcSbLa9UcqT0SUdFb3HBxkc5A809JeZ5ZRRRQMKKKKACiiigAooooAKKKKACvVvgB8L5viH4mP21CmhWeHvJeQWB6RqR/E2PwGT6A8j8P/Cl/wCKvEFjZ2No9wJZxEAMY3dfm/2QMsx9Aa/QzwL4V0/wb4atdH0uONUjG6aVUCtPKQN0jY7nH4AAdAKe2pN7uxr6ZYWml6fb2OnW8VrZwII4oYlCqijoAKwPHfjC08J2CsyG61GcEW1oh+aQjqx67VHc/gMkgVZ8Z+KbDwnpP2y/YtI7eXb26Eb53/urn8yewGa+ftW1O91S8e81DULd7y4GGlLfJE3aKPuqDJx75JySTW9Cjze89jCvW5Fyrci1nWk1a/kn1i5U3VyQxuHBKRjPCAfwqOmPxOTk1RuZ5TPOJAflAPm27Bg2B1IPaq80krK1peJ5d26kb3IdH57H1p373FuzxiCYR8iMghfUke9d5wEiXaMixfZYi0jnIUlSeM9D0NJAfLYNFG6543b/AJk9z61DMVMEcrNEkpcqQRgOP7wP9KkLyWZiuNMZZ0fkxk7t69+PWgB98gkQyxypKVOCGO1gfXFWXMyyrcysgIGf3jAqRj25qBkjkCZkRPMcnzMnGAPuEVE0gfckWwq2QIXU7mX1FAFhWSRXlc+WzrvMS9Tz2qcqty+yeHzEkzsfumPWq6s9tIBciGOZAPLlCFgynoCOo+tKJGHyXO+0uZTukgQ/K2P4hjtjFAEkKzASWixwgnnYRgAH0z1qUzTDMk0MtvMo8l9mDkjgEj3pjl0jFx5kMqD7iCQlyvcVF9o+0Fo4p9pmwU80EOhA+6aALCXMxtgkbC8ljchlXgqPelZo7ZozBu2DBiwuAD/tCobWQm7WeEbmYbcI23/vr3p0jXUPmLJNC0THl8bmA9CaYEkVzaqZUluAJZsl8RH90x70yCWM27eWsc+P3ZwpBK5+9/WrC3J8xgRbmN0JaZV5xjjr/KqkErSxpIrj5eFZlKAL3BoAt3aLGSkNsqx7R5bycAt6YFM82KC0aWPKtJhSJDkk98e1JLuTyyHj+9vilL5T6HPeie5hvJGnit44iuACxOMjqQKQDorp/MWBFSV1AeQzsNpHfn+lRyCUTedIHWOUkbsgBfw9MU9hHDFE0EQCYMuHGepxz/hVVIXLXEZaOTzI9wZ34Uf0NAE1tKsU8xSLB6I2/k++Kc805ZRAYVRlxNMhyCfx6YqEzwBow1wJZxFw+0GRQv8AD9Peo45OFZVj8qQZaHJXf7n0pgW55FF1EAzO7/KWTkZA7+oqKeeDypIyhkIbOxTjBPcCoTEEYeaiKNpKmOQ/IewFRpndG9nagxY3TbuGwerFvSgC3PPHZ3LwTSxyzR4ZlHPUetUgFZJPOWK2imPm+fKx3MR/CnpUm2GyuiUgF0zHcSWB7Y6+wqo02neb5kFs09yDtQyf6uL8D396ANM3Md0lsYQy20ZyH6Fj/PFCT2pWZ5Sv2ZAdy9HlPpxyB0qlJc+d5T3EYdIzgLHlVPpz2FKfOjvGZI4UkxlSoDBPpTFYcs/nQxvNbkKozHErEBeeh9Pxq011H5ePNSIL0K/MW/2RWfHcFYjEpkuyrlpcsAWbp+Qq4kYt3BWGNYgdqDcC5OOSP8aAIred2Fy4lkhDOFWNo/nI9vqKkTUGaZhBbiCMcFSMcAfzqnNJNPNHMhVcEqrzP834AUspcwM0jlIhLtJWQEyN+HagCyWFztiiEgl3ZcsflH0qOxeHT7wahYXctteQyeZE4Te7sOhx0x7VWF89zCslws/2SMkCOLAJ/wBpj1pYrqYzSG3TahJEbK33QR1PvQCPo/4d+M7bxbpp3hbfVrcAXdpnlD2dc9VPb06HkV0Wr6bZaxplzp2qW0V1ZXKGOWGUZV1PavlPTdQvNF1mLV9LmVNXt1/cgk+XOrfejkweVPp2IBGCAa+mvBXiW18V6DFqNrFJbvuMU9tLjfBKMZRscdwQe4IPevOr0eR8y2PRoVedWe58KfHb4a3Hw58WyQwxyNod2TJYzsCRt7xlv7y9/UYPevNK/Sv4keDNO8deFrrSNThR2Kl7eRusMuCFYH8efavzq8T6Fe+HNautN1KB4Z4JGQq2D0OOo47Vha6ubJ2dmZNFFFIoKKKKACiiigAqSCIzTLGpALHGT0Huajrq/AuijVb5Vk2hHYoXyQYxjqPr0/OqhHmdiZy5Vc+m/wBknwNb2mnXPiuZGMkha0sg3TYMeZKPUsRtz2Ckd6978S65YeG9FutV1WbyrS3XcxAyzHsqjuxPAFY3hCbRfD3gyxtori3trKztwWJYBR3Y56ckk/jXg3xH8a3/AI01+2FtCYdEtZiLWKQkee3QyHGQT1x6An1NbRouU9VoYSrRjDR6kXiTW5vFusSa1rth+9RNljAsjFLaMnJGR1YjGTjOfYAVmhIkuiUiitZCDjzmyr/Q0XMdyu6PT4ZPkI8wOQ2PcEU27eSUIyoFuAQwheMcjuR9fSu5RUdEcDbk7sikaAmOOWyEQQnawmyrH1Bo02OeQOl3bxxOQRFKTkSH0YjgU6RRMXCaX9tQn5oAQcA9dvpTEMG2PEU9vEoMf2aVSCT26elMCazsxHGImeOVSxYIx6nuoNLFbKgYxx7Iivryh+opLOAKFb/Rxj/Uq/ysG9PpTrVZlSeQosEj/Kwgb5QfbuKLAPj2WrRmT7QzIxZCoBDZ6nnrVk3TG4bZfxlc7RJKg+Unpj0NQ7LmXzZLaW2ScAJtkJfYfXjoTTJ1MkivPZQpKq4mQLhZD6jPX60wHQ3E8cbx3JW8+Y7Xd9hP+NSItsdiW8Uk0mzmXksvPTNMS4hnbyd0aKMFVbIwfYdCaSG78pkaO3u7Scg+YAch/fHpSAWaJlPJcMmCrSMA6+9WRJFLOtzdgGVUwsu04bPUEf1qtHLCYkMYkmjbPzEBXU9+vUURJFJEHZ5YI+oEgyGI9RQBbuLmKFGjkZBG0XyuBk59DUUskUENq72M1vFnEkjOGV88Aj60sslpa20e23kZLg4i3Q5Tf/QGkF15LvFdWkcdsTt2pyq/n0FPcB88kMVxHH+/cuAsiFcg+mDTZII5WlVbicFThFZAMZ6qfUU2ZsRhWa68iA7WATcuOwz14pbuIFVuo5ki+T52xuZgAMHHakAyWICP93JB9niIkAPIkOOfl7GmiRJRHJeyskGc7Y4+FHoTSXEkN7bQy2jqxzscypsjIPr6GnFrmKGRxaQq8fygF9ysMjoKQySFVFwIjIRGFZhGcgv6YoTLecB5n2aRAGmVQSCO31qlLLLG07T2hEqOFikL4wD0zntRDdm3cA4aZj90j5GPqR607gzQ81/KuDa7EgKjNxxwO4/GqMMRFwXgZFRlHmM4IJB6AZqrLaW8jyTDznT5v3CSFYg+evv+NWbm5S1sWaSVW2Y8xZHyqL6qOpNAEwuI7eVWEyPGwOWZeA3TGaoz3DSoIEl+1OvVIyVwnfNEk8ZgMkQkWCdflZoMIw7kelMAaKBmMkigkKsUQHJ9c9aBFqG7njjBQwi3jICw7R5jHuT3xTpLiS4gkzMyKG/1caj5vYntVSO3n+S4aE3FwjZXGPMC+/bHtTmlM8zPPawRowyP4GU+/rRcCWKMSJEHAdCTiNZuMf41HbXzGVY7cWmELI3z7Ao/2ie9VmmIjAU2Frb22SSH/etntz3NEly80OBaQeXuB8oIoLegJ7mmBdi1C6dBtgT7KgKtIOev93ufrVeCBlk867dIoVGxVYksxP8AOmTK8shutTee0KEL5cLABEHQYFUpb60a7jCSyljnaSSwQAcZXrk0CNKR3Kwx+bZxkqRsHDMPTHaqdy4Dpb28Fsro25jCW8pPct3NZ8XnXMjJLHGJnGwNGMNj3z0qZImgcrDdwqY8FYW5RvU+5oAvmBn3F5Hlt3+QHftVanmlkdGibKgERqqgHK46n/69c/fX9kz4dbiW4MxYJGcLkDqR/Sl8yxvHlaaSeBQ4UqWwH9yaYG1FP++nYiN541ARI1zj/ePb8K7DwR4nu/C+vW2oyPmwuFEV/aRJvYoOkoA53JknpyMj0xwdq0KuVjljgiDF8xybQD0AY960oXaKNnjUxWruN8pwC/HTJ7fSk4qSsxxk4u6PsC2niubeKe3kSWGVQ6SIcqykZBB7givnz9rD4eQ6von/AAlFmCt5ahY5gFzvBIVD+ZCn6r6GtT4JeMf7OvV8LapNGllMS2lvJINyknmD6dSv4r/dFe0atp9tq2mXVhfRiS2uY2ikX1BHb0Poe1eZKDpSs9j0oy9rG63Py4ZSrFWBDA4IPGKbXXfEfwtqHhvX72K+gdNlw8DSHJV3B6g9wRg5+tcjUSjyuxpGSkroKKKKkoKKKKAJ7OBrq6igT7zsBn0r3HwVo32TSR9lR1uORndjafQKeo9687+GWjyaprEUcUM7y3MqWsJQKVLMRkHP/Af1r7s8KfD/AE3RNDis7j/SrjGXlcZCsf7oPQV00nGmuaXU5aylUfLHofLNzJrd5cyWktqVQSB5/KnHzAdBgnFatjatHbRzzwTyCJ/kUqUePP8AEpU4IqrYaM7Xd1I6eYs1w0xkSQ7wu7oU6YrWvLm2KOLLU/sjIgQIMjn2x39q77HAQyShmle5mnYMQYzFCY3z3DGhtqRsttOySdcuMs/0PTNSxXfmQP5ytPIqD9+xKlj0Oapy3UcMbG5hj2k7T5bbwp7ADsaBDzObljcTW0ykAcmUJ8w77h6+lNmjie4Ms8Mlq0o5Eku8E+oIpsSi5+z7IZA8WWfYM7xnoc9RUMsTQ7vNP2m23f6lIyDE3agZPCtol0qQ3F1GhBJjaIsCfY+lEpt5oZBcu0LoCpljYMQRUIkkMRhMoGW4DN8yDHNMSJFSQQWyzYI2PPD973GOtAE6XMIeISthmQGK4V+XX0bHT6GrG7zNktleQ3G0BvKuASZc9lPTNRQT2928zRCKxuYgOuF8w9xilMU0dmri1ZFifkIQyHP8RzyDSAsm4aWZo4rRIAVBcSDofQHtSTQ3cii4up4REn3JvNClvRWH1pn/AC1QSqUDr80gcEOp9PeoJbSywD9sM0cTBI4pVwgPv3z70wLrMbmHF9Ck0mzfHsIPlMPTswol1N5ozGYIum5d5BGfXA6H2pzqVlZJCHUsOIQQ8X17GqtsbcYDac0x3t/qQA7D6GgZaiuWuBFblifm+aQPhce69ufSlhNyWCOYi5yrRxqXwP71RrJcySRLJHpvl5+UBTHIn+yx9aW7vXjkaG4sJmuEzgwSZDd8EdqAI7a6urVG8gtebAySFx5bR/Rf61MYnkYmNGeOUAkpwV45BqR5opwsVxPZtNJHsCHcdn++aqkvbsEe8MkD4IEKnp6H1pDHvHayQRJeSy7VIBMuVTcDkDjrUcEYSebMcV7HKd4iUmP5R7mljkKS7o4VuYyx8qMnHOPekmKXVsz5ngwfmQYZj/u9sZpAWmv0ZndxdGIPhVVMxj29z7UlzGJGdYQsokUEFTsdT6gdvpVRjcFNkm4rLhUiY7Me596gtGPkSsn78xMc7j86jpj3p3AkvIZIY1kiku2aT5NqKpXPp/8AXrPtHZ54keKYzkMhmEeNn1zxV2WWLHy2UgunXaZzJtO7+6Fqldzyt/x83y/Z9hRoIJV3t7sO3NJgOt5LmOyaW582BWbCSzruD84IVRVT7XObkQQo/wBnmJAUKEzjuD2rOvdTaxtwJIN4iYKm2Y4j9sHr9ary6rdrEoluLW2bO/yIV/1gPrmi4WZ0lpciaFPJVWuVyB5bfNEv+160t/d29uhVpJ7lzgKjYRS3qfaues5LWadJnZ7ZScZWUFWHcH61qbgZLeWOS0MA6HaW8ts8bie1Ai1HMCxmazHyAgs7fISeAT3NQ3KQt5OYvtMrMQCnyYPrn0FF0t/9qle2WzS6QBmu1l3RnPoD7VheKtVuLCwSd8Nc8CPYcKB3JHrmm3ZXY0m3ZEOo6vFYSOZzJNIo2rsbq3cfhWGfF1zHGsVtiC3VjtUAb8d/m61y17dyXc7PK7EFtxI4qoSMnH3ewJzXJKu2/dO6GGil7252UHipCyNOzRZf5oowSAP949a6K/msxClyH8t7hdyrGxJYDvj615Wg+YZXIz0JxXS3Wprp8lu0Y8x/LAUf3R+NVTrNp8xnVw6TXKaS6rcxyySXkylHGV2rksfw6Gq0WpTPetO8skcZ6s4P5D1NVVuBfRtdMqBycbQwRQfpUF4xa5eIlbcgA7pJSyn/ABNU5vdAqa2sdv4b1SKJgzSGdQpIZ02E+3v9a6uNoniSXaZndt29W3gegI7fWvNdEWUX8Rtbpp3A3edGoCqP7vPeu/0+42L5KKVA5ldl25PfBB5reEro5Zx5XYtTxWps0ml3iR5FQyb8PuzxtI6Yr6C+HHxNsdZ0qa31mdLfVbI7Jd/HnL2ce5HUDvXgNrcu3yQWU7F2O3dg4H94e1ZGomawvIdS+0tDc2yt5kSx7Tg9z+tTUpxqKzHCpKDvE7b4/abp/ifUrq5gKvNJHmAIxOWxhWI7cjn2NfLDqyOyupVlOCCMEGvottQW9tJJGcMqxDZICM7W7FugNeNeP9O+yat9pQgxXPP3w53DAOSPXrXPiaSUU10OjC1HzOL6nL0UUVxHcFFFaOgRRy6vbLPE00QYu0a4ywUE45+lNK7sJuyufWP7LHhG1E82tvCrDTYxZ2023G6V13St9QGC/RjX0NrN/HpWkXuoTY8u1geZgTjIVSf6Vznwk0EeG/h3olg0JhnMAnuFZdrCWT52De4LbfwFP+KFw0Pg66jjDmS4eOEbFDcFwW4PbaGrT46luhl/Dpt9T58itE0uxivPLhinAwTbZkdQepKH69qqfari81CSMSbNihllEYjLHsSOgqXWr4veEQYiVTkSICXH4HpWJfNZXGYdQlmEp53KCN47E4zxXpnlouSy3c7l7rybi5iY4AIzzxjHSqsgGJZ5RFbSphSxTa3044IqNJLeKJ4I7q2aZfmGx8ysPeiO4triKKDfeRSlikgkj4BPde+aALjxXMk0zQW/2YSIC0kcm5Dx+amqs7GG2Z7iyufKLAiSCXzA2PUDkCmww3EVxm0lnMP+rafywQ3sQD1pUMFuyi0upYWZypEI2o/qpz09qBk0i2TDz3P7+PBWQRngH+Fh6Uk91fxTQb4WVCuMO4EbgnjDdqdGLgSvdqpd4lCswYH5T6jpxSBYlhKPdRCN/kEUYLmTPc54xQAt9cgMLW/jGnT4Drti8xJc9g470/fFA0l1HPJengSRNHgD/gBIP41T+0XWjuI/tMP2cLxFcBpEPoA38JqaYQK/nMtu0zDdskUtj/dYfyNICw4FsJJrcvPvIc22zYVH+FPktwgDySru1ADyYCdzREdRn0+tV4ZbyIu0SqTMdsbK2Vf6MOmB2NRm7ELC3mhgluDwJgGcAnsT/WmBdNpPCXEN95FwuGEco+Vh3Ge9RzbluofNRkuJW2kDI8wdsN/DUcmmp/Z8b3Qe3lXIS4ALZ9due31qSO3aS2k3faEWTCpceaGcn+8F7UhlqMWCpLDPuitWO+X7Rl3Vh0Ab0pVnQ7hLK00R+UXGOV9CAeT6VFaSKmImlmmJ43ufnHGAWHYU+3ZBDGIZrb7cjcLIxYZ9PbvxQFxRdRbWh86LKgOsV1wG/wBoEdD7GmJN5bu13EZYXOYwj8b/AGI4xST3hhmKaobW5jmfAjuE2A+q5plrC6M8Nm01vpr5HlqdyRj0U0AWFd2nkdJUtppDv3GDdgjsOwqF7OObz55d9vNGgVLyOUFCc9ClV7aRrcNbK9zJLGd8bzEsX9MDuKZew7XkW8u1umlUSR2ca4d29MDpSAkjhmjjkguz86OJfN3EqWHcf4VCHm8w3KmGO7G4onmYWVSepA75qWaW4u7QFXnWRBtYM3ELenPXFUbiM6fcq8clvLduMuzcEJ7N2oGZ7/bbOYtcxG3uhKGWJW8zJPVi1LPaWmZ7hYbVr1cOBGCMn3PSrE94InndlWOCZs583LK2P61nagtrfQGbUZYrInCh4GIEin+8mOaTAxfEN/Lti8u3jiWQnzxw5DdiG9aw7e5dGlhlilVAdx34O4duetdDqaxhzJb20MtuUKrHbp8i4HX61kGEHY12YIoWITzJWy6j2HfFZSTubwataxKJJ7lI3EYtlRgFHt3xWjps8STyQreNdxdJACUCg9m9axfJuYisck8ssbEmN3OFKitdhBbxK6ahZuJMCSKI5YN/eAqotkyS2R0Vg1tEy48lowQVO0yAAduK47x3dzzXMazmFgCWV402lxngFT0rqNPmaCx8y8e5XOTAhZUyPXaK4bxqkTX3mm5RncAhGBLe5JorO0AoK9TU5vBMm1uD15pNwAzg57GgYIy5wvt1poIz8+SOnFcJ6RYs0E1ym/LZcZJ9K0PFBk/tWQFv3SgbWyDxj2qhprBb2MsiMueQwzmp9eydSkLbMdAEIOBVr4DN/GvQq2swhBPmEZPIA/rW3cNaNbRtbP8AvHG4xbcn6ljXNmug8NXBkmNu0MbKeAxXp+Ip03ryiq6Lm7HUeE4bS6RDewQgOm2ONmOSf73HerPiDVLbTY5RaSSG4BEaSbvkA7gDv+NUp7y3tYHhiuWllhYhook/dqPx5zWLraW96pksXd22/vEB5B/GuuUuWNlucUY887y2NDQ/EF2mpRvPfXDR/wCrBZcBQfau41e6tQ6NBBIzXKjzEkRn809j7V49p8nl3S+c7gAYCnqK9N8IaxdanFLp0D7mB3pKCc5HYnsKVGpzKzHiKXK7xPVfhd4OufFumR6gbCBIo825cybUDDB4QdcZFcH8U/B13aw6np18uy+tv9IiSJMI4UHkeuV3flX0J+zhLO/gjUI7qKOKWHU5Y9qHOBsjPPvzWj8afDf9reH4tTt4vNvNLYy7MZ8yI8OPwHzfgfWs5VrzdOWxao2gqkdz88KK0vEVimma7fWcLboYpWWNickpnK598YrNrias7M7U7q6Cu1+F+jnV9Vnj8rzA6rAATgZdgPzriq9z/Zw0xpNT024lt98U2pRqGb5lIVkJ47d+a0or3rmdZ2jbufcIGBgdK4X4uuB4et0EhjkE/mLtGTgIwOP++hXdV5H8aJppL6OFbqCCGG137myWVnYgnj2UVWHV6iJxLtTZ4hrMjPdrbut1cowLmeJgjLj1B9KzVujKPIWdreKRSGn2dCOhP+cVYNyl1M32HU5L6dBs8pgMsfUDrgVIkl9azR/byyoq/LHcR5yffHavRPMIbZJLiUJbSw3pXGTDAElfH+32/HrVjz9UkeYzW/mqg3+arAPCoPTb1J+lUcWxlbyVhh8slpfJHlls9yM4YVE10YbSMz77eFTtjmjDAYPqev50AaqR325L2yUxwyAqd5UM/ufQ0/7TB58CrCFliOFSZyxc/Q9ahuoZNiPbeakLqCxKbjM2OMD0qPz4FEKSLA11IDsaZtrR+4z0+lAy1BcKS0qWEcGXKuid2Hc57UizW1qJHmkUTKcMjAn5T6EdKgkt9VkxJKsbzRsNgR8FgPQ9KvfaxJEJPOgt3kfZhkLNMVH3aAI4J3023LWlwJbXO9ouJt3oPoKZLCl1HHcaerpMGG2PaRhj7HirEsywsrx28kEswx5cqrGH/wB0CmvY3EcMiXEVzaea3Mcbb8/7QoArxxXdoZLieJp3bKeTbnDL6kn0p0k1zGsUaXttp5I+VkXzS/oGz0qOKcvG8Fv9pkydslkzbGIH8Qfrz6UtuYJElS4ggtLgDcsEgOXA6gg9TikMs2jXEMM96dS+2QxnErGEkBu+0envTZofLaO4SUQwlfkRU+bnr+H1ptpb2clx5mmXMljKY8tbTqY44lHUD3NWJLb7XZwJFCLJW5D/AGgsJkB5+WgESSSzwxhbm3kZEj2q6BfMI7MfUVSgtLeeHfBJJLC6/NFNFg7vbGCBU6LcWKf6G9taAEKPMlyNvfjqKdFBJFfM76kt08qcO7BDx2UdDQBftbqM27RXVxDLISVlRIdypjoFJ/iFZvkfZ5vKsTdRXDdZZCNqDOc4NJLBLcSoLaK6gjPDDILbv75PRRVua0kt5olm1JEcD9zLMoaORh2b1pbgULKOcod8k11MWJZgoVh9PQVGbFkdPtNxDHcyyExtGS20+7Vfnu7ISym9S2kuGIRiuURh6rjoaynsZ2n+zW2Bbh/MVWBzk9genpzRYdx014zxIbh1vCX2FydvmN0AAFUV+2SNiForyJXO4OmPl/u8elSTJdQ27IsUTXUJ3iFHG1ADywY96yryXdC8cF/NBG5zLHEpSSNj0YnvSCxoIGaaU6dHZwnho1uYyZAR159M9KpRpfPML68uDJbv+6LiLhZPYGp4JEKAXP268ZFEKyEAhR/eyOc+9SRDXIpTHbypd2qkllR94Ix2P96mBkarbXU5eO/G4E/LGn7pvqCODWK0KK00KPKEjTcBModyfb0FdLq2juqC5hXUN7nJeVw0rKewHas+xsb6K8Etwki2yxlHVIgWYf7RPQ89ahq7Ki7IzIrx9OsRI7tL5zf6pogdh9R6Vm2zuboS/LIN2/bgAn2z2rf1iwCGKbShdRW6nmN3DDPcA/0qe0jktIi0Kwt5oyY/JDTKD2Y9FFLldy+dJX7lpzMtm8un2uXuU4KYcKR1G49K4HU2ubnTGmuIUVomC54BA9B616VHpxu/DrQb13M+WEIYFfbFcDeLLp2kXlqTEjeb8p8rLMOeN3alVWg6Ds9NzlWYs25myfWgHacjBPpinPuLbm6+vSk3YVlyRjpx3riPRBT8+WOGz/n6U1gdxwB+HNSRSCNiQgk453Co87icYH6UAIc456dq6bwRbXS3j3cEDuiIwyCME46VzOPcV0PhSW5f7VFC6hRHnB4x71dK3OrmVb4HYzri6mOoO0rNEWPzbeStWp794Jo0twGQAA5GWc1lssjXBTOX3HktV2LKxBXgm8sYMh37ce4pxk9RuK0GSRu12zMBEXGdpGTj6dq6fwi13a6hGSrRvJ92RpAAPcisa0jhldhawSM4/hPzBh6mt6ztbS2kjZhh3GRt5xW1KOtzCtNcvKfVv7NskscPia1mkWT/AEiC73K2QTJHtJx2/wBV+lezuqujI6hkYYKkZBFeAfsuXBe98RK7xFngtSNq4JCmUZP5ivoCufEK1RmuH1po/O/436FDoHjCW0t1ZUhaS357+WxCn8UKGvO6+h/2u9Nig8UzXSW2x5JonMoGA26EA/rGK+eKmr8V+46Xw27BXvHwKaDTrXR79t1u5v0ZpC3yyASDjj2GK8Hr2TwUHXw1YwiQu+N4JO5VBycHHTGfStcMryfoZ4qVor1Pu8kAEkgAd6+bfHmtLq2vaneWlzcRxylUjYplGVRgA/z/ABq54k+L93qHhs2FpLaW18YglzMcsOeCRj17ivPbeO72ys9/bSOygr5IJXHcADoK3oUXTu5bnPXrKpZLYqXDEeZF5iWpkYEN5Q4HqGA4/PvUl1DqFhGTHYW95AfmkljbDKuP73NRBzF5yOJfMzh0mJKMP7w/+vVm6tg0YGm2kUEsifL5O4xsT13Ed66DmM6S2hSFo5I44fMUMHmfcoGfbk/WrF1Y2sKebbyPHdFAolmn8xHA7hD1+hpjWMqswkWyigZfK/eTbZQf9njgU220mS3Efm3qXa/ddQgIz9SKAHiKwRA6X12dQbBW4BKH3Ai5Aougl1d7L62gulRDsuJ8KeemQO/vUazXMTXSW/mSzMwLi2xtQdPmbt+FLdR2udmpyWlwGG2VM7sE9GyMYoGBS1hQQSWnnTRLlIklYxyZ7g+vtU1rb28SNLsmsmXJeLJk59R6fWsqLTR9mtxFDFHbIxeSV7kqQg6FB3NacUq+VHDCkc8XpNI2Jh1+buD644pANubsWSpJdDdPISV3PvIX9cH6VPDPaTxRypeTnALFopdpk9jnpipU+0TXEf2g2OmAZ8mS2G/jspPrUM8aYZrgxapasMNmHDRv7YxTAnnW4K4W4S8WPDiYJhoz/cJ6k9s0RXE+pWkSX5jeBDg+ZH+/iPb951qFLm0tRFM5uWk35+zJ8vl/WotQvxdzm5uI9SuniH7uHy9nlA9Rx940AX9QSf7UDC08kG0b4pipLgDs3rVY+VumkdzLb5DEHMbwt7KOoPfFVoLt4TMbWKNQ65ZBPyq/7S9jUqeeUimgluzctlfMjQBwCOjZ/h9DQMltre8lOLO309mSQODE48xUxyCW4JqadCqrJFJCZGAaW3uYvnXnqD/D+FULqfy7XkW11PHIuFbhkH97A+8ahP2hbg+dk3QBBkfcisvX5sZA9KQHQvbi9ee2CFIxHnybdyocDuzH+VVbaCS3+STSY2WVcwYl3yRkd8N2qNLaB5nS/N2IXVdsLOTGi9Mhh2pI4ra1/wBGtlmu4Ivm3lizKpPAQ4pATm0FnbTTyXKtNcYeRWjD+UDxkAVZt0Z9kkjRllwBPHKAuOgG31IqraW9jFLL5UUdlMwzJGrF5HUeo96hjMJZ5BFbyxsxURrEeG/h49RQMp32mWl1d4Rjawod26VW6E52nPNWrN4nv4rO3imiReSbhAwcdsP/AI0s7PJPNHdyXcj4z8oGz/cbNLe3QjARJo7WPAVFPKNnHfsaAFu7e2a3MtvDM9yNyudwjjz2HFVI7q8t/Ja3srYKil/s6c5J4PzDk1JeQy2MUL3k4uJfuxui5UE9A2O1V53aC6L+XJDJtBY2jDBP+z6H2NMTERZ7hkE9gWkdy/mh2KxKPQA5zRFBFJdiJBd224NuuJT5ij/aKN2qlf6fd6loeqR6VfSCVXV1kuGaN8A5K5HAqzox1K0tIVur5ru6kgUszHzdmOeB60r6jtpcLaNbyeS3j00X7MV3XinYmf7wXsarx6PvvJYkt4TvbLrJLhXIP3c5zWzbfb8+dFeXKXbyrujMY+Ydjx0rnvGOoS+G/sl7dot1eTzMTA0eyMKOvPUntQ7RV2EU5OyNyCKw09gJ7yWyJGRFagyJz2JrifF9hH9onigeaeUgvu2bRj39x610VubvU9Sj1W7ks9M0mSJWgtsB2XI4+Ufzq3e6ZZanHLHNamCBBzKcr5rD69qTXNGw4twlc8PaBzKyBSWHJA5xUbfeOQ349a9E1rwuLFmuLtLmBWXETxpxIfQe1cDeQtDMyMwYg4+9kiuKpTcNz0adVVNi3ps8dtbXDtGkkhG1Qeo96zXYsSTjPsMVoaiDBbwQ+YZCV3bsYAB7VnHj0qJdi4237h2rovCRjDXfnW6TKyBcebtb8B3rna19HgDSMN0qMRw0YBP4GnS0lcmqrwaIZoA1ywtoHGGxk5G38KsxWd093Gs6F/M+YoGzgCuhTRLSV1nFzIAMAvJJ+8f24rUsxaxyTCBGSXbtW3lYbl47Dqc10xodzmliVbQg0ouI0RbZU3D5OMMyj1YdBVplupLcCMxW0KPg+WM5JPUk9avwy3Jtop9XtBtEZ2RFgFcepXqTVaNo/szzwTMS7gCExlVbtgDsK6EtDkb1ue2fs0yiDxNeR73C3NowAfC7nR1PA+jE5r6Or46+Et+uieOtHvLmS3jxcGN42dvkWQFCR24z+lfYtcWKjaSZ3YWV4WPlb9rC2N9dakUijeS0t4HyDyq7sknnr835V8qV9RfH2+Fzf+L38mJhgwq5TdjYqoeexypxXy7UV425fQqhK/N6hXr3h+aZtAsorfyynkoCE4fdt79yP05ryGvTdCaK78P27LcbZxBt8qUDGFyuQRz1HQ1eFdpMjFq8UeueBvhxeazokmrJYys0qsU2yYBxxgZPPeshfO0u5uLdoYok/wBV5DRkl3B4Of4a+oPhzZJp3gLw9axgAJYwk4/vFAWP5k15d8b9MlsNaW+s4oI4r2H5mLAFpVOD9OCv61tTr80+Uwq0OSHMeUrBfW8ykzwlHyDDJmQFvTPao0iDiaKQXFuEO4xxvsDH1U9qht7yS2jMa2Isr1Dw0T70b35yD7mrUeoPJHsku0vJW5ctEHRV9xmuk5ygJLuZCRahrZz5atcSAsMcED1zURgWwuriCxtYbltobbLMQEB6jnpTZ51uJmtFns7kh8gPP5bp7hegq0wa4mC2KWtxII9rq8oQsc9TzmkA9LyaWIWTxxpaOTviWPIBx0VhiqkaytI8XkBkU7SyoowmPvHPU1ea3mQM9uklvLu3NMFBAA9z0Paqq+ebYf2hd2wijG9mdd0pPYKQQPwoGQRBUuTEf3qbtqzuuPL44GB1qyUeJnmuJLTcflEyFvMPbgdqq3ggJaS4Se5PylVRCr8fp+NQ2ysbwzW9qtywP7szRt+79t3T86BFlbpZLQ2tm0whabE5VO/+0eo/CrsVob1ZkS4SyvY2wjMxdWQDuBwPxoNw96JEmutLuLhU5gs3Kqp9GPc1CpuJo2tFtLdEaPE4SUKyvjj5u/0oGV/IZ5HtbC6SW9lYBhOm449ieO3akWxvLPzgmoq91CQcBOQO+GrSDXTpFDYfa7W4hjAWSaAGJiPRutQw3Rt5/wDTGM8tziPz4fmRznkFR0+tICs1wLELeRNCl5KhCZjLZPv25960Li4ig2Nc3Mv2xogAUwAMjoMdR61PbPfQwSxXF5BHYFmItlQGQA9snoKy4ntnkgaxght2T5Y5nB4z7n1oGVr77I9nGzXguo872nSPb5Ht6t9Ky7eazjM3latqDiQ5yIyisR2KnqK6LVLK8jhEF091FMzhkWONdkh/2iB39azp9Pe2mj+3KjFkYLHdNnH+6RxSaGnY19Ne6v7Eobi1yQUWNEOAPUkd6twiG3ija8ubz7REShUjCsB0GB0rIsmiVi0szWzMoCw2swYN6e/etH7ZfWcqS39qVYfI0TIfMYdmx/WgRbnvS6pLGI4t7gYRSSrEdC1ZOr6zDAjxyTOiYJcJHzkdcEd/eotR1WPS/N+0XkUVlId2yP5tjgcE993tXmPiHxDc6rO7xg28RGDtOGk929z6CoqVFDc1p0pVHpsej2x0+bSY7i/guZrVsyMXuXDp9ce1TWc1tpgkGjwrNYS4ZYZoyxwepQnkn3qvpUf2e0si87NYrCkuwkEtkdc/0NWrtL263ahYxKvk5RnBDKE7cetUjN9i/Zn7NC8l7EiLcEYV+cH69Kp3Btre2lOoqsZxkPDGThc8E+9LdTI+hBAQFnBP719oQ9/LB5rGjuZpFVb28lKbdnmKn3lHYDoTVCN5buwu7mN1lnDiIlonGFf6ipE1b7LHbJBbGBHHlxvBtZsHsVIyPrWLavZ2M0c0VzbgOfkMg/e7T0K54ODT4Ly7uLqSI2HlOxy96qbyR2Zk7fhQG5rf2gzmS3VnWRD8lyg+cZ7e1Q6lbaVfXEceoTw3g67JlLEvjHJHT8KoyXOp6fDPIZrppFGGdYl2Op6HPYGrGnXN3bqI7O1MEpUSSxiH5cHnKv3NPfQFdCXgFupikBhj2AiCKHcr46AN2p15cJqChoIL+6tpFKJEYwscR7hsnIqC31e8MLIdTvJMNlZUtQybieVkz0HuKZdXka2zPPeyQzM2yUtHhOfegRd/syxS1ZSk8cyqquZJGdIzjovPSvPdc0W1kvUW3liRmI3FVJAb3JroZpJZLuWztZmjVsFbmMt5coPY5HSoZ7fUoA9tbQ6cQy5uJo/vMPQg1EoqS2LhJxd0zhPENpO2oMqxbtgALIcg8fpVKLS7mRd+0BAfmbOQv1xXcxQWpjdZZmQDqsI3MT6knpVa+sLILJJazRLE7B/LuJGUtjg7SB1rCVBN3OmGIsuU4hIQ7Yj3SMTwqKTXa+FNAvftEryweXGy5AZghP0FS2+kXUc6mxliJYfJFECw/Bsda1beN40e3Vp5thDN5vSNh2B9etVSo8ruya1fmVol4WlhZJva4h+1suTApBf2IPY0lo8cEbv/AGlFaySZywhDzD6n+tV4kszA8YsIhOzdI1yy5/iLGnRRWNlIkfDFxh1Jzs/Hrn2rpORmnaXNotvvtVhnKvt+1yJudm7nafugUy8mvJIpmkuxPArD/j2gAVfXJ/wqeJoULi2EUAHRJLcqOnXJ65qNLWTbG1rBAxJLFVdo0P4dKYrli1uJIFtzZajEioN37yFnCkjpur2zw/8AFlNO8HL/AGpPDNqEcZCEuQWPbqOa8WnZneEyStaSheVRtqs3pg13+qfCbVf+EKF/elFeCMym2J3OATnkY/HrUVFBpKZpBzV3A808dXrN4V1CSJZAlwrO4fJ+ZmGT/wDXrw6vXviLLJB4alggUQRfKroBnd8w/KvIa48Z8SXkdmDXut+YV6P4DNpdaZaRXZRIllkhkLDOQRuBPoMt+lecV6D8JZZnvbq3hRZDGBPtPJx908fiKzw7tMvExvA++fBM0c/g7Q5INnltZQ4CdB8g4H06Vz/xh0tdQ8KrKY43e2mVvmOOGyhGewyyn8Kb8F79bnwVFZmMxy6fK9u6NwQCd6nH+64H4Gus8QacuraJfWDqjefEyLvzgNj5SfocH8KlP2dX5lNe0pfI+RdVtZbd/LeOFIcckEPswegqhM4Vo5be3di7DcjRhWb0x2FaGsQ3duC9xbCa4WQo4VwCDnBUDuRg1lC4kEhN3evapnEUZUsyH8utemeWWb2O3hT99ZpMDli6Qoxb29SayNm6aHbphh3ocZCxk8+5+WtHbYQWwlcXKEdXlO0Me5A65rKlksbprYXH2u+j35DXMZCxqfQjg/jQx7l90tLZoi+ovHcvjbbbTMGPb5s44qxLFqALPexR6msQBJhKxyJ+FZdvc2sUcyW1jcbQ+PMDgRhfcHkfhUtrLHCWfSFtJBsZTL9oCEN2zupIDQt7uGRdtvHf3Ee07jMpXyiP4R/eqHzrvyHW7+0XTrICqKBEo9AccGrC3ol2HUpZSFj5VnDR/gw96hkbhZZtShs7f/Vja2zb6EA5z9adwD+zV3SSLZW+ilwQ0rZlPPOAPWn3FulpAHCH7MceZOibst6FeuTVHUbh7OQRSwS3J4Ed2jLjHqWHr9KtxmWOSK/trm4t2mjO6Ewgu5/vZ70gEleaJP3UckwHCSspdYh6EDinYM7CK3uGt9QjXPlwrmMH1Pv7D1qT+0fJgjOLlIsgbdgDyuf7y9hnvSzpdxgvfmyd5IztSzDAD3Zv4aYEd3aXTRq889zITzKssOFGOpB9Kmee/eFI9OvNPkiPyCMRjj2APOao7Hs5zNBfOTMMGOSUtFj0J9asLjUYYRe7IpmbIkxsZGX+76g0hk6QtBPKrD7VHNh5vKmJ2P6Yz+gqtqenWcqqW8qLy/vRTSNIee+O30qScRJI7JcGWJk5kt3VWRvQr2+tPaeBJY4sxRPsBdY03MfQnPU0AV7bTNO0rT4Zbm78q3lbLPDGdxYdAO4HvTr7UIbOye5g1BDCD+7aVDLMR1xuPasrxHqsVlapJIgj1GNSYxK+0yKeuV/pXFWceo+K9et7KwhBu7txHHDHnDN71lOooaI2p0nPV7GxqGt6HfeHLi3a2aG8mbzS+C0hlH3cdgp7itzwJ8EPGfixoJW0x9K02T5jd3w8slccFYz8xz2OMV9OfBr4P6T4DsEu72GG98QyfPJdOoYQcD5IsjgD16nJ7cV6rXFUqczO2nDlVkfPdt8GbrTNIhsYtPjupkG1rn7QCNvsrEVxXjS2j8GOv9r2/wBlhlG1AYmQtj6V9c1S1fS7DWdPlsdWs4LyzlGHhnQOp/A/zrSOJa3RlLDJ6pn51+M9YN7rUU9ncGSCAAwuNwHrnaenpXY6ZfTahaQyCJJVdQS7J5Yzjseldx8aPgD/AGEZtc8JLcXGjhjJcWOdz2y9SUPUoOeuSB68muB8D3cd5YPDmIRbTEbbcSpUdCa1oycm33M68UopJbEf2Xz9kRaG51FSS8Mo/wBWM9j64q3aQQCKL7QNQhU8JNDJsdeOn+0KmmlWzjEb3MFpaq+1o2jPnS/7p9KbeGJBFImlTTxAYEty5CKPUEGumxzMg87fCRG99dRkbWkchQ3OOc9aRrg28620kRkKgeWzXRTZ9Owp0hlkjhs4re3+ySOHjfzCwVvcVeSxMKyJdzQNcRlpY9sW/cvTAU9aEIzra0s7i6g8vVW2q5MkQZhn1yV61Kkq2ZngvbKC7s5G2K/mDbtz6dfzptzLA32d7ZpLWdh5e9YfKOf9pP61JFLFbKP9HspW3na5TGeOgx/Wml2E2VRJHNNc28KzRRMm2CWG5wVwemO4plqbaKSFrRHknXO4ynLb/Q+taAm+2RTW8n2e1fIMbJCXCnvhvenRWS297aNqD6dqAYlHDRmP6EEd8dzQBl3xSSeN47cSSZ2SqmE2kdeM9am8y7gUybC2AV3SIJNo6emPyqzHbwW7SRQ20MmZTsllwzxf7JI4pHP2e48+f7BPcbsNDHIwwv8AeXt+FAiEXNtOyxLqN5ZRhdzJHGVWU+o7irQeby8GFJraV1MU7vuJI9u341JMDcq9vY3IvFk/eAkKDEe67uMdqqPD9hD77WOR3ADoQWU+5ye3tTQmVbmeaAyNJBO0TEs6pCCMZ7CmwNYXioDf/OoO2JLUxS/icYP1pwvgoltpI7a2hicfuYmx1755NNbWLeSad5n3lMIgLkFh/nFLcr5F/wAm3C27NcXERi6JLdZJ46jPGKSbaYIkRLgvuy4Mjkue2CPlArNN5bSsD5KyBRlVVg7E+tWIElvcK0tyip8u2WQCMntgY4NVfsK3c9h+Dvh19Z8SW0eorC0Nsv2yZJcSs4Bwg3dgW5x6A19I36JJY3CSnEbRsrH2IOa8v/Z20ZLPwpdan5W1r6bZG27OYoxtGP8AgZk/Su98aaiuleFNUvC4RkgZUJGRvb5V/wDHiK86vJyqWXQ9GjHkpXfU+GviTcIvhxEEjtJI8YOUIDdTn9K8qrvfinMEube0VSAnPDhlJAxkfnXBUYp3qBhY2p37hXSfD7Um03xPbsGRBODAzMucbumPfIFc3T4ZGilSRDh0YMD7isIS5ZJm8480Wj7X+BmvrZ+K7nSLhpSuqQCS3Z8n54gSV9sqSc/7Fe9V8d6T4guobXT9a01FWKFo7qNjncxBBIbnp1U/U19WeEvEFl4o8PWerac4aG4QFlDZMb/xI3uDkVviYa8y6nPhp6cj6Hgvxa0aS28a6h5Fp5NvKyzrKp3s28ZZgP8Ae3DFeXX0LafdSm3uizMc75QUOP8AZzxXt/x2FwniizlsgnmNZiMkscqd7Hp06GvJtRj1K90+MztCTGdpwmBn3HOa7abvBNnFV0m0YcUTbftLXSZIC+XcAsM54wc1JcvdqbaSeSO9YuNkMMewj2Cj+dTPd31urMYLaeQjakCocgeufSo7u/gsbSNnhYXTsD5ZwfbC45zVEEV3eXFzBcKbJJJo+olTBHPOMduKZHPJO5Jj0x43Ak8yGAHy2HBADd60oL+OUW6Mss8z5wixn5e3zfSs65RHaOKbbM8PymG2gw2PQA9/f3pAS2SrfxMJtjyxA/u4V8sH03dganW3iZml0xIzegBHgYDa2e/zcVC00oeJihgeLBjhEfzMB644zRdJbyIWuFlTzX/dwZDTlz/Ey9hTAlj04wyXBFrBabgoZZZckMDyR2p8cMIlwXQMj/IDlQwPq3pUFvBZXEa22nmSe4OQ0LyfKGH3jnsaRI2s182S1N7AxKsi8qn455oGTvDGJ3muZWkuGGxUgYOAD0x60RRxRs7xQyWUxGW3yFiR3AB9anto9R1J4VjdRbkhpIpP3BAB+6CB/Wq5EtodkNoz3juR5UbklB6hj1OKALDaitx5atayWkwyFjWLzUbjG9l7Z9Kimiub11FxaTTxy4JeFCPL2+x6H2qCXULmOYBpzZws+DAjeZKy/wB5j2qwJJZWa40vU/KGdphuHw7E8fKO/wBaQyu8LCCT7PFLBJM3JeIO8ijpx/DUcutiz003V2ttDNgrFK67nYjscdPrTtSDpeie5Gy7+7IRkKgA4b61xvjPxKl472tlNI1uFVSGQAZHUjvUTnyK5dODnKyOf1rUJNU1Ka6mChnOSEzj8M19EfsdeEobrUtT8T3sKu9mBb2TEn5GbcJGx64wPxr5pizk193/ALMVhHZfBzRpEiMbXZkuHyMEkuVz+IUGuBu92z0rWtFbHqtFFFZFhRRRQAjqrqysoZSMEHkEV8QeOvCJ8FfF7WNJtIlisLyL7VYnkrHGxz0zn5SHX14zX3BXzF+2BbrZa74Q1mIyRT/vbdp1P3VHI/H5mrWi7SuZVleNjy95WWLLalBqce9TGvk7XY+g3dx71DLJbrdG3CXEM5+8blt6BuuABwKW4urOPT447zTJtQvHVkMgYhJA3RsjuPas+C5s7Z0hubdd7JtRWJ4PYZ716TPNtcvyNauI4b7UZbIsNoDxBsehJXoKiZLc27Lb3kiXUbEbjIxd17EZHQ0WT2r3CpGch/mmCMNvHoT0NXptQa4cly22M7bdpMKB/slh1prUnYge+8q1t5ZEcRXHB8xvmVh1wx6ZpkiidZHjgeSzkAkjkhcF4ZB/ePcUqiCeC6t7u8863YBxB5eXhIPY96bCukrarJZwsk8ZIwqkCQ/ieDQGg57yYRmOSDUb6IL/ABSLCq59R3xVS006WdJHTTr4urYMscwjwR6Kev1FaT2Mm77XNpMsEzMrBhJkuMdCnTHvUcUX2uK3e4tYDckth/PIfr0254I7UWC9gtwLO3m+x293cRgj7Qk4UAZ680kclnMd8Vnp7qfkaGR238f3exyKl2h1BspJRg7VnkzGyc9weDVWSZ5LiRJ7qBJIpNpkjhDbmHo/TBpiGNaabJHDHcSX1sUJCwNJnIPb5R296ZJpzi3+WG4eIHcszHAIHbk8fSlUmR2jWRklB3kSkIfqvYilaRYVETuqgMEYu/yAt147D3+tGgXZE7To7tIlhHDgbpogGdvY96veebmPdp+XIZRJBGFd2x6bh6VEIZftQG2zhdMKsn3opMD+8eDmqt9aQXMoiuk2XBx+8skO0j+WaAVi3fWjRTkhZYfO3ZknRdyf7OAKn8O6XLd3MSLHezSTOsEclnINskjEBQVPQ5I61kW2n3L3axW8j3cDHannA7wM9cCvXPgDpK6p8TortbhZE02B7iVQhUM5HlqCD3G4n8BUylyxci4R5pKK6n01oOmQ6LolhplsSYbSBIFZgAWCgDJx3OMn3NcV8adZWx0K109LjyZ72bccLk+XH8zH2+bZ+deiV8r/ABX8a2Wra3qWox77i1tsW9ttQY8pMl2yfVske22uDDx56l30O/ES5YWXU+e/iLfR33iaZoZfOVBtL9AzZJJH5iuXqxf3H2u+uLgjb5sjPjOcZOcVXrKpLmk2a048sUgoooqCz0j4YasBZ3VhJFC7x/PH5kxXKnORjvg/zr0HwN8VLz4e6+ttHam40a9YGa287IR8ffT0OAAfXA9BjwfQNSk0rVre7iYDa2Hz3U8H9K9F17Tk1jSFu7SQCVW+Ty5M7vccZJxXdSlz0+Xqjhqx9nV5ujPQ/iJ4rg1vXLq4kkuZFdCYo4ZMqFx9e1YVjcRJCGieZI549r5yrsO+3rj61wfhFbm7M1g1s7XqZyxw5lz/AA/XFdAlxPoU32DU7L7KHAUSTQsOD1Cn1rojJNXOaUGnY35ZTawF4xdNZqAqRg4kHoSSMnmo5LybZLM2nlXChmmWISHd/sk8/lV6KNr63ngiAluExsIY7lXqOfelYpBEgc6kiKo4E4GDj0AOBVkGdDPcXUbb2extpVGXJCFR398k0qJ5HmzRzDyVXYzuQC3vnpioJA7+TILIeWWYl55GKsPWora40+WR4ftFrKz/AL3y9hjjyB2NICuTKJZmsb0LbnDEtKFy2fzIpyrd3lws9lb2U7s4DurBZJCO4JPA9qstdCK9jludPgSd4yUyTJuPQe3So7Wa+kaQnT7ZYSQQ2zo3948UmNBNbTxQRxXk5t4fMMnk7Rv3nrkjtUqMizreLBb2SyERvLI+FJ6AKg/nUVrDcSRyyPLE1sW3S7jggjuvb8KhYWMloSblL4M2I1htsuhz1JJ/WhgjQa5jmjVJHuLyaCcrst2HlxnsTnk0okVA5hnkRmOZV+zEygt/Du6YqheOxkV5DaW0nEYZRv3kdMKvf3q6jT75c6hLdXJX94qj5E9CBTAYbm28ySJ7q6811AjitoQASOobjIqustlfmSe8eSFlOxTCVRgR1ye34VZe6uZYWUQyxSgbpJ4zlnHoR/SuS8Z6va2EH2KxaG5uZUPmSkcw57Y7NUykoq7KhFzfKhniPxayyNp2myt5EbENcSHezj3J/pXETyvNM0kjbmJ5OMZqup6+/XNPB4571wTqObuz1KdKNNWRPFwMntX6H/BS2+yfCbwpHliDp8UgLdcONw/Rq/PJUOzpkMDiv0M+CWpR6r8JPCdzDJ5ijT4oC23HzRjy2GPZkI/Cs3sU9zt6KKKgYUVBZ3ltexmSzuYbiMHBaJw4z9RU9AXuFfNn7ahhOieGY2dvP8+dlTsyhFB/mK+k6+Wv21L6NrnwxY8eZFHPcHB5wxRR/wCgn/Iqo7ky6HiGhTC8tFWa6a5TG3yhlWjbsQO/4VrIk0dytuIoLlDIArSZAX/aBNcZol2lhqBiuAGViOW6Lx1IrsWmS4gW0lkgRImIBZCWaM+ntXo0pc0fM8+tHll5FuOxEUc6X+nWl/A4JZrViJIiP4gQcGq0Fuktk0emTySYyxgnXk+o9M+9EWn+TbySwPJ5cOPLUIdjgHuOvWrkE7hE86PEEpMpFmmWQ9CCp6/hWhjdkNtaIDHJc299bfIY1YyKDGeuemSAaFnYQ4lkMhiIEcqx72fPrU6JepcSRwQ2uoKgyklz8hHsQen0qve6tC6Si40WK2D/ALt5opdwVs+npRsFmwltzBM8kck4hKD5y7KynvhQTiqzR2t3D5pF3JIp2OY/lYejcjntUk0KQ3ErW2qwyz4WRGK/OBjkDsRUZvLqeYfa0+0uCCyzkxBh22kdaYbFg21w8LXCTOtvKBEUuZAPMx6enNV4JrW0iZLhliYNzGY2cEdO3B+tS30MMO6SHS7OOOQ84mLleQd2G6GpJdRMSEXsrXMEq/II0VSR6bRRsLfQmhkidIUuW+0RI5KLJGV8tew9eDSy3ivJKJJJfs4TnbGCy/7Qz1FU5ZLNlByvmMATBcSNleeMY5q3DtmDtNBBcliNuyXbtX+dMRApuLkCK3SK9ttu8ObfYT7cnt7Ur2ab4MXHltwA5bYME9jVswvPBJbKEQIwdWLYkXPYAcGrVrayQw+ZcyIyKcgkKVbHqDRYVyveWk9jYkR6ikisfmLHLKPTctexfswy/Yb+9gu3iaW+iDQn+MhSTz+ZP5V4PrGrwQ3y2WmrLLfXbf8ALLGIgfTrz7V0fgrWNQ8O6g+radqHnxWKmMhzt3OR6YPr9KiSU04o0i3BqTPpr4y+LJtF0T+ydIZH1vUUZUXdzDFghpMD8h7knsa+Rfilq8Uenx6fFcpJdMAsiLblNq9SQ3Q8gCtK51O+up73xBqU8F7eTSc3RmZZFz/AF6Y5ryrXdRfUr95WkZ4xwmRjA+lc0l7CnbqzphetUu9kZtFFFcR3BRRRQAV23gG9idntZH8mXHE7SYCrn9K4mpIJXglWWJtrqcg4rSnPklczqw9pHlPefDVvb6b4p0vUJCSiXC+bcD5Qw3YJ2jqcE819Z6z4L0DXLKS21OxS5jfLBmJ3ISOqnt618S+GNUXxBayrqmopCxGAjKPn9sjn0r6p+B/jKG+0a18OajdRtqtlEEgOCPOhUADBPVlHBHXAB55x1V3JxUoPQ5KEUpOE1qcH45+FV94USTUdLa51nQ0BMluiAXUC/wB4sP8AWr64GR6EZNcRG9rNaRXFvBstWYKsq5YH6ivsivJPiZ8LJtUu59Z8I3C2uoynzLuwkcpb3xx1yAfLkP8AeAwe4yS1TSxPSZVXDdYHhskQklmCKZIiVysiF1B9ieBWXfvMkcoivrS3H3JNlv8AKBnpnGc/Sma9rk1tO+leK7q+02SIbZ7E24R4iD8uOm4EYIYZBGCKqQ3Wm38UcdndgxJx5TMC7+hK9a6+ZPY5HGS1sTxWzpNbeXfWS5OQ2C0jfnwOKju71pZmsYL4hjlWEZ3NkdOlMNtLPchVufKbBE6W0QfYvufU1BAIrOPybKGeIMSybiqO4PXP1oEPj8ydY4Z1muZYecsDtUd8L3q5GdomgacyK+GFtCgQMP8AbPXH0qtFcXoggEs86NzsiyBxnu1QJe2MStdXE0i7W8t/McLjnsDzRcNTTtpbSxQvvSxVOH+wx7mJ9MtnA9TTUiSeV3tongV1O+5IHp1Nctd+M4bGSaK0WO6ifKsqZVWHux5NczrPibUdUi8mSYxWgAUW8RwmB0z6mspV4R8zeGHnPyOj8T+IbSwAtNGmknuEQo9wXO1Seu0evvXAsxZiSSSeSTzT44mkBIGFGfmPA+n1ppA+g+tcdSbnqzup01TVkIOfWnoOcZFbsfhHVR4cbXruD7JpeQI5ZwUM+f8AnmD978KxFHzHsP5VLi1uWpKWiLEGfXjqc/zr7w/Zl0zUNL+D2jrqRYfaGlureJhgxwyOWQde+d//AAOvGP2d/gd/bkdn4p8YQsmkhlmsdPkTm8wQRJKD/wAsj2XHz9T8uN311UNjM/xBq9roOi3mqag+y2tYzIx9fQD3JwB7mvi34j/ErxB4y1eZXvri104ZjNrbzOluoBON6g/OfUtn2AHFfX/xE8OHxb4K1bQ0nFvJeRbY5WGQjghlJHplRn2r4H8TaHqnhrxDd6XrFs9pqEDHKMSFkXJAdCR8yHHBFaU7GU02y/pfinWtJmE2larPazY2s0TFC30Ir6f/AGf/AIszeL2k0LX3jOrwx74Jhw06Dhgw6bh1yOozwMZPxw5c/MgYxjkF+B78179+yx8PNXufFNr4zvI5LHSrJZBbCRCDeNJGVyuf+WYD53dCeBnBxc2mtQjC2qPravhP9pzVLnUfi3rqXO5UsxDaQo38KCNX/VpGb8a+7K+a/wBrL4ay38K+NNEt3kmgjEWpxRICTEuds+BydvRuvy4PAQmsEaM8N8TaZDrPgPSdZtvs6apaR+XeIuA1wueH9yuOe+D7Vz/h/WYIAUuozL5hCxs0hzC3b/gNVPDuqPpmp2rlg9ssn3Wb5VzwWr2ZvghJ4z0W41nwlNax3w5lsZXwkuRuBjccAn3wPcV2c1/3kfmcrjy/upbPY5xV1IRwTTXHlSu752HaBngVHc2ryX8SSpcLcLFvjYzYAbuQR2Ncvp15qHhrUZdF8SQ3tiqkrLFPGVePPQlTzjvkdq7G3W1eyi8u/FzbkEIW6qeuM5rohNTWhy1Kbg9TJj+z3MjrcwXjXg4JD/eOeASKfIVNl82mxAMdilmK7j6lv8a1Y3gkxZ3EUS3LL+6IcIsg9P8AerNlEOxnibbLCCHtbhtjMB6DvVmZWe3ijYxywzw3EO1isYWXBPvS39qrSyPIoHQhfNyhP0PIp0jS3UUbabPaziD5jGw2SR8f+PVVWbc6S28MPnqhMqSRblI9Qfp2oHqNjjgiRJJpNsZB+ZHMiL/stntUk0Mcarbw3kEBZgyeY27J/wBlh0psMf2lQ2n/AGaIyLllj+4fYhuhpBBdQLsuI7DyJWHCr8re+e34Uh/MmFy7SLBfJa3Pk8NJIcNtPPDYzmtG2tdPaZPK+whH5QiZpNrf7Xr9KyGt4F/4+BvQjrCTuj5429iPrWnZW6zJbiO9luod2GgCqjDnOcetNCe2hoW0B+0Ex4u24ZjCTAVPqDR4h1V9N+y21iFv9UuwEs7SOMTMzswGGUck5PA6k1qeFdH1PXtSfQfBscN/fJl7i4ulYW9kDnHmsAeSQQFAJPpwa+kfhb8KdD8AwGeJV1DXpR/pGqTxgSMechBk+WvPRTzxknArCtiFDRbm1DDuWstjwT4dfs5a7qDJqni6X+zZZX8wwBwZQOvJU4BPp2rI8X6JHZ6tPBo32e3gspTHlmyW7EZ7g+4r608d+JrXwl4butTumUuo2QREgGWUg7VH5En2Br4g+JXiWWOzSw8wTXEo3+aG+aNTyenXPrUUKloNvYuvT5ppR3OX8aa4LojToYbXyoTzNGhBdu/t2xXJUpOaSuSpN1JczOynTVOPKgoooqCwooooAKKKKALem3j2F4lxGoZkOQDXsvgvxgpksLwtFaPGwckHLPKOjKf4fpXh9SQymKVHUA7WDYPQketbUqrhp0MatFVNep+g3w9+KWna+8WnapNFBqrt5cboCIZ2OcKpP3X45U9T93PQekKoUbRnHuc1+fXhfxY2oTG1uVgjt2X5oAOGPrz/AJFe8+AvinqujQJDqDHWtKBCL+8H2iADsrH/AFg9mOf9rtWk6KkuamZwrOL5am57F8RPh/4f8f6ULLxBalmQ5huoSEngP+w+Dwe4OQe44FfCfxQ+H2o/Dvxc2kalcxNEyefa3qgqs8ecZCjJVgQQV9R3GCfvrwz4t0bxHCrabeJ55GWtpSEmT1BQ8/iMj3rmvjt4YPib4fXq21pFc6laf6Rah0BIYdQCemRn8hWMV73LI2lK0eaJ8HPr11HAEtbwhEwApjALf596pya3qEkgeS4LOOQSoOPpWxfeHtQtbiSK6tYJrpichHB8v646fjWTc6NPAobBcEYPljdhvQ1tJVd9SIuk9rEE2q38zZlvbhj7yGqsjvK5eR2dz1Zjkmux8P8Awy8Va+kbaZpNzIH5yyFRXqvhn9lnxPelH17V9N0qFgTtiVrmVT2BX5V/JjWUlJfEaRlD7J88hSelTRQlpEVQHkYhVQAksc8DHU19seGv2Z/A2mITrH9oa1KygETzmGNT6qsW0j8WNepeFfBvhzwnD5fhzRbHT8rsaSGIeY4znDOfmb8Sai5dz4s8IfAjx54okhkl0z+yLFhnz9SPk7QCOBEMyZwcjKgHHWvpH4b/ALP/AIT8HvFd36Nr2qpyJ71B5SHnlIeQO33ixBGQRXsNcL8RPiTofg+2liuZZLnUCuBbWuGkXPALf3f50K8noTJpLU8D/a9tmn8UaerXczxx237i2DARRnPzH6nipf2afg3pGvaQfE/imCO+heTbZ2xbMfykhi4789ulebfECfXPF2ovcywzJEWZ4hOmG2nuT3r2z9k/xN/Z/hqfw9rBECpO0lpKT8rA/eU/3eenrmumcGlojmhNW1e7Po1VCqFUAKBgADAFDMqKWYhVAySTgAVWv9Qs9PtDdX11Db2w/wCWkjhV56c18/fGDWLfxjfNZtemXRYceXa4ISZ/75x9456Z4HXAOawp0pVHobVKsaa1PoW2ure6DG1nimC8ExuGx+Vc/wCOPA3h7xvp4tfEWnx3DID5NwvyTQE90ccjoDjocDINfJdh4JubHUorrRLqXRtTX5rSSN/LO70JHbt3HqDX018GPGs/i/w1JDrCiLxFpTi11GLK/O+PlmAHRXAJHAGQwHAzTnSlT1YU6samiMbwr8APAugyiWezutalVtyHVZhMi8Yx5YCof+BKa9XijSGJI4kVI0UKqKMBQOgA7Cq+p39rpen3N9qE6QWltG0ssrnhFAyTXxl8TvFnizxxeTahcG9sPDxYtaWbStCqRZ+VnRT88hHJznGcDjrEYym9CpTjDc+16K+Vvgt4+8UaNrVhYard3Wq+GrgiHN0cvaZIAkDsNxQdCpJAByMYwfqdGV1DIQysMgg5BFEoShuEZxnseO/Ez4AeFvFqXF5pMS6HrT5bzbZcQyt/00i6c88rg5OTu6VwP7NF9feF9Y1nQNQtZbmS3la2Plkbo3VsFcE9Mg19NX93BYWU93dyCOCFC7sewFfEJ8fyjxpqGsWS3VqZ797ks8YHylywG4d63oWd0zGu2rcp9cfED4feHfH+mC28RWAaVR+6uo8JcQf7r88c9DlT6GvmzxT8EPFHgl7i60OP/hINHUEgQD/SI14+9Efvf8AyTjoK+lvAfjzQvGenxz6Vdp9oI+e2kO2RSOvHce4/SurrKMpU2aOMakT4aWez1OB57GZLoRgOi5AeMjqrKay9TkkuJHMz6ebiP7nlNhivZSexr7M8WfDzwx4qnN1qulxf2gV2i+gzFcYxgZdcFgAOA2R7V4T41/Zqu1guJfDt9DqLZZo47n9xMo7KGUFHP1CV1xxKktdzllhnF+R4/eac93HJ9ntrhpAqtuDAOp98dRVQpII4zKlzHMGBz5gMbfl0NcvrNs2n6lJa3k2oWt7bt5UsdxGVeMjqCM5FZTTzDcouXKN1+Y4NEq6T2Kjh21udxewzq5nD23lkZJHykH3Hf61nSX9lGhWTULkRsuGijAbB9q5NR5jYZ1HuxNavhzw7qfiPWrbStDtXvr+dsJFF6dySeAo7k8DvWbrt7I0jh0t2XH1tI1aOB7iZf4XkxHj0zjNew/Cz4PeL/HSWupa5cyaH4bmCyqygLPcxkn/VJ1XIHDv2ZWAYV7J8FPgTpfgdU1PXxbar4iyGSQKWhtMdPKDDJbPO8gHpgDnPtVYyqyelzSNKK6GT4Y8O6T4W0iPTNAsYbKzTnZGOWbABZj1ZjgZYkk4qzrOqWejafJe6lOsFtHjLN3J4AA7k+lYHjXxxpvhePyXIu9TcEx2cbgN0zlz0Rfc/gDXyl8Ufilc6pd3Aubx5ZicxxJjybbHaPHU89TyfYDAIU+b3paIU6tvdjqzU+OHxJlu9UWSWVJFJK2tpwRbpzh2GT857n6DtXzpNLJPIZJXZ3JySTUl7cyXV1LNLLJK8jbmeRssx9TVelUnzaLYqnT5dXqwooorM0CiiigAooooAKKKKACiiigArf0XxFcWUyefLOY16NGRuH4Hg/jz71gUVUZOLuiZRUlZnpVv4x00eUiRzJICf9KLcoevAzkV0MPxL8SS2ii38R30looCt5krybvZsnIrxSnpI6Z2Oy564OK2WId/eRi8NHozuhcXIv555o5WjmYsxRRljnPU9au2ety2MjPZpHJIoP7podxBPQ/8A164u21u4jG2cCdCcnJ2n8xWrYa8jzv51xJECQE3DgA9V47VvCtF6XMZ0WtbH0J8CPjFaafO2k+KHFtFISy3kgwqH0JHTPT8q+n7S5gvLdJ7SeKeBxlZInDKw9iODXwTZ6pYNDHDF5cryAqAmNh55BzWrZyLG+y8uQ+P3UcMeGCg9DnpSqUOd3TFCvyaWPtXUtd0nS22ajqVnbPjISWZVYj2XOTXL6v8AE3R7KF3tIbu9I4UpH5aE/VsH9DXzrbajPbQIYpI432+Ud6DAPr61TfUJC+691WIxu2VjUDIYcc0RwsVuwlipPY9H8V/E3Wr4GP7XNpcJyTHYR/OF9GkbJz7rtrx5pC08FzIs0MUjkq8bjJ57k9zWlPq13IoSFbRnjYjJb7y+h96pJNGjhryVJWB3iOJfkQ54xXRGnGOyOeVRy3Y65itYonm1W61F4WyUBmJk/DsBVjQb8WU0a6abkmYHE0hAXHv6moRb3N1fBYJrWYt8ziRwOPQH1pk7XNuMOYmFvuIResWT3qrE3O6OqyT2cUWqyT3kJceXFLJlVPQkDsKz7u7HnqqFbeMuQowW5Hp6fWse10+5mshIlvDcSOpwWk2gDrnFTxRmG6tre+eONB2PBC9yfQUWC5Z81FeDfNtlVi8c33mf8+K7P4PQapP8SYL/AE2/VbYW7Q30cigfaIuSvA6MrHIPuR0JznavqOnJpjaHHFYvPAnnW86AEkeg96f8NtQuLPUjewXEUU4Uxv5ihcf41M480WioS5ZJneftJNNJ4d0q1lu1ttMmuw1ypziUqNyK3+zuAOPUD0rx0t56mAx43oMIoyp9xmu0+IviO51+AWuoR/a7GGXKyogHlvjgnArg7tbURlLeSPzxtbg8L+NTRp8kbMqrU55XRuG4ezVzc2kyLgb3jHT61s6J4z1bSpW+x6z9mt48A208e+MZ9M9B34IqhfjTJ9Hij0fUpGkjJa6uA2Rux93B6/8A1q5Q6t5kDRLK3mW7ZSQxgrKOhGe9aNKWjM1Jp3R0vjP4ialr0f2W81CAJHksIo8Rkgdh1PpznrXnc15YpC01vBOqyDOSoaJm9COorS1F4bieK8WSMXO0kNs/hHbFZdxLbrbz5jk3SgMFUEqT/s/WkopKyG5OW5f0GC1idLhIrq1uUmWRPJZkKMP4kIORXrnhz4k+JNLlgimmXVbJmCql3jzdvtKvU+7Bq8UtMpIXSd4WRSSJMhgCOgqXTdSMcSLNZjfk8pIV3c/ePpSlTjLRocako7M+u9A+Img6riKe4Gm3feG7ZV/Jwdp/PPsK7BWDqGUgqRkEHOa+Kvttykb+X5aTITsVnyr56jPTpVmXWbvT7VZbW7vdJuAQu6KdlViR0IU4/GuaWFX2WdMcU18SPYP2gvAvgfWIE1XX5TY6qgwHtXVJbhegDAg5x2JHtXyJdeGrMSuLS8mZSTsWWMK2P9r3rvtX1fUJ3kOqwx34RfmdmZ87uck9fxrI3QzusEmnpbEkbHMvAU9cntWkaEbWlqZuvK946IwLHwh9qYQpvE2fulgGI9R619gfAfwr4e8E+Hz5dzZnUZxmaaVlEmPTJ5A6cV8owLfW7n7JeEASN5bP95QO4PQikuvENvaJKkl0008RwsgLbm9sdMfWiVOCi+g1Um5LqfbXiD4neF9GOw3/ANuuCcCGxXzj+YO0fiRXj3xI+ON9AjRWUq6dGwIEFviS5bjux+7+ABGetfNt1461Zo/KsnW2h27cKASffJrmbid7iZ5JGZ3c5LOcsT9a5eanD4VdnVy1J/E7I6rxH441DVVlWKV4Vl5kwTuc9yzE5ye9ck7s5BckkDAzTKKylNy3NYwjBWQUUUVJQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVuHULyFQsVzKgByMMaqUU02thNJ7mqmv6mrFjdyOScnec1IviG+G8kxsWOSSvNY1FUqk11JdOD6GwPEF6pYoUUt94rnJ9+tNm1y6mUbyQwXaCpI/Md6yaKftZ9w9nDextafr91ZYWOSdo87sGXnPscVYHim6UswU+Y3DMXJyK52imq01omJ0YPdHaWHjUwMXeKcSlCokWTJT02jjFWZfGK3sKfapVDhSp8xW3EdssM1wVFUsRNEPDU30O9HjZbRybOOAADaG2MzAf7OcYqvd+MpLyVZJ7y7UxsWiWOBQFJH+/XFUUPETYLDwWx30XxA1HypVOoTk4AXzl+Vh6EDP506Dxm7q7m1to2cneDIpDfgTXn9FCxM0Dw0Ox6OfGTwSD7OluEmP78eYnPr3xU8HjW0hyslpHJtJ2hpVKqPQYNeY0VX1mQvqsD0S+8eKquLMKDJhgVi+aM+mTisxfGk7RNFNuKM25tqLn8DniuOoqfrMxrDU+x1j+KQB8guHYcq0hGc/4U6DxzqMcTrIFduNmQOB3BrkaKXt59x/V6fY7qLxrJ0IgWNgSUZSdpPuB60ybxiJFMAjVIjjc/JBP0riKKf1mYvq1PsdBd+JbtpJFjMbR5GG2kHjp3qnda5f3ORLPuGQRlR8vsPasuiodWb6lqlBbIsSXc8oIkmdkOMqWO049qr0UVDbe5olYKKKKQBRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lobulated liver abscess by CT scan in a patient with melioidosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39522=[""].join("\n");
var outline_f38_38_39522=null;
var title_f38_38_39523="Bone scan of Paget affecting both femurs";
var content_f38_38_39523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 570px\">",
"   <div class=\"ttl\">",
"    Bone scan of Paget affecting both femurs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 550px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone scan in a patient with Paget disease affecting both femurs. Note the intense uptake, beginning in subchondral bone and moving in one direction through that bone. There is a suggestion by this bone scan of PDB in the R tibia as well.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Margaret Seton, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39523=[""].join("\n");
var outline_f38_38_39523=null;
var title_f38_38_39524="Burkitt lymphoma";
var content_f38_38_39524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Burkitt lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left panel: Lymph node touch inprint from a patient with Burkitt lymphoma shows multiple small noncleaved cells with a thin rim of basophilic cytoplasm containing numerous vacuoles. The macrophage in the center (yellow arrow) contains abundant cellular debris (ie, tingible body macrophage). Right panel: Bone marrow from the same patient shows two small noncleaved cells with eccentric nuclei, a thin rim of basophilic cytoplasm, and vacuoles aggregated at one pole of the cell (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39524=[""].join("\n");
var outline_f38_38_39524=null;
var title_f38_38_39525="Oxcarbazepine: Patient drug information";
var content_f38_38_39525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxcarbazepine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     see \"Oxcarbazepine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=see_link\">",
"     see \"Oxcarbazepine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxtellar XR&trade;;",
"     </li>",
"     <li>",
"      Trileptal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxcarbazepine&reg;;",
"     </li>",
"     <li>",
"      Trileptal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad rashes have been reported. Talk with your doctor right away if you get a rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat painful nerve diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxcarbazepine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures that change or get worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3311838",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Extended release tablets:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. This could cause seizures. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature. Throw away any part not used after 7 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10935 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-220.255.2.117-02C9EFC5AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39525=[""].join("\n");
var outline_f38_38_39525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204790\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020987\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020989\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020988\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020993\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020994\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020996\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020991\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020992\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020997\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020998\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=related_link\">",
"      Oxcarbazepine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/46/16104?source=related_link\">",
"      Oxcarbazepine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_38_39526="42 yo MS brain MRI";
var content_f38_38_39526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    42 year-old female with multiple sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T2-weighted (A) and axial fluid attenuated inversion recovery (FLAIR) (B) images show multiple, ovoid shaped, hyperintense foci consistent with MS plaques. Sagittal FLAIR (C) image also shows these lesions to be radiating out from the corpus callosum. Axial precontrast T1-weighted (D) image shows that many of these lesions are hypointense, consistent with black holes. Axial postgadolinium fat saturated T1-weighted (E) image shows that some of these plaques enhance in a ring-like fashion consistent with active plaques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39526=[""].join("\n");
var outline_f38_38_39526=null;
var title_f38_38_39527="Diabetic neuropathic arthropathy";
var content_f38_38_39527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diabetic neuropathic arthropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39527/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39527/contributors\">",
"     Lesley D Hordon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39527/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39527/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39527/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39527/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/38/39527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of musculoskeletal conditions have been associated with diabetes mellitus. These include specific arthropathies of the hand and shoulder, spontaneous infarction of skeletal muscle, and limited joint mobility. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=see_link\">",
"     \"Musculoskeletal complications in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1526?source=see_link\">",
"     \"Diabetic muscle infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12534?source=see_link\">",
"     \"Limited joint mobility in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the loss of sensation to a joint may result in a chronic, progressive, and destructive arthropathy. The prototype of this disorder was described by Charcot in relation to tabes dorsalis. Similar changes are seen with other neurologic disorders, such as syringomyelia and diabetic neuropathy. Diabetes is the most common cause of neuropathic (Charcot) arthropathy in the western world. Diabetic neuropathic arthropathy is also called diabetic osteoarthropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of this condition remains uncertain but it is probably due to a combination of mechanical and vascular factors resulting from diabetic peripheral neuropathy (",
"    <a class=\"graphic graphic_algorithm graphicRef74711 \" href=\"mobipreview.htm?33/34/34349\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As an example, lack of proprioception secondary to peripheral neuropathy may result in ligamentous laxity, increased range of joint movement, instability, and damage by minor trauma, to which the relatively insensitive neuropathic foot is prone.",
"   </p>",
"   <p>",
"    An alternative theory suggests that autonomic neuropathy results in vasomotor changes and in the formation of arteriovenous shunts. These, in turn, result in reductions in effective skin and bone blood flow, despite the good and sometimes bounding foot pulses in these patients. Another unproven hypothesis is that an exaggerated local inflammatory response to trauma, mediated by proinflammatory cytokines, results in the osteoarthropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible cytokine-associated effect is suggested by the finding of enhanced osteoclastic activity in surgical specimens from patients with Charcot arthropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/5\">",
"     5",
"    </a>",
"    ]. Other laboratory studies suggest that both receptor activator of NF-kB ligand-dependent and -independent pathways may be involved in the increased bone resorption seen in this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the initiating mechanism, there may be an initial resorptive phase in the development of a neuropathic joint which may then be followed by a hypertrophic repair phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to tabes dorsalis, which primarily affects the knees, hips, and ankles, and to syringomyelia, which affects the shoulder or elbow, the diabetic form of neuropathic joint disease most commonly affects the joints of the foot and ankle. The most frequently involved joints are the tarsus and tarsometatarsal joints followed by the metatarsophalangeal joints and the ankle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Although unusual, involvement of upper limb joints can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact prevalence of neuroarthropathy is difficult to determine, as series often come from specialist centers that treat more severe cases of diabetes. However, among the general diabetic population, neuroarthropathy is uncommon, affecting approximately 1 in 700 diabetic patients, with either insulin-dependent or non-insulin-dependent diabetes. These patients typically have longstanding diabetes (average duration 15 years) and peripheral neuropathy and are in their sixth or seventh decade, although patients as young as 20 may be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A high frequency of Charcot neuroarthropathy (12 percent) has been reported in patients following simultaneous pancreatic and kidney transplantation, a group characterized by severe and longstanding diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of this disorder are variable. The patient may present with sudden onset of unilateral warmth, redness, and edema over foot or ankle, often with a history of minor trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/11\">",
"     11",
"    </a>",
"    ]. Recurrent acute attacks may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/12\">",
"     12",
"    </a>",
"    ], or there can be a slowly progressing arthropathy with insidious swelling over months or years. Involvement of the foot is characterized by collapse of the arch of the midfoot and bony prominences in peculiar places (",
"    <a class=\"graphic graphic_picture graphicRef67753 \" href=\"mobipreview.htm?26/18/26927\">",
"     picture 1",
"    </a>",
"    ). The neuroarthropathy is bilateral about 20 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/1\">",
"     1",
"    </a>",
"    ]. A delay in diagnosis is very common and can lead to progression of the neuroarthropathy and to an increased risk of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The arthropathy is relatively painless. Although pain is commonly felt, the severity is less than might be expected from the clinical and radiologic appearance of the affected joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high index of clinical suspicion is important, and the diagnosis should be considered in any patient with diabetes who presents with a unilateral warm, swollen, erythematous foot, particularly in the context of peripheral neuropathy and longstanding disease. Most often, the skin is intact. However, early neuroarthropathy can coexist with foot ulceration, and ulceration can be a consequence of the foot deformity associated with late disease. The early stages of neuroarthropathy often can be mistaken for cellulitis.",
"   </p>",
"   <p>",
"    Investigations are aimed at confirming the diagnosis by identifying characteristic radiographic findings and by excluding other conditions which could be confused with neuropathic arthropathy, the most important of which is septic arthritis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Careful clinical history and examination is essential to confirm the presence of peripheral neuropathy and to look for portals of entry of infection. Diabetes mellitus is a common condition which may be complicated by other coincidental joint diseases such as gout, calcium pyrophosphate arthropathy, osteoarthritis, and inflammatory arthritis. As a result, joints with effusion should be aspirated, and the fluid obtained should be evaluated for organisms and crystals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic findings are variable, depending upon the stage and site of the arthropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In early acute disease, the plain film radiographic changes may be mild or nonspecific, showing only soft tissue swelling, loss of joint space, or osteopenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the forefoot, bone resorption may predominate, leading to osteolysis of phalanges and to a variety of changes including partial or complete disappearance of the metatarsal heads or &ldquo;pencil-pointing&rdquo; of phalangeal and metatarsal shafts.",
"     </li>",
"     <li>",
"      In the midfoot and hindfoot, osseous fragmentation, sclerosis, and new bone formation, subluxation, and dislocation are more likely to occur (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64186 graphicRef76978 graphicRef57519 \" href=\"mobipreview.htm?30/7/30837\">",
"       image 1A-C",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/1,9\">",
"       1,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stress fractures, which may be difficult to diagnose, can complicate the neuroarthropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/11\">",
"       11",
"      </a>",
"      ]. An uncomplicated stress fracture can be located by scintiscan and can be confirmed by magnetic resonance imaging (MRI) or serial radiography. However, both MRI and scintiscan are less specific in the diabetic neuropathic foot, and delay in diagnosis may occur if one waits for the radiologic changes to become apparent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While a second radiograph some weeks after presentation may clarify the diagnosis of acute early neuropathic arthropathy, delays in diagnosis and treatment are inevitable. Unfortunately, other radiologic tests are not more helpful. Bone scan, for example, may be nonspecific, with increased isotope uptake seen both in patients with diabetic neuroarthropathy and in those with peripheral neuropathy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of stress fracture and visualization of torn ligaments and of intraarticular fragmentation may be facilitated by MRI. However, the changes of acute neuropathic arthropathy may be indistinguishable from osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/7,15\">",
"     7,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast enhanced MRI may provide additional diagnostic value. This was illustrated in a retrospective study of 128 neuropathic joints (42 with concomitant osteomyelitis) of which the majority had joint effusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/16\">",
"     16",
"    </a>",
"    ]. The presence of one or more of the following features on contrast enhanced MRI favored osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A sinus tract",
"     </li>",
"     <li>",
"      Replacement of soft-tissue fat",
"     </li>",
"     <li>",
"      A fluid collection",
"     </li>",
"     <li>",
"      Extensive marrow abnormality",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An absence of infection was associated with a thin rim of enhancement rather than diffuse signal throughout an effusion and with the presence of subchondral cysts or intraarticular bodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of gadolinium-based MRI contrast agents is relatively contraindicated in patients with diabetic nephropathy who have moderate or severe renal functional impairment, as use of these agents has been associated with an increased risk of developing a scleroderma-like disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link&amp;anchor=H4#H4\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\", section on 'Gadolinium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with metal implants that degrade the signal in the area of interest or those with other contraindications to MRI (eg, a pacemaker) may be assessed using positron emission tomography (PET) scan, if available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/17\">",
"     17",
"    </a>",
"    ]. Further study of PET scanning is needed to determine the sensitivity and specificity of this imaging modality as a test to distinguish neuropathic arthropathy from osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are too many causes of joint pain that can affect both diabetics and nondiabetics to discuss even briefly here. The approach to the adult with joint pain is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link\">",
"     \"Evaluation of the adult with monoarticular pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following sections include disorders that the author and editors consider particularly important in the differential diagnosis of diabetic neuropathic arthropathy. Those already mentioned above include septic arthritis, gout, calcium pyrophosphate arthropathy, cellulitis, osteoarthritis, idiopathic inflammatory diseases, and osteomyelitis. Another disorder, complex regional pain syndrome (formerly referred to as reflex sympathetic dystrophy, Sudeck&rsquo;s atrophy, algolodystropy, etc), which may occur in the setting of diabetic neuropathy, is also discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Septic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience suggests that septic bacterial arthritis occurring in a patient with diabetic neuropathy may cause less pain and may be associated with a greater range of joint motion than a similar infection in the absence of neuropathy. Although the majority of patients with septic arthritis are febrile, neither the absence of fever nor a normal peripheral white blood cell count excludes septic arthritis. If a joint effusion is apparent on physical examination or on an imaging study, joint aspiration is the best way to assess for joint infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=see_link\">",
"     \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Crystal-associated arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint aspiration also allows the most definitive assessment of the presence or absence of monosodium urate (gout) or calcium pyrophosphate dihydrate (CPPD or pseudogout) crystals. In the appropriate clinical setting (eg, prior history of crystal-proven gouty arthritis or pseudogout) and in the absence of clinical features suspicious of infection (eg, fever, leukocytosis, foot ulcer, sinus tract), the diagnosis of gout or pseudogout may be made without resorting to joint aspiration. It should also be noted that the presence of crystals in synovial fluid does not exclude septic arthritis. The clinical manifestations and diagnosis of these crystal diseases are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal symptom associated with osteoarthritis (OA) is pain, which is typically exacerbated by activity and is relieved by rest. With more advanced disease, pain may be noted with progressively less activity, eventually occurring at rest and at night. Cartilage space narrowing and osteophyte formation are characteristic of osteoarthritis (OA). In the absence of a history of significant trauma, bony deformities, fragmentation, and callus formation are not seen in OA. Frank inflammatory features, such as erythema or soft tissue swelling and tenderness, are also uncommon in uncomplicated OA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33287?source=see_link\">",
"     \"Diagnosis and classification of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inflammatory arthritides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various sterile inflammatory arthritides (eg, rheumatoid arthritis, psoriatic arthritis, reactive or postinfectious arthritis) are considerations in the differential diagnosis of painful joints and may initially present with a single inflamed joint. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=see_link&amp;anchor=H9#H9\">",
"     \"Evaluation of the adult with monoarticular pain\", section on 'Systemic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Complex regional pain syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the clinical features of complex regional pain syndrome (CRPS), such as burning and sometimes throbbing pain, diffuse uncomfortable aching, and sensitivity to touch or cold, are similar to or are indistinguishable from those of diabetic neuropathy alone. Vasomotor disturbances that produce altered skin color and temperature are suggestive of CRPS if there is no evidence of infection or of peripheral artery disease. The radiograph is usually normal in the early stages of CRPS but may show patchy demineralization. With increasing duration of symptoms, patients with CRPS may have thickening of the skin and of articular soft tissues, muscle wasting, and the development of brawny skin.",
"   </p>",
"   <p>",
"    There is no definitive diagnostic test for CRPS, and imaging studies cannot unambiguously distinguish between CRPS-related soft tissue and bone changes and those of diabetic neuropathic arthropathy, soft tissue infection, or osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy depends upon the stage at which the condition is diagnosed. A patient with a warm, swollen, erythematous foot of relatively recent onset may respond to therapy, while patients presenting with chronic joint deformities may have already progressed to irreversible joint disintegration and damage.",
"   </p>",
"   <p>",
"    Classification of Charcot arthropathy into one of four stages by a modified Eichenholtz system is helpful for considering appropriate treatment and prognosis and for clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/18\">",
"     18",
"    </a>",
"    ]. The stages are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage 0: Early or inflammatory &mdash; There is localized swelling, erythema, and warmth with little or no radiological abnormalities.",
"     </li>",
"     <li>",
"      Stage 1: Development &mdash; Swelling, redness, and warmth persist, and bony changes such as fracture, subluxation dislocation, and bony debris start to appear radiologically.",
"     </li>",
"     <li>",
"      Stage 2: Coalescence &mdash; The clinical inflammatory signs decrease, and radiological signs of fracture healing, bony debris resorption, and new bone formation occur.",
"     </li>",
"     <li>",
"      Stage 3: Remodelling &mdash; The redness, warmth, and swelling has settled, and bony deformity which may be stable or unstable is present. Radiographic appearances may show mature fracture callus and decreased sclerosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the diagnosis is made at Stage 0 before significant radiological damage has occurred, then successful treatment is much more likely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Acute therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the earlier stages of neuropathic arthropathy, in which edema, redness, and warmth are present, avoidance of weightbearing on the affected joint should be recommended until resolution of the edema and erythema occurs, with improvement of radiologic signs (eg, resolving resorptive changes, resorption of osseous debris, and evidence of repair). A minimum of eight weeks without weightbearing has been recommended for disease of the midfoot, progressing through partial weightbearing in a cast brace to full weightbearing in about four to five months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/1\">",
"     1",
"    </a>",
"    ]. Good chiropody and well-fitting shoes are essential at this stage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians are concerned that prolonged three-point weightbearing through crutches and the unaffected (but also neuropathic) foot can lead to problems and can also be difficult for the overweight patient. Thus, the total contact cast for offloading and immobilization is increasingly becoming the treatment of choice with or without an initial period of non-weightbearing immobilization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Alternatively, some centers use a weightbearing total contact cast for early neuroarthropathy from the time of diagnosis.",
"   </p>",
"   <p>",
"    Whether weightbearing or not, the cast should be changed every one to two weeks to allow for the decrease in edema. There is progression to protected weightbearing, usually with the aid of an assistive device, prior to a return to permanent footwear in four to six months. Following the total contact cast, a number of offloading modalities can be used. These include the Charcot restraint orthotic walkers (CROW), other total contact prosthetic walkers, a pneumatic walking brace, or similar removable cast walker which might incorporate a cushioned foot bed or insole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/19\">",
"     19",
"    </a>",
"    ]. As an example, an uncontrolled study of 10 patients with stage 1 Charcot arthropathy utilized such casting with cast changes every 14 days. A transition to custom-made orthoses and commercial footwear that could accommodate them was possible at a mean of 9.2 weeks (range of 8 to 16 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary study of six diabetic patients with the swollen uncomfortable hot foot of active Charcot arthropathy showed marked improvement after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    infusion, with three patients maintaining remission for over one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/21\">",
"     21",
"    </a>",
"    ]. Subsequently, 39 such patients were randomly assigned either to pamidronate (a single intravenous infusion of 90 mg) or to placebo. In addition, patients received standard foot care with reduced weightbearing on the affected foot.",
"   </p>",
"   <p>",
"    Symptomatic improvement was significantly greater in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    group over 12 months of observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/22\">",
"     22",
"    </a>",
"    ]. Skin temperature fell in both groups by 3.6 and 3.3 degrees, respectively, an insignificant intergroup difference.",
"   </p>",
"   <p>",
"    Oral bisphosphonates may also be useful. As an example, in a randomized study, patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (70 mg once weekly) or placebo; both groups were also treated with total contact cast boots followed by pneumatic walker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/23\">",
"     23",
"    </a>",
"    ]. After six months, the alendronate-treated group had decreases in pain and in a marker of bone turnover (urine C-terminal telopeptide of type I collagen) and had increases in bone mineralization in the foot as assessed by dual emission x-ray absorptiometry, which were significantly better than those of the placebo group.",
"   </p>",
"   <p>",
"    However, a study of 39 patients with neuropathic arthropathy randomized to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    infusions (4 mg monthly for three months) or to placebo was disappointing. Patients receiving zoledronate required a longer immobilization time before clinical resolution than did controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intranasal calcitonin has also been tried in acute Charcot arthropathy. A small randomized study of 32 patients noted a significant reduction in COOH-terminal telopeptide of collagen excretion and bone alkaline phosphatase in the treated group, suggesting decreased bone turnover compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/25\">",
"     25",
"    </a>",
"    ]. Both groups were also treated with standard offloading by removable contact cast or cast walkers. However there was no clinical difference in outcome as measured by skin temperature difference between groups. Calcitonin treatment may potentially be useful in patients with both Charcot arthropathy and renal insufficiency (28 percent of their group), in whom bisphosphonates are contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/25\">",
"     25",
"    </a>",
"    ], but clinical benefit remains to be proven.",
"   </p>",
"   <p>",
"    Bisphosphonate treatment has not been approved by regulatory agencies for use for Charcot neuroarthropathy, and any decision to use this treatment should be carefully considered in the circumstances of the individual patient. If used, the treatment should be considered as an adjunct to and not as a substitute for offloading the affected limb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Joint disorganization and surgical correction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late presentation may mean that joint disorganization is severe and irreversible. Disease of the hindfoot and ankle appears to have a worse prognosis than disease of the midfoot. Common deformities seen are the &ldquo;rocker bottom foot&rdquo; caused by collapse of the medial arch (",
"    <a class=\"graphic graphic_picture graphicRef67753 \" href=\"mobipreview.htm?26/18/26927\">",
"     picture 1",
"    </a>",
"    ), medial convexity deformity caused by medial displacement of the talonavicular joint, and tarsometatarsal dislocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/3\">",
"     3",
"    </a>",
"    ]. Such deformities transfer weightbearing to areas which tolerate it poorly and which may lack sensation. Ulceration and infection commonly ensue.",
"   </p>",
"   <p>",
"    Surgical correction is best",
"    <strong>",
"     avoided",
"    </strong>",
"    in most patients. However, in carefully selected cases, surgery can give acceptable alignment, thereby preserving soft tissue integrity and viability and avoiding amputation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skeletal deformity following nonunion of a fracture in a neuropathic foot can also be corrected by surgery, but this has a relatively high failure rate of up to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/27\">",
"     27",
"    </a>",
"    ]. Failure is seen mainly in patients who have active ulceration relating to the deformity at the time of operation; as a result, surgery should be postponed until the ulcers have healed. Even with surgical success, orthotic devices are often still required.",
"   </p>",
"   <p>",
"    Achilles tendon or gastrocnemius muscle lengthening has been successful in decreasing forefoot pressure to allow ulcer healing in selected diabetic patients with ankle equinus and forefoot ulcers, including some patients with midfoot neuroarthropathy. Patients with hindfoot neuroarthropathy were excluded from this study, and some cases of heel ulceration were seen in response to the surgical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39527/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24803269\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes is the most common cause of neuropathic (Charcot) arthropathy in the western world. The pathogenesis of this condition is uncertain, but it is probably due to a combination of mechanical and vascular factors resulting from diabetic peripheral neuropathy (",
"      <a class=\"graphic graphic_algorithm graphicRef74711 \" href=\"mobipreview.htm?33/34/34349\">",
"       algorithm 1",
"      </a>",
"      ). A major hypothesis is that lack of proprioception secondary to peripheral neuropathy may result in ligamentous laxity, increased range of joint movement, instability, and damage by minor trauma, to which the relatively insensitive neuropathic foot is prone. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetic neuropathic joint disease most commonly affects the joints of the foot and ankle. It typically affects patients with longstanding diabetes and peripheral neuropathy and occurs in both type 1 and type 2 diabetes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation varies. Patients may present with recent onset of unilateral warmth, redness, and edema over foot or ankle, often with a history of minor trauma, and, occasionally, recurrent acute attacks may occur. A minority may have bilateral involvement. Alternatively, there can be a slowly progressing arthropathy with insidious swelling over months or years. Neuroarthropathy of the foot may involve collapse of the arch of the midfoot, leading to bony prominences on the plantar aspect with later pressure ulceration (",
"      <a class=\"graphic graphic_picture graphicRef67753 \" href=\"mobipreview.htm?26/18/26927\">",
"       picture 1",
"      </a>",
"      ). Although the majority of patients experience pain, the severity is less than might be expected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early diagnosis is essential to give the best clinical outcome, and clinicians should have a high index of suspicion for this condition when a diabetic patient presents with a swollen foot. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic evaluation is aimed at confirming the diagnosis by identification of characteristic clinical and radiographic findings and by the exclusion of other conditions, including infection, which could be confused with neuropathic arthropathy. In patients with a joint effusion, we perform synovial fluid analysis to help rule out other conditions, including septic or crystalline arthropathy. Radiographic findings are variable, depending upon the stage and site of the arthropathy. Magnetic resonance imaging may be helpful in some patients, but use of contrast is relatively contraindicated in patients with moderate or greater renal impairment. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important considerations in the differential diagnosis of diabetic neuropathic arthropathy include septic arthritis, cellulitis, gout, calcium pyrophosphate arthropathy, osteoarthritis, idiopathic inflammatory diseases, osteomyelitis, and complex regional pain syndrome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Septic arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Crystal-associated arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Inflammatory arthritides'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Complex regional pain syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the earlier stages of neuropathic arthropathy, the avoidance of weightbearing on the affected joint should be recommended until resolution of edema and erythema occurs, with improvement of radiologic signs. Many consider the total contact cast to be the treatment of choice, with or without an initial period of non-weightbearing immobilization. There is limited evidence for benefit with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      treatment, and there is no evidence of benefit for treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      . Bisphosphonate treatment should not be considered as a substitute for offloading the affected limb. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Acute therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who present later in disease, joint disorganization is often severe and irreversible. Disease of the hindfoot and ankle appears to have a worse prognosis than disease of the midfoot. Deformities are common and can transfer weightbearing to areas that tolerate it poorly and or that may lack sensation. Ulceration and infection commonly ensue. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Joint disorganization and surgical correction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of treatment in these patients is to maintain a stable plantigrade foot that is free of ulceration and infection; this can be difficult to achieve, even with good podiatry and with the use of specialized footwear and orthoses. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical correction is best avoided in most patients. Surgical correction of skeletal deformity following nonunion of a fracture in a neuropathic foot has a relatively high failure rate (over one-quarter of patients), mainly in patients who have active ulceration relating to the deformity at the time of operation; thus, surgery should be postponed until the ulcers have healed. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Joint disorganization and surgical correction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/1\">",
"      Giurini JM, Chrzan JS, Gibbons GW, Habershaw GM. Charcot's disease in diabetic patients. Correct diagnosis can prevent progressive deformity. Postgrad Med 1991; 89:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/2\">",
"      Brower AC, Allman RM. Pathogenesis of the neurotrophic joint: neurotraumatic vs. neurovascular. Radiology 1981; 139:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/3\">",
"      Sinha S, Munichoodappa CS, Kozak GP. Neuro-arthropathy (Charcot joints) in diabetes mellitus (clinical study of 101 cases). Medicine (Baltimore) 1972; 51:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/4\">",
"      Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005; 366:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/5\">",
"      Baumhauer JF, O'Keefe RJ, Schon LC, Pinzur MS. Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study. Foot Ankle Int 2006; 27:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/6\">",
"      Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia 2008; 51:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/7\">",
"      Sequeira W. The neuropathic joint. Clin Exp Rheumatol 1994; 12:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/8\">",
"      Forg&aacute;cs SS. Diabetes mellitus and rheumatic disease. Clin Rheum Dis 1986; 12:729.",
"     </a>",
"    </li>",
"    <li>",
"     Resnick D. Neuroarthropathy. In: Diagnosis of Bone and Joint Disorders, Resnick D, Niwayama G (Eds), WB Saunders, Philadelphia 1981. p.2436.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/10\">",
"      Matricali GA, Bammens B, Kuypers D, et al. High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation. Transplantation 2007; 83:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/11\">",
"      Slowman-Kovacs SD, Braunstein EM, Brandt KD. Rapidly progressive Charcot arthropathy following minor joint trauma in patients with diabetic neuropathy. Arthritis Rheum 1990; 33:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/12\">",
"      Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care 2000; 23:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/13\">",
"      Wukich DK, Sung W, Wipf SA, Armstrong DG. The consequences of complacency: managing the effects of unrecognized Charcot feet. Diabet Med 2011; 28:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/14\">",
"      Edmonds ME, Clarke MB, Newton S, et al. Increased uptake of bone radiopharmaceutical in diabetic neuropathy. Q J Med 1985; 57:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/15\">",
"      Seabold JE, Flickinger FW, Kao SC, et al. Indium-111-leukocyte/technetium-99m-MDP bone and magnetic resonance imaging: difficulty of diagnosing osteomyelitis in patients with neuropathic osteoarthropathy. J Nucl Med 1990; 31:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/16\">",
"      Ahmadi ME, Morrison WB, Carrino JA, et al. Neuropathic arthropathy of the foot with and without superimposed osteomyelitis: MR imaging characteristics. Radiology 2006; 238:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/17\">",
"      H&ouml;pfner S, Krolak C, Kessler S, et al. Preoperative imaging of Charcot neuroarthropathy in diabetic patients: comparison of ring PET, hybrid PET, and magnetic resonance imaging. Foot Ankle Int 2004; 25:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/18\">",
"      Wukich DK, Sung W. Charcot arthropathy of the foot and ankle: modern concepts and management review. J Diabetes Complications 2009; 23:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/19\">",
"      Frykberg RG, Zgonis T, Armstrong DG, et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). J Foot Ankle Surg 2006; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/20\">",
"      Pinzur MS, Lio T, Posner M. Treatment of Eichenholtz stage I Charcot foot arthropathy with a weightbearing total contact cast. Foot Ankle Int 2006; 27:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/21\">",
"      Selby PL, Young MJ, Boulton AJ. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabet Med 1994; 11:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/22\">",
"      Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001; 44:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/23\">",
"      Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 2005; 28:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/24\">",
"      Pakarinen TK, Laine HJ, M&auml;enp&auml;&auml; H, et al. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial. Diabetes Care 2011; 34:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/25\">",
"      Bem R, Jirkovsk&aacute; A, Fejfarov&aacute; V, et al. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care 2006; 29:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/26\">",
"      Bono JV, Roger DJ, Jacobs RL. Surgical arthrodesis of the neuropathic foot. A salvage procedure. Clin Orthop Relat Res 1993; :14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/27\">",
"      Thompson RC Jr, Clohisy DR. Deformity following fracture in diabetic neuropathic osteoarthropathy. Operative management of adults who have type-I diabetes. J Bone Joint Surg Am 1993; 75:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39527/abstract/28\">",
"      Mueller MJ, Sinacore DR, Hastings MK, et al. Effect of Achilles tendon lengthening on neuropathic plantar ulcers. A randomized clinical trial. J Bone Joint Surg Am 2003; 85-A:1436.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5608 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39527=[""].join("\n");
var outline_f38_38_39527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24803269\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Crystal-associated arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inflammatory arthritides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Complex regional pain syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Acute therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Joint disorganization and surgical correction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24803269\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5608\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5608|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?33/34/34349\" title=\"algorithm 1\">",
"      Neuropathic arthropathy in DM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5608|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/46/9967\" title=\"diagnostic image 1A\">",
"      Diabetic neuroarthropathy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/42/15023\" title=\"diagnostic image 1B\">",
"      Diabetic neuroarthropathy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/23/9599\" title=\"diagnostic image 1C\">",
"      Neuropathic disease of foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5608|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/18/26927\" title=\"picture 1\">",
"      Charcot foot",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/33/538?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1526?source=related_link\">",
"      Diabetic muscle infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12534?source=related_link\">",
"      Limited joint mobility in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_38_39528="Treatment of Pseudomonas aeruginosa infections";
var content_f38_38_39528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Pseudomonas aeruginosa infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39528/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39528/contributors\">",
"     Souha S Kanj, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39528/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39528/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39528/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/38/39528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudomonas aeruginosa is one of the most commonly considered gram-negative aerobic bacilli in the differential diagnosis of a number of probable gram-negative infections. This organism is frequently feared because it causes severe hospital-acquired infections, especially in immunocompromised hosts, and is often antibiotic resistant, complicating the choice of therapy.",
"   </p>",
"   <p>",
"    The treatment of infections caused by P. aeruginosa in noncystic fibrosis patients will be reviewed here. The epidemiology, pathogenesis, clinical manifestations and diagnosis of the various pseudomonal infections are discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following principles apply to the treatment of serious P. aeruginosa infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed therapy correlates with increased mortality.",
"     </li>",
"     <li>",
"      All infected catheters should be removed, and, whenever possible, abscesses or obstructions should be drained or removed.",
"     </li>",
"     <li>",
"      Combination therapy is indicated in certain high risk patients and in severe infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Combination versus monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most controversial management questions involves the use of combination or monotherapy for serious infections due to P. aeruginosa.",
"   </p>",
"   <p>",
"    Treatment for serious P. aeruginosa infection is frequently empiric until the organism is isolated and susceptibility testing performed. When a serious P. aeruginosa infection is suspected, especially in febrile neutropenic patients, a combination of an aminoglycoside plus either an extended-spectrum antipseudomonal penicillin or a cephalosporin with in vitro activity against Pseudomonas is recommended by most authorities, but there is no conclusive evidence to support this practice.",
"   </p>",
"   <p>",
"    Commonly cited reasons for combination therapy include the potential for synergistic efficacy as well as the potential benefit of reducing the risk of emergence of resistance. However, there is no evidence that two agents offer improved outcomes for treating P. aeruginosa infections. The best rationale for the use of combination therapy is to provide initial broad spectrum of activity when there is risk for multidrug resistant P. aeruginosa (eg, if the P. aeruginosa is resistant to one agent, it may be susceptible to the other).",
"   </p>",
"   <p>",
"    Studies evaluating the efficacy of combination therapy in the treatment of P. aeruginosa infection have produced conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The authors of a widely quoted retrospective study analyzing data collected more than 20 years ago concluded that combination therapy reduced the mortality rate compared with monotherapy for P. aeruginosa bacteremia (27 versus 47 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/1\">",
"       1",
"      </a>",
"      ]. However, this conclusion was hampered by a number of methodologic problems, including the lack of randomization, the choice of therapy (which may have been influenced by the severity of illness), and monotherapy in many patients consisting of an aminoglycoside alone, which is associated with a mortality as high as 70 to 80 percent when used for the treatment of P. aeruginosa bacteremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A number of subsequent observational studies of Pseudomonas or gram-negative bacteremia reached the conclusion that combination therapy was not superior to monotherapy with a third generation cephalosporin with in vitro activity against Pseudomonas or, in some cases, an aminoglycoside alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/2-7\">",
"       2-7",
"      </a>",
"      ]. A similar lack of benefit was noted in a randomized trial of cancer patients with febrile neutropenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two meta-analyses published in 2004 reached somewhat conflicting conclusions, perhaps due to the different populations studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis evaluated 64 randomized trials comparing beta-lactam monotherapy with combination therapy with a beta-lactam and an aminoglycoside in over 7500 immunocompetent patients who fulfilled criteria for severe infection; most trials did not require demonstration of bacteremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/9\">",
"       9",
"      </a>",
"      ]. There was no survival advantage with combination therapy, even in the subset of 426 patients with P. aeruginosa infection. In addition to lack of benefit, combination therapy was associated with a significant increase in nephrotoxicity.",
"     </li>",
"     <li>",
"      A second meta-analysis evaluated 17 studies (only two were randomized trials) of patients with documented gram-negative bacteremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/10\">",
"       10",
"      </a>",
"      ]. There was no mortality benefit from combination therapy (odds ratio [OR] 0.96). However, there was a significant mortality benefit in the subgroup of patients with P. aeruginosa bacteremia (OR 0.50; 95% CI 0.30-0.79).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies comparing combination therapy with monotherapy in pulmonary infections in patients with cystic fibrosis have shown no differences in outcome, but the density of bacteria was lower in the sputum and the time to the next pulmonary infection requiring hospitalization was more prolonged in patients receiving combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. An in vitro study suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    and imipenem might be an effective combination for preventing the emergence of resistance during treatment of P. aeruginosa infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment strategies in patients with serious P. aeruginosa infections remain controversial, largely because of the paucity of well controlled comparison trials using clinically important end points. Studies indicating that early appropriate antibiotic therapy significantly lowers mortality underscore the need for well-designed comparative trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC CHOICES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon suspicion of P. aeruginosa infection, an aggressive approach for pathogen retrieval should be initiated prior to beginning of the first dose of antimicrobial treatment whenever possible. Delay in treatment has been linked to increased mortality even when a patient is considered clinically stable at the time of initial evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intravenous antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of antimicrobial agents have reliable activity against P. aeruginosa including the following specific drugs within certain antibiotic classes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antipseudomonal penicillins (ticarcillin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"       piperacillin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Combination drugs of a penicillin plus beta-lactamase inhibitor (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Third generation cephalosporins (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , cefoperazone [not available in the United States])",
"     </li>",
"     <li>",
"      Fourth generation cephalosporins (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Monobactam (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Carbapenems (imipenem,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fluoroquinolones (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       Colistin",
"      </a>",
"      (for multi-drug resistant P. aeruginosa)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aminoglycosides (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    ) are frequently used in combination with other antibiotics for the treatment of serious infections but are generally not recommended as single drugs except in treating urinary tract infections.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    has been advocated in combination with other antipseudomonal antibiotics for use in cases of P. aeruginosa bacteremia refractory to standard treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following antibiotics, grouped by class, have reliable activity against P. aeruginosa. Dosing is intravenous unless otherwise specified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antipseudomonal penicillins including ticarcillin (3 g every four hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"       piperacillin",
"      </a>",
"      (4 g every four hours).",
"     </li>",
"     <li>",
"      Combination drugs of a penicillin plus beta-lactamase inhibitor including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      (3.1 g every four hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       piperacillin-tazobactam",
"      </a>",
"      (4.5 g every six hours or 3.375 g every four hours). With administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"       piperacillin",
"      </a>",
"      -tazobactam, the dose is usually given over 30 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tazobactam inhibits AmpC-type beta-lactamases but does not have direct antipseudomonal activity. Such inhibition of AmpC results in a lower MIC for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"     piperacillin-tazobactam",
"    </a>",
"    than for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35030?source=see_link\">",
"     piperacillin",
"    </a>",
"    alone.",
"   </p>",
"   <p>",
"    An extended infusion strategy (3.375 g infused over four hours, every eight hours) is an alternative regimen that may be associated with improved outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/16\">",
"     16",
"    </a>",
"    ]. The proposed mechanism of benefit is that bacterial killing is enhanced if the free serum beta-lactam concentration exceeds the minimum inhibitory concentration of the organism for at least 50 percent of the dosing interval.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Third generation cephalosporins including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (2 g every eight hours) or cefoperazone (2 g every twelve hours, not available in the United States).",
"     </li>",
"     <li>",
"      Fourth generation cephalosporin",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      (2 g every 12 hours).",
"     </li>",
"     <li>",
"      Monobactam",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      (2 g every eight hours).",
"     </li>",
"     <li>",
"      Fluoroquinolones",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg every eight hours). Although",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      has no advantage over ciprofloxacin in anti-pseudomonal coverage and is primarily indicated for the treatment of respiratory tract infections, levofloxacin (750 mg daily) can reasonably be used in the rare situation of a polymicrobial infection that includes susceptible strains of streptococci and P. aeruginosa.",
"     </li>",
"     <li>",
"      Aminoglycosides including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (both dosed 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two or three divided doses) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      (7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours).",
"     </li>",
"     <li>",
"      Carbapenems including imipenem (500 mg every six hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g every eight hours). The propensity of antipseudomonal antibiotics to cause resistance during treatment is highest with imipenem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/17\">",
"       17",
"      </a>",
"      ]. As a result, this drug should be reserved for the treatment of multidrug resistant P. aeruginosa infections or when the infection is polymicrobial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Alternative intravenous agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    may be effective alternative agents for treatment of multi-drug-resistant P. aeruginosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. As an example, in a study of 22 patients with metallo-beta-lactamase-producing Pseudomonas infections, the use of IV colistin was associated with a favorable response, but mild nephrotoxicity occurred in two-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/22\">",
"     22",
"    </a>",
"    ]. It was concluded that colistin may be a useful drug when choices are limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=see_link\">",
"     \"Colistin: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential therapeutic options are still in development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inhaled antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled antibiotics have the theoretical advantage of targeting drug levels to bronchial secretions in patients with pneumonia while reducing potential systemic side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Colistin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled polymyxins have been used successfully in the management of multi-drug resistant P. aeruginosa pneumonia failing to improve on IV therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    in treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa was evaluated in a retrospective study of 21 patients in Singapore [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/24\">",
"     24",
"    </a>",
"    ]. Overall clinical and microbiological response rates were 57 and 86 percent, respectively. Most patients received 1 million units [approximately 80 mg] of colistin twice daily. There was no significant change in renal function or observed neurotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=see_link\">",
"     \"Colistin: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     Colistin",
"    </a>",
"    is approved by the FDA only for intravenous or intramuscular use; it is not approved as a liquid to be inhaled via nebulizer. When the drug is mixed into a liquid form, the product can break down into other chemicals that can damage lung tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/26\">",
"     26",
"    </a>",
"    ]. Instructions regarding preparation of nebulized colistin are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=see_link\">",
"     \"Colistin: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent aerosolization of antibiotics into the respiratory tract using aminoglycosides, antipseudomonal penicillins, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    has been used as adjunctive therapy in the treatment of patients with cystic fibrosis and recurrent episodes of Pseudomonas pneumonia due to increasingly resistant isolates.",
"   </p>",
"   <p>",
"    One study has shown that endotracheal administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    plus intravenous therapy increased bacterial eradication from the sputum compared with intravenous administration alone; however, the overall clinical outcome did not change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study evaluated the effect of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    (80 mg twice daily for 12 months) on early P. aeruginosa colonization in patients with CF. Eradication was confirmed by sequential respiratory cultures and serum antibody titers that were negative for P. aeruginosa. This regimen was found to maintain pulmonary function at high levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/28\">",
"     28",
"    </a>",
"    ]. Inhaled tobramycin also improved pulmonary function and was associated with weight gain in adolescent patients with CF over a two year period of long-term, intermittent use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pending more data on therapy, we do not recommend routine use of inhaled antibiotics for the treatment of P. aeruginosa pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of mechanisms of acquired resistance to P. aeruginosa have been described. Acquired resistance results from mutation or acquisition of exogenous resistance determinants and can be mediated by a number of mechanisms, including degrading enzymes, reduced permeability, and active efflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. With respect to degrading enzymes, plasmid-mediated extended spectrum beta-lactamases (ESBLs) have been described at a limited number of geographic sites. TEM, SHV and CTX-M ESBLs have been reported in P. aeruginosa, but are uncommon; VEB ESBLs are prevalent in the species in East Asia and are now scattered elsewhere, and PER types are widespread in Turkey. These enzymes confer high-level resistance to antipseudomonal cephalosporins and some, such as PER-1, also degrade cephems and monobactams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential impact of PER-1 was illustrated in a series of 26 P. aeruginosa bloodstream infections (BSIs) from Siena, Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/30\">",
"     30",
"    </a>",
"    ]. Nine expressed PER-1 and the other 17 did not express any ESBL. Seven of the nine PER-1 BSIs failed to respond to antibiotic therapy, including carbapenems. In comparison, only 4 of 14 non-ESBL BSIs failed to respond, including only one of eight treated with a carbapenem.",
"   </p>",
"   <p>",
"    Resistance to carbapenems, particularly imipenem, can arise by simple mutation resulting in the loss of a carbapenem-specific porin, OprD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/32\">",
"     32",
"    </a>",
"    ]. Less often, metallo-beta-lactamases (MBLs) are responsible: VIM and IMP MBLs have been reported internationally, whereas clones with SPM-1 enzymes have disseminated in Brazil. Some have caused major outbreaks, with dozens to hundreds of patients affected over prolonged periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also conflicting evidence about the ability of combination therapy to prevent the emergence of antimicrobial resistance in patients with P. aeruginosa bacteremia. Emergence of resistance during therapy for P. aeruginosa infections can occur, resulting in increased rates of morbidity and mortality and higher costs. Combination therapy with two antipseudomonal antimicrobial agents limited the risk of emergence of resistant pseudomonal strains compared to monotherapy in an animal model of pseudomonal peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are little or no clinical confirmatory data for the above conclusions. Most studies of human P. aeruginosa infections have been underpowered to address this question. An observational study reported that resistant P. aeruginosa emerged in 10.2 percent of 271 cases during treatment with four individual antipseudomonal agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/17\">",
"     17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     Ceftazidime",
"    </a>",
"    was associated with the lowest risk and imipenem with the highest risk. Addition of an aminoglycoside did not alter this risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of supportive data, we advocate empiric treatment with at least two agents from different classes with in vitro activity against P. aeruginosa in the following cases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumonia",
"     </li>",
"     <li>",
"      Meningitis",
"     </li>",
"     <li>",
"      Bacteremia in the neutropenic patient",
"     </li>",
"     <li>",
"      When signs of septic shock are present",
"     </li>",
"     <li>",
"      When there has not been a prompt (eg, within 48 hours) response to monotherapy",
"     </li>",
"     <li>",
"      In settings of high incidence of antimicrobial resistant P. aeruginosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The basis for these recommendations is that mortality in pneumonia due to P. aeruginosa is notoriously high. In addition, high-risk neutropenic patients die rapidly from P. aeruginosa bacteremia. Finally, the potential risk for emergence of resistance is high in patients with pneumonia since eradication of P. aeruginosa from bronchial secretions is difficult or impossible in most cases, even when the clinical signs of pneumonia improve with therapy.",
"   </p>",
"   <p>",
"    Aminoglycosides should be one of the drugs used for combination therapy in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacteremia in the neutropenic patient",
"     </li>",
"     <li>",
"      Endocarditis",
"     </li>",
"     <li>",
"      Meningitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An aminoglycoside should not be used as monotherapy for pneumonia because they perform poorly in an acidic environment. Aminoglycosides should also be avoided in patients with renal insufficiency or in those hospitalized in institutions with a high percentage of P. aeruginosa resistant to aminoglycosides. When using combination therapy that includes an aminoglycoside, the aminoglycoside can be discontinued after culture and susceptibility results return if the risk of toxicity is judged to be high or if signs of toxicity appear during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of severe immunodeficiency, invasive infection due to P. aeruginosa bacteremia at the time of hospital admission is rare. Among patients with suspected gram-negative rod bacteremia, empiric anti-pseudomonal treatment is warranted for patients with &ge;2 of the following predictors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe immunodeficiency",
"     </li>",
"     <li>",
"      Age &gt;90 years",
"     </li>",
"     <li>",
"      Receipt of antimicrobial therapy within the past 30 days",
"     </li>",
"     <li>",
"      Presence of central venous catheter or urinary device",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of this approach was illustrated in a review of 4114 episodes of gram-negative rod bacteremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among 250 cases of gram-negative rod bacteremia in the absence of severe immunodeficiency, the risk of P. aeruginosa bacteremia was substantially higher for patients with &ge;2 predictors than for those with no predictors (1:3 versus 1:42, respectively).",
"   </p>",
"   <p>",
"    The choice of empiric therapy varies with the severity of the infection. Treatment with two agents active against Pseudomonas is appropriate in the setting of neutropenia, serious infection (eg, meningitis, bacteremia, endocarditis, pneumonia) and in burn patients (because of a high likelihood of multidrug resistant P. aeruginosa). Treatment with one agent active against Pseudomonas is appropriate for urinary tract infections and infections of the skin, soft tissue and bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment choices for known Pseudmonas infection should be guided by susceptibility testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Skin, soft tissue, and bone infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin, soft tissue, and bone infections may treated with a beta-lactam, carbapenem or fluoroquinolone agent listed above; in general aminoglycosides should not be used for infection at these sites.",
"   </p>",
"   <p>",
"    The usual duration of antimicrobial therapy for skin and soft tissue infection is 10 to 14 days. Occasional patients will continue to have local signs of cellulitis at the end of two weeks of treatment. We recommend continued oral antibiotic therapy in these patients until resolution of all erythema has occurred.",
"   </p>",
"   <p>",
"    The usual duration of antimicrobial therapy for osteomyelitis is six weeks following surgical debridement. If the isolate is fluoroquinolone susceptible, therapy may be with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (750 mg twice daily).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Urinary tract infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy with one of the antibiotics listed above. Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg PO twice daily) has been successfully used in the treatment of complicated P. aeruginosa UTI. Treatment of resistant isolates must be tailored to susceptibility data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32503?source=see_link&amp;anchor=H17#H17\">",
"     \"Other Pseudomonas aeruginosa infections\", section on 'Urinary tract infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of treatment for P. aeruginosa UTI is three to five days for simple cystitis, at least 14 days for urosepsis, two to three weeks for pyelonephritis, and longer for intrarenal and perinephric abscesses.",
"   </p>",
"   <p>",
"    The value of chronic suppression following a curative course of antibiotics for P. aeruginosa UTI is limited by the lack of truly effective oral agents with significant antipseudomonal activity. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    usually has good in vitro activity against P. aeruginosa, this agent often rapidly induces the development of resistance when used for suppression.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/57/3989?source=see_link\">",
"     Methenamine",
"    </a>",
"    &nbsp;salt administered in combination with ascorbic acid has been used by some for chronic suppression of P. aeruginosa UTI, but we do not endorse this practice since the long term efficacy of this agent is poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of P. aeruginosa pneumonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the neutropenic patient, we suggest treatment with combination therapy using two antibiotics from different classes to which the isolate is susceptible; one antibiotic should be an aminoglycoside, unless the use is precluded by nephrotoxicity. In the nonneutropenic patient, unless the patient is septic, antimicrobial therapy with one of the antibiotics listed above except for an aminoglycoside. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14775?source=see_link\">",
"     \"Pseudomonas aeruginosa bacteremia and endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In neutropenic patients with P. aeruginosa bacteremia, treatment should be continued for at least 14 days or longer until recovery of the neutrophil count. By contrast, when bacteremia is secondary to a central venous or an indwelling urinary catheter infection and the patient is a nonneutropenic host, treatment can be stopped after 7 to 10 days if the catheter has been removed and the patient has responded promptly to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with two antibiotics from different classes to which the isolate is susceptible; one antibiotic should be an aminoglycoside, unless the use is precluded by nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14775?source=see_link\">",
"     \"Pseudomonas aeruginosa bacteremia and endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of therapy should be for at least six weeks.",
"   </p>",
"   <p>",
"    Tricuspid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonic valvulectomy without immediate replacement is indicated in patients with right sided endocarditis who remain bacteremic after two weeks of therapy or relapse after a six week course. This procedure has an 80 percent success rate and can be followed by tricuspid valve replacement six to eight months later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with two antibiotics from different classes to which the isolate is susceptible; one antibiotic should be an aminoglycoside, unless the use is precluded by nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=see_link\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend at least 21 days of therapy, although therapy should be individualized. Repeat CSF analysis and culture should confirm clearance of the organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Alternative therapy in multidrug resistant infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some severe cases of multidrug resistant P. aeruginosa,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    is the only therapeutic option, despite its well known propensity for causing nephrotoxicity and ototoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/36\">",
"     36",
"    </a>",
"    ]. Intravenous colistin was shown to be useful as salvage therapy in a nonrandomized case series of 23 patients, 14 of whom had septic shock and 21 of whom had preexisting renal failure requiring dialysis; 18 of the patients had P. aeruginosa pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/37\">",
"     37",
"    </a>",
"    ]. All isolates were sensitive to colistin; 12 were sensitive or intermediate to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    . All patients required dose adjustment for creatinine clearance according to the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate renal dysfunction (serum creatinine 1.6 to 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [141 to 221",
"      <span class=\"nowrap\">",
"       &micro;mol/L]):",
"      </span>",
"      5.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided into 2 doses administered at 12 hour intervals.",
"     </li>",
"     <li>",
"      Severe renal dysfunction (serum creatinine 2.6 to 4.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [230 to 354",
"      <span class=\"nowrap\">",
"       &micro;mol/L]):",
"      </span>",
"      2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day as a single dose.",
"     </li>",
"     <li>",
"      Serum creatinine above 4.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (354",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      or in hemodialysis patients: 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day as a single dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of treatment ranged from seven to 36 days. A favorable outcome was observed in 14 of the 23 patients (61 percent), although three of these patients subsequently relapsed; seven patients died during therapy and only nine survived the hospitalization. One of the two patients not on dialysis at the start of therapy developed renal failure requiring dialysis while on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    for the treatment of multidrug resistant P. aeruginosa is also a reasonable and safe treatment option. Twelve critically ill patients with P. aeruginosa respiratory tract infections received polymyxin B in combination with other antipseudomonal agents in a recent study. All isolates were susceptible to polymyxin B. None of the patients died at the end of therapy although 20 percent of them did not survive to discharge. Nephrotoxicity occurred in three patients but did not require discontinuation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Combination therapy for highly resistant infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The difficulty in treating P. aeruginosa infections caused by strains that are resistant to all or all but one antibiotic has led investigators to use novel combinations of drugs that separately have no activity against the isolate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vitro studies identified the following regimens of drugs as having enhanced activity in combination:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ticarcillin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/20/17733?source=see_link\">",
"       Polymyxin B",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A fluoroquinolone plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       Clarithromycin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      plus one of the following:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/14/43238?source=see_link\">",
"       Colistin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanisms for the enhanced activity are unknown for most combinations.",
"   </p>",
"   <p>",
"    There is little clinical data to support such combination therapy. A single clinical series of 64 nosocomial pulmonary infections with a highly resistant P. aeruginosa used the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , the least inactive antibiotics by MIC determination and those which showed synergy in vitro, for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/46\">",
"     46",
"    </a>",
"    ]. All patients were treated with this combination and 44 (69 percent) survived. Controlled clinical trials are necessary to determine whether novel combinations provide efficacy against these infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pseudomonas in chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolation of P. aeruginosa from sputum samples of adult patients with COPD is associated with advanced pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one cross-sectional study, Miravitlles et al documented that patients with a predicted FEV1 of less than 50 percent were more likely to have H. influenzae or P. aeruginosa isolated from sputum during exacerbations than patients with less severe impairment of pulmonary function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study by Eller et al demonstrated that in patients with predicted FEV1 of less than 35 percent Enterobacteriaceae and Pseudomonas species were the predominant isolated bacteria from sputum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lode et al recognized that the presence of enteric gram-negative bacilli and P. aeruginosa in the sputum of patients during exacerbations could be predicted by severe airflow obstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39528/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Furthermore, exacerbations in the presence of P. aeruginosa in the sputum are linked to respiratory failure and the need for mechanical ventilation. These interpretations may suggest that P. aeruginosa is a more frequent cause of infection as COPD progresses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There exists a subset of patients with COPD who become chronically colonized with P. aeruginosa, but whether such patients benefit from antimicrobial therapy is still unclear.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/1\">",
"      Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/2\">",
"      Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/3\">",
"      Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/4\">",
"      Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/5\">",
"      Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/6\">",
"      Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/7\">",
"      Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/8\">",
"      Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/9\">",
"      Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/10\">",
"      Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/11\">",
"      McLaughlin FJ, Matthews WJ Jr, Strieder DJ, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983; 147:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/12\">",
"      Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/13\">",
"      Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005; 40 Suppl 2:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/14\">",
"      El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009; 64:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/15\">",
"      Korvick JA, Peacock JE Jr, Muder RR, et al. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using the Zelen protocol. Antimicrob Agents Chemother 1992; 36:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/16\">",
"      Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/17\">",
"      Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/18\">",
"      Furtado GH, d'Azevedo PA, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/19\">",
"      Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/20\">",
"      Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007; 30:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/21\">",
"      Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/22\">",
"      Sabuda DM, Laupland K, Pitout J, et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008; 19:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/23\">",
"      Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B. Diagn Microbiol Infect Dis 2007; 58:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/24\">",
"      Kwa AL, Loh C, Low JG, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005; 41:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/25\">",
"      Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000; 162:328.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/cder/drug/advisory/colistimethate.htm (Accessed on July 30, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/27\">",
"      Brown RB, Kruse JA, Counts GW, et al. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. The Endotracheal Tobramycin Study Group. Antimicrob Agents Chemother 1990; 34:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/28\">",
"      Ratjen F, D&ouml;ring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/29\">",
"      Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/30\">",
"      Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/31\">",
"      Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11 Suppl 4:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/32\">",
"      Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 Suppl 1:i29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/33\">",
"      Mich&eacute;a-Hamzehpour M, Pech&egrave;re JC, Marchou B, Auckenthaler R. Combination therapy: a way to limit emergence of resistance? Am J Med 1986; 80:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/34\">",
"      Mich&eacute;a-Hamzehpour M, Auckenthaler R, Regamey P, Pech&egrave;re JC. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987; 31:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/35\">",
"      Schechner V, Nobre V, Kaye KS, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis 2009; 48:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/36\">",
"      Levin AS, Barone AA, Pen&ccedil;o J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/37\">",
"      Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:e154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/38\">",
"      Sobieszczyk ME, Furuya EY, Hay CM, et al. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 2004; 54:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/39\">",
"      Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/40\">",
"      Zuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J Lab Clin Med 1983; 101:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/41\">",
"      Urena MT, Barasoain I, Espinosa M, et al. Evaluation of different antibiotic actions combined with rifampicin. In vitro synergism against Pseudomonas and Proteus. Chemotherapy 1975; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/42\">",
"      Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002; 50:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/43\">",
"      Gunderson BW, Ibrahim KH, Hovde LB, et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/44\">",
"      Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002; 46:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/45\">",
"      Timurkaynak F, Can F, Azap OK, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/46\">",
"      Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol 2001; 39:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/47\">",
"      Murphy TF. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2009; 15:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/48\">",
"      Miravitlles M, Espinosa C, Fern&aacute;ndez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/49\">",
"      Eller J, Ede A, Schaberg T, et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39528/abstract/50\">",
"      Lode H, Allewelt M, Balk S, et al. A prediction model for bacterial etiology in acute exacerbations of COPD. Infection 2007; 35:143.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3135 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3A9BE56C6A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39528=[""].join("\n");
var outline_f38_38_39528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Combination versus monotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIBIOTIC CHOICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intravenous antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Alternative intravenous agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inhaled antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Colistin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Directed therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Urinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Alternative therapy in multidrug resistant infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Combination therapy for highly resistant infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pseudomonas in chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23031?source=related_link\">",
"      Colistin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/47/32503?source=related_link\">",
"      Other Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14775?source=related_link\">",
"      Pseudomonas aeruginosa bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_38_39529="Clinical implications of ischemic preconditioning";
var content_f38_38_39529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical implications of ischemic preconditioning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39529/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39529/contributors\">",
"     Derek J Hausenloy, MD, PhD, MRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39529/contributors\">",
"     Derek M Yellon, PhD, DSc, Hon FRCP, FACC, FESC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39529/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39529/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39529/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/38/39529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myocardium possesses innate physiologic adaptive processes that render it more resistant to potentially lethal ischemic injury. A number of these adaptive mechanisms have been identified; one is the phenomenon of ischemic preconditioning which provides the myocardium with the most powerful means of protecting itself against myocardial infarction that has been identified. A related phenomenon is ischemic postconditioning, which may have greater therapeutic implications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic preconditioning refers to the protection conferred to ischemic myocardium by preceding brief periods of sublethal ischemia.",
"     </li>",
"     <li>",
"      Ischemic postconditioning refers to the ability of a series of brief coronary artery occlusions after a severe ischemic insult to protect against ischemic-reperfusion injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other protective mechanisms include the long-term development of coronary collateral vessels and myocardial hibernation and stunning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8216?source=see_link\">",
"     \"Coronary collateral circulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence for the existence of ischemic preconditioning and postconditioning in the human myocardium and possible future therapeutic applications of these phenomena will be reviewed here. The definition and pathogenesis of ischemic preconditioning are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISCHEMIC PRECONDITIONING IN HUMAN MYOCARDIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic preconditioning was originally described by Murry and coworkers as the protection conferred to ischemic myocardium by preceding brief periods of sublethal ischemia separated by periods of reperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/1\">",
"     1",
"    </a>",
"    ]. In this report, four five-minute episodes of regional ischemia in the canine myocardium, each followed by a five-minute period of reperfusion, resulted in preservation of high energy phosphates, and significantly protected against myocardial necrosis during a subsequent prolonged period of ischemia. The net effect was a 75 percent reduction in infarct size compared to a control group of dogs.",
"   </p>",
"   <p>",
"    There are obvious ethical constraints to studying ischemic preconditioning in humans. Despite these limitations, there are now several lines of evidence suggesting that the human myocardium can be preconditioned [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/2\">",
"     2",
"    </a>",
"    ]. This evidence arises from in vitro experiments with human atrial trabeculae and ventricular myocytes, studies in patients with naturally occurring ischemic syndromes such as \"warm-up\" angina, unstable or preinfarction angina, and variant angina, and studies in patients undergoing revascularization procedures which inevitably involve brief periods of ischemia such as percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     In vitro studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human atrial trabeculae obtained at the time of surgery have been suspended in an organ bath and subjected to sustained periods of simulated ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/3\">",
"     3",
"    </a>",
"    ]. Subjecting the muscle to a brief period of simulated ischemia prior to an episode of sustained ischemia preconditioned the tissue, as evidenced by improved percentage recovery of tension during reoxygenation. Similar findings have been demonstrated in ventricular myocytes in cell culture using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/50/27426?source=see_link\">",
"     trypan blue",
"    </a>",
"    exclusion and metabolic end points of injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenosine A1 receptors, protein kinase C, and ATP-dependent potassium (KATP) channels may play a role in this protective response as they do in animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The role of KATP was demonstrated in this in vitro model by studies involving atrial trabeculae obtained from patients taking oral hypoglycemic sulfonylurea agents, which block KATP channels; these tissues were not protected by ischemic preconditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Warm-up angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Warm-up angina\" refers to the improvement in anginal symptoms reported by some patients during the course of the day or after a period of exertion. Exercise sufficient to induce ischemia will improve the anginal threshold during a subsequent period of exercise later in the same day. If the first period of exercise is not sufficient to induce ischemia, no such effect is seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms responsible for this adaptation to ischemia have been investigated in studies of consecutive exercise testing or consecutive ischemia secondary to pacing-induced tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. These reports have documented a reduction in the severity of angina, the degree of ST segment depression, and the degree of exercise-induced left ventricular wall motion abnormalities during the second period of ischemia, independent of the intensity of the exercise protocol.",
"   </p>",
"   <p>",
"    The warm-up effect was illustrated in a study of 32 patients with multivessel coronary disease who performed two bicycle exercise tests 30 minutes apart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/13\">",
"     13",
"    </a>",
"    ]. The onset of chest pain or 1 mm ST segment depression occurred later and at a higher rate-pressure product in the second test. In addition, regions of the left ventricle that developed dysfunction in the first test showed improved function in the second test.",
"   </p>",
"   <p>",
"    Preconditioning triggered by exercise-induced demand ischemia is not abolished by sulfonylureas which block KATP channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/11\">",
"     11",
"    </a>",
"    ]. Recruitment of collateral vessels also did not appear to play a role, as evidenced by similar coronary and great cardiac vein blood flow measurements. These findings suggest that warm up angina is due to a rapid metabolic adaptation of the myocardium, which induces tolerance to subsequent ischemia, a process that closely resembles classic ischemic preconditioning in animals.",
"   </p>",
"   <p>",
"    The \"warm-up\" phenomenon with exercise may reflect both early, or \"first window,\" preconditioning and late, or \"second window,\" preconditioning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    .) This biphasic effect was described in an analysis of 30 patients with stable angina and a known LAD stenosis who presented for elective PCI and were randomly assigned to one of two exercise testing protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"early\" group, who underwent three exercise tests at times 0, 15 min, and 90 min, followed by PCI 14 days later",
"     </li>",
"     <li>",
"      The \"late\" group, who underwent the same first three exercise tests as the early group, followed by two more exercise tests, 15 min apart, 24 hours after the first three, followed by PCI 4 hours later",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the exercise studies, early ischemic preconditioning was demonstrated in both groups by a significantly greater duration to onset of ischemia (477 versus 356 sec) and rate-pressure product at onset of ischemia (17 percent higher) on the second versus the first exercise test; these effects were attenuated by the time of the third exercise test.",
"   </p>",
"   <p>",
"    In the late group, the enhanced exercise duration and rate-pressure product recurred in the fourth test; there was no further enhancement for the fifth test. During the first balloon inflation at PCI, peak ST segment elevation was significantly reduced in the late group compared to the early group (0.29 versus 0.59 mV). Both of these findings demonstrate late ischemic preconditioning.",
"   </p>",
"   <p>",
"    In contrast to patients with chronic stable angina, those with cardiac syndrome X (angina with normal coronary arteries) do not manifest a \"warm-up\" phenomenon in response to repeated exercises testing. A possible explanation is that the ischemic stimulus in cardiac syndrome X is too mild to induce preconditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19864?source=see_link\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preinfarction or unstable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the outcome of patients suffering an acute myocardial infarction in relation to the presence of preinfarction angina. Reports in the thrombolytic era have suggested that patients with a history of preinfarction angina have a",
"    <strong>",
"     more favorable outcome",
"    </strong>",
"    than those without prior angina. This beneficial effect of angina occurring 24 to 48 hours before infarction may not be seen in diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] or among elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]; however, in older adults, a high level of physical activity preserves the cardioprotective effect of preinfarction angina and is associated with a lower in-hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17705?source=see_link\">",
"     \"Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings have been observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Smaller infarct size, based upon peak or total cardiac enzyme release [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/21-23\">",
"       21-23",
"      </a>",
"      ], associated with a greater degree of myocardial viability in the infarct-related area [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Improved left ventricular function and regional wall motion with reduced frequency of severe congestive heart failure and more rapid recovery of contractile function after the infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/16,22,23,25-27\">",
"       16,22,23,25-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced occurrence of life-threatening ventricular arrhythmias associated with reperfusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/21,28\">",
"       21,28",
"      </a>",
"      ]. Preinfarction angina also protects against out-of-hospital ventricular fibrillation, primarily in those with an occlusion of the left anterior descending artery (odds ratio 0.25 compared with no preinfarction angina) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lower in-hospital and one year cardiac mortality rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with an acute inferior myocardial infarction, lower rate of right ventricular infarction and reduction in the incidence of hypotension and shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=see_link\">",
"       \"Right ventricular myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the TIMI 4 trial, for example, 218 patients with and 198 patients without a history of previous angina at any time were compared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/22\">",
"     22",
"    </a>",
"    ]. The patients with previous angina had a significantly lower rate of in-hospital mortality (3 versus 8 percent), of the combined end points of mortality, congestive heart failure, and shock (4 versus 12 percent), and decreased infarct size (119 versus 154 CK integrated units). Similar trends were noted in the patients who had angina within 48 hours of the myocardial infarction compared to those without preinfarction angina.",
"   </p>",
"   <p>",
"    In a second study, the in-hospital outcome of 2264 patients with an acute myocardial infarction was analyzed based upon the presence or absence of prior infarction and the presence or absence of previous angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/31\">",
"     31",
"    </a>",
"    ]. The in-hospital mortality was lower in patients with previous angina who had a first infarct (6.9 versus 11.4 percent in those without previous angina, p&lt;0.01) or a prior infarct (17.7 versus 25.3 percent, p&lt;0.05) (",
"    <a class=\"graphic graphic_figure graphicRef61136 \" href=\"mobipreview.htm?34/36/35406\">",
"     figure 1",
"    </a>",
"    ). The improvement in survival was largely due to fewer deaths from myocardial rupture in patients with a first infarct and to fewer deaths from congestive heart failure or cardiogenic shock in those with a prior infarct (",
"    <a class=\"graphic graphic_figure graphicRef81307 \" href=\"mobipreview.htm?17/5/17501\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The occurrence of angina prior to an acute myocardial infarction also reduces the event rate after hospital discharge. Among 3002 patients entered into the TIMI-9B study, those who had angina within 24 hours of myocardial infarction had a lower 30 day event rate (mortality, recurrent infarction, heart failure or shock) compared to patients with angina more than 24 hours before the infarction (4 versus 17 percent, P = 0.03) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/32\">",
"     32",
"    </a>",
"    ]. This benefit was not based upon differences in the use of antianginal medications or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . A history of any angina alone was not associated with a reduced event rate.",
"   </p>",
"   <p>",
"    This improvement in outcome with preinfarction angina is independent of the coronary collateral score, cardiovascular risk factors, and antianginal drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, the time interval between the last episode of angina and the index myocardial infarction appears to be important. The available evidence suggests that prodromal angina is only protective if it occurs within 24 to 48 hours of myocardial infarction; a time-course that corresponds to that of the delayed phase of myocardial protection following ischemic preconditioning in animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link\">",
"     \"Definition and pathogenesis of ischemic preconditioning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential efficacy of prodromal angina was illustrated in a study of 350 patients with an acute anterior wall MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/33\">",
"     33",
"    </a>",
"    ]. The 89 patients who had angina within 24 hours of the infarction, compared to those without prodromal angina, had significant increases in the rates of reperfusion with a thrombolytic agent (76 versus 56 percent) and attainment of a patent infarct-related artery (34 versus 22 percent), a significantly lower rate of in-hospital mortality (6 versus 14 percent), and a higher rate of five-year survival (86 versus 73 percent). Previous angina at any time before the infarction was associated with a nonsignificant lower rate in-hospital mortality (9 versus 15 percent without previous angina), and there was no significant difference in five-year survival between patients with previous angina at any time and those without angina (79 versus 74 percent).",
"   </p>",
"   <p>",
"    The mechanism of protection conferred by preinfarction angina is not known. It is possible that both \"classic\" and delayed ischemic preconditioning are important. In addition, some investigators have suggested other mechanisms which are not mutually exclusive from ischemic preconditioning. One such mechanism is more rapid thrombolysis, leading to earlier reperfusion of the infarct-related artery following thrombolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/34\">",
"     34",
"    </a>",
"    ], due, in part, to an adenosine-mediated mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/35\">",
"     35",
"    </a>",
"    ]; however, this finding has not been confirmed in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/23\">",
"     23",
"    </a>",
"    ]. Another possible mechanism was suggested in an animal study in which a brief period of antecedent ischemia attenuated platelet-mediated thrombosis in damaged and stenotic coronary arteries and improved vessel patency, due primarily to an adenosine-mediated effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Variant angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have variant angina, the result of coronary artery vasospasm, represent another group with repeated episodes of spontaneous ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    .) One study of 10 such patients utilized 24 hour ambulatory monitoring; an average of 150 episodes of ST segment elevation were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/37\">",
"     37",
"    </a>",
"    ]. Episodes of ST segment elevation separated from the previous one by less than 30 minutes were less often associated with complex ventricular arrhythmias than those separated by a longer period (3 versus 29 percent, p = 0.0001) despite a similar magnitude and duration of ST segment elevation. Similarly, in patients with clusters of two to six ischemic episodes, complex ventricular arrhythmia was more frequently seen in the first (92 percent) than the last (23 percent) episode of the cluster, even though the degree of ST segment elevation was similar and the ischemic duration was shorter in the first compared to the last episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Percutaneous coronary intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCI provides a unique opportunity to study the response of the human myocardium to brief periods of controlled ischemia and reperfusion. Some studies have evaluated various indices of myocardial ischemia including clinical, electrocardiographic, metabolic and hemodynamic measurements during consecutive balloon inflations in patients undergoing elective PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. These reports have consistently shown that, if the duration of the first balloon inflation is longer than a \"threshold\" of about 60 to 90 seconds, all indices of myocardial ischemia, including angina severity, left ventricular wall motion abnormalities, reduction in left ventricular ejection fraction, ST segment elevation, QT dispersion, ventricular ectopic activity, creatine kinase levels, and lactate production are attenuated during subsequent balloon inflations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. Preconditioning during PCI is not, however, seen in elderly patients, possibly because of attenuated activation of the KATP channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/45\">",
"     45",
"    </a>",
"    ]. Assessments of the collateral circulation by angiographic grading of the collateral vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/39\">",
"     39",
"    </a>",
"    ] or measurement of cardiac vein flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/38\">",
"     38",
"    </a>",
"    ] during successive balloon inflations, have shown that, although collateral recruitment occurs in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/46\">",
"     46",
"    </a>",
"    ], it cannot explain the adaptation observed in others. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8216?source=see_link\">",
"     \"Coronary collateral circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in the in vitro studies described above and in animal models, both KATP channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/47\">",
"     47",
"    </a>",
"    ] and adenosine receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/48,49\">",
"     48,49",
"    </a>",
"    ] appear to participate in the increased tolerance to successive balloon inflations during PCI. In one report, for example, the intracoronary infusion of adenosine prior to PCI mimicked the protective effects of the first balloon inflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/49\">",
"     49",
"    </a>",
"    ]. In addition, a role for bradykinin and activation of bradykinin B2 receptors is suggested by a series of 30 patients in which pretreatment with bradykinin, 10 minutes before angioplasty, significantly attenuated the amount of ischemia during the first balloon inflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/50\">",
"     50",
"    </a>",
"    ]. The ST segment shift and chest pain score during the first balloon inflation in the bradykinin treated patients were the same as those during the third balloon inflation in the control group, indicating that the degree of protection from bradykinin was comparable to that due to prior exposure to brief ischemia.",
"   </p>",
"   <p>",
"    Additional evidence has suggested a role for opioid receptors in mediating ischemic preconditioning during PCI. For example, one study of 20 patients found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , an opioid receptor antagonist, abolished the adaptation to ischemia observed after two sequential coronary balloon inflations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/51\">",
"     51",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coronary artery bypass graft surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing cardiac surgery are subject to myocardial ischemia that is both planned and of moderate severity. The most direct evidence for preconditioning in humans has emerged from a study in patients undergoing cardiac surgery in which the resistance to global ischemia was assessed; changes in collateral flow do not play a role in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/52\">",
"     52",
"    </a>",
"    ]. Intermittent application of the aortic cross clamp was used to deliver repeated episodes of global ischemia to provide the preconditioning stimulus. Patients subjected to this protocol had better preservation of ATP levels in myocardial biopsies during a subsequent 10 minute period of global ischemia. These metabolic changes were almost identical to those seen in a dog model of ischemic preconditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study, using the same preconditioning protocol, monitored serum troponin T as a marker of myocardial cell necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/54\">",
"     54",
"    </a>",
"    ]. Prior to surgery, troponin T was not detectable in the serum in any patient. At 72 hours after surgery, patients in the preconditioned group had significantly lower serum troponin T concentrations than those who were not preconditioned (0.3 versus 1.4",
"    <span class=\"nowrap\">",
"     &micro;g/L).",
"    </span>",
"    We have confirmed this finding in subsequent studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, applying this preconditioning protocol when using hypothermia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardioplegic arrest has produced mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. In addition, preconditioning in cardiac surgery has met with resistance because intermittent cross-clamping can prolong surgery by 15 to 30 minutes, represents an embolic risk, and has not been examined in terms of mortality and morbidity. In addition, ischemic preconditioning in cardiac surgery may offer no more protection than the drugs used for premedication (opioids) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/58\">",
"     58",
"    </a>",
"    ] and anesthesia (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/59\">",
"     59",
"    </a>",
"    ], and cardiopulmonary bypass itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other studies, pharmacologic preconditioning with adenosine or adenosine agonists produced negative results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/55,59\">",
"     55,59",
"    </a>",
"    ], while bradykinin was only weakly cardioprotective and produced significant hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Role of nitroglycerin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that endogenous nitric oxide plays a role in delayed preconditioning suggests that nitric oxide releasing agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , may protect the human myocardium against later ischemia. This concept was tested in a study of 66 patients who were randomly assigned to a four hour infusion of nitroglycerin or saline placebo and underwent PCI the following day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to placebo, the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    markedly enhanced the tolerance of the heart to ischemia associated with repeated balloon inflations; there was an attenuation of regional wall motion abnormalities, ST segment shifts, and chest pain. Collateral blood flow was the same in the two groups. In an animal model, the cardioprotective effect of nitroglycerin was maintained for at least 72 hours and was not affected by the development of nitrate tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent study used the same protocol of four hour infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or saline placebo in a crossover design 24 to 28 hours before exercise stress testing in 28 patients with stable angina and known ischemia on stress testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/64\">",
"     64",
"    </a>",
"    ]. Nitroglycerin pretreatment was associated with an increase in workload during the test as manifested by a higher peak rate-pressure product and a 40 second increase in exercise duration. Despite the increase in workload, there were significant improvements in the ECG manifestations of ischemia as measured by maximal ST segment depression, the sum of ST segment depressions, and time to resolution of ST segment depression. Whether similar evidence of late preconditioning is induced by standard oral nitrate therapy is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THERAPEUTIC APPLICATIONS OF PRECONDITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence outlined above demonstrates that the human myocardium is amenable to preconditioning and that preconditioning occurs as a natural feature of some ischemic syndromes. This suggests that there are possible areas in clinical medicine in which therapeutic preconditioning may be utilized to benefit patients with ischemic heart disease.",
"   </p>",
"   <p>",
"    Early and complete reperfusion remains the most effective means of limiting ischemic injury. However, the time interval between the onset of symptoms and the initiation of reperfusion is crucial; reperfusion should optimally be achieved within 70 minutes with the benefits of treatment diminishing as the interval increases (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"mobipreview.htm?30/18/31021\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/54,65,66\">",
"     54,65,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the majority of ischemic cardiac events are unheralded, there are certain situations in which the attending clinician can control the timing of treatment prior to the onset of potentially lethal ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute coronary syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite pharmacologic and interventional approaches in patients with unstable angina, there is still an appreciable incidence of death or myocardial infarction within 30 days. These patients may comprise a reasonably well-defined cohort who might benefit from pretreatment with agents that trigger or augment myocardial preconditioning over a period of several days or weeks, maintaining the myocardium in a protected or \"preconditioned\" state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29257?source=see_link\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44361?source=see_link&amp;anchor=H22#H22\">",
"     \"Epidemiology of coronary heart disease\", section on 'Non-ST elevation ACS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of these patients may be naturally preconditioned by their preceding ischemic episodes. As described above, however, protection is not observed unless the episodes of preinfarction angina occur during a narrow time window (within 24 hours) in relation to the acute coronary syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/32\">",
"     32",
"    </a>",
"    ]. Furthermore, animal data suggests that the protective action of classic ischemic preconditioning is lost after prolonged periods of repetitive ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that tachyphylaxis can be overcome by exploiting the prolonged time course of the \"second window of protection,\" the delayed phase which lasts up to 72 hours. As an example, intermittent (every 48 hours) pretreatment of conscious rabbits with a selective adenosine A1 receptor agonist maintains the animals in a preconditioned state over a 10 day period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link&amp;anchor=H13#H13\">",
"     \"Definition and pathogenesis of ischemic preconditioning\", section on 'Second window of protection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another agent that might be used in this setting is the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/27/38322?source=see_link\">",
"     nicotinamide",
"    </a>",
"    derivative nicorandil, an antianginal agent with both nitrovenodilator and KATP channel opening properties. The CESAR 2 trial randomly assigned 245 patients with unstable angina who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , a beta blocker, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    to treatment with either oral nicorandil or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/69\">",
"     69",
"    </a>",
"    ]. Compared to placebo, nicorandil significantly reduced the incidence of transient myocardial ischemia and the frequency of nonsustained ventricular or supraventricular arrhythmias.",
"   </p>",
"   <p>",
"    A number of patients with unstable angina are candidates for therapeutic procedures involving a potentially injurious ischemic insult, such as PCI or CABG. The time course of the possible protective effects of preceding angina in this situation is not known. One study of 67 patients with unstable angina noted a time-dependent relationship between angina occurring spontaneously before PCI (0 to 6 hours, 6 to 12 hours, 12 to 24 hours and &gt;24 hours) and the presence of an ischemic response during initial balloon inflation (50, 65, 77, and 96 percent respectively) (",
"    <a class=\"graphic graphic_figure graphicRef64414 \" href=\"mobipreview.htm?19/27/19902\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/70\">",
"     70",
"    </a>",
"    ]. In comparison, patients whose last episode of angina was more than 24 hours before PCI showed the greatest amount of PCI-related preconditioning with the second balloon inflation due, presumably, to the almost universal anginal episode during the first inflation (",
"    <a class=\"graphic graphic_figure graphicRef78208 \" href=\"mobipreview.htm?25/38/26222\">",
"     figure 5",
"    </a>",
"    ). Such patients may therefore benefit from pretreatment with agents that mimic preconditioning or augment the protection afforded by the first balloon inflation.",
"   </p>",
"   <p>",
"    The potential benefit of intravenous nicorandil given to patients with acute myocardial infarction and undergoing reperfusion with percutaneous coronary intervention was evaluated in a trial of nearly 600 patients randomly assigned to either drug of placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/71\">",
"     71",
"    </a>",
"    ]. There was no difference between the two groups in the size of the left ventricular ejection fraction or the total activity of creatine kinase.",
"   </p>",
"   <p>",
"    A potential harmful effect of nonsteroidal antiinflammatory drugs (NSAIDs) was suggested by the observation that upregulation of cyclooxygenase 2 (COX-2) is a mediator of late ischemic preconditioning. In a study in rabbits, low doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (comparable to those used in humans for antithrombotic or antipyretic effects) did not interfere with COX-2 activity, while higher doses (comparable to those used for antirheumatic therapy in humans) completely abolished late ischemic preconditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/72\">",
"     72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link&amp;anchor=H13#H13\">",
"     \"Definition and pathogenesis of ischemic preconditioning\", section on 'Second window of protection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Stable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison, patients with stable angina undergoing routine PCI have a relatively low risk of complete coronary occlusion and myocardial infarction (&lt;5 percent). However, considering the potential benefits associated with preconditioning, it is possible that application of pharmacologic preconditioning agents could be used routinely prior to elective PCI.",
"   </p>",
"   <p>",
"    The role of nicorandil was evaluated in the Impact Of Nicorandil in Angina (IONA) trial of 2565 patients with chronic stable angina [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/73\">",
"     73",
"    </a>",
"    ]. There was a 2.4 percent absolute reduction in the primary end-point of coronary heart disease death, non-fatal myocardial infarction or unplanned hospitalization for cardiac chest pain (13.1 versus 15.5 percent with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39513?source=see_link&amp;anchor=H14#H14\">",
"     \"New therapies for angina pectoris\", section on 'Nicorandil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Coronary artery bypass graft surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar issues may arise in patients considered for cardiac surgery. Ischemic preconditioning has been shown to protect the hearts of patients undergoing routine coronary artery bypass surgery (CABG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently it was suggested that high risk patients with poor preoperative left ventricular function might also benefit if the degree of protection could be improved by invoking endogenous cellular adaptive mechanisms. This issue was addressed in controlled trial in which 70 patients on cardiopulmonary bypass were randomly assigned to receive or not receive ischemic preconditioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/75\">",
"     75",
"    </a>",
"    ]. The patients who received ischemic preconditioning had a significant improvement in left ventricular function and a decrease in the need for inotropic support after cardiac surgery. In contrast, evidence of ischemic preconditioning could not be demonstrated in a report of 17 patients with a left anterior artery stenosis and normal resting left ventricular systolic function who were undergoing minimally invasive bypass surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue is whether ischemic preconditioning might prevent ventricular tachyarrhythmias after CABG. A 2008 meta-analysis, comprising 22 studies and 933 patients reviewed the effect of ischemic preconditioning in patients undergoing CABG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/74\">",
"     74",
"    </a>",
"    ]. Ischemic preconditioning was associated with significant reductions in ventricular arrhythmias (pooled odds ratio 0.11; 95% CI 0.04-0.29) and inotrope requirements (pooled odds ratio 0.34; 95% CI 0.17-0.68).",
"   </p>",
"   <p>",
"    Further large clinical studies are required to determine the effect of ischemic preconditioning on long-term clinical outcomes in this patient group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=see_link\">",
"     \"Early noncardiac complications of coronary artery bypass graft surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Remote ischemic preconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the effects of local ischemia, remote ischemia can protect distant organs or tissue during subsequent ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/77\">",
"     77",
"    </a>",
"    ]. This has been termed remote ischemic preconditioning (RIPC) or cardioprotection at a distance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/78\">",
"     78",
"    </a>",
"    ]. In animal models, ischemia of the lower limb reduced subsequent myocardial infarction size after coronary occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/79\">",
"     79",
"    </a>",
"    ]. In humans, three five-minute cycles of ischemia to one upper extremity prevented endothelial dysfunction induced by subsequent ischemia to the contralateral upper extremity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=see_link&amp;anchor=H14#H14\">",
"     \"Definition and pathogenesis of ischemic preconditioning\", section on 'Remote ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential use of RIPC has been evaluated in three clinical settings: before surgery, before percutaneous coronary intervention (PCI) in stable patients, and in patients with ST elevation myocardial infarction (STEMI) treated with primary PCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small randomized trials have reported that RIPC using either brief upper limb or lower limb ischemia, is capable of reducing myocardial injury by 40 to 50 percent (measured by serum cardiac enzymes) in both children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/81\">",
"       81",
"      </a>",
"      ] and adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/82\">",
"       82",
"      </a>",
"      ] undergoing elective cardiac surgery, and in adults undergoing elective repair of an abdominal aortic aneurysm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the CRISP stent trial, 242 patients with stable angina were randomly assigned to receive either three 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper arm, interspersed with 5-minute intervals of reperfusion, or an uninflated cuff around the arm approximately one hour before PCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/84\">",
"       84",
"      </a>",
"      ]. Median troponin release at 24 hours was significantly reduced by remote ischemic preconditioning (0.06 versus 0.16",
"      <span class=\"nowrap\">",
"       mcg/L),",
"      </span>",
"      as was the severity of chest pain and the extent of ST segment deviation during the procedure.",
"     </li>",
"     <li>",
"      In a trial of over 300 patients with a suspected first STEMI, individuals were randomly assigned to either arm ischemia (induced by four cycles of alternating 5 minute inflation and 5 minute deflation using a standard upper arm blood pressure cuff) or no arm ischemia during transport to the hospital [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39529/abstract/85\">",
"       85",
"      </a>",
"      ]. There were 142 patients who underwent primary PCI and had infarct size measured using imaging with single photon emission CT (SPECT) both in the peri-infarct period and at 30 days. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23066?source=see_link\">",
"       \"Assessment of myocardial viability by nuclear imaging in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary end point of myocardial salvage index (the proportion of area at risk salvaged by the intervention) was significantly higher in those patients who received RIPC (0.69 versus 0.57).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ISCHEMIC POSTCONDITIONING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic postconditioning refers to the ability of a series of brief coronary artery occlusions after a severe ischemic insult and at the time of reperfusion to protect against ischemic-reperfusion injury. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6394?source=see_link&amp;anchor=H26#H26\">",
"     \"Ischemic reperfusion injury of the heart\", section on 'Ischemic postconditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21540950\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic preconditioning refers to the protection conferred to ischemic myocardium by preceding brief periods of sublethal myocardial ischemia. It has been reported to protect the heart against perioperative myocardial injury during cardiac bypass surgery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ischemic preconditioning in human myocardium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Remote ischemic preconditioning refers to the protection conferred to ischemic myocardium by applying brief periods of sublethal myocardial ischemia to an organ or tissue away from the heart. It has been reported to protect the heart against myocardial injury during cardiac bypass surgery, elective PCI and primary PCI. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Remote ischemic preconditioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemic postconditioning refers to the protection conferred to ischemic myocardium by interrupting reperfusion with intermittent short-lived episodes of sublethal myocardial ischemia. It has been reported to protect the heart against myocardial injury during cardiac bypass surgery and following primary PCI. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Ischemic postconditioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether these interventions improve clinical outcomes remains to be determined.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/1\">",
"      Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/2\">",
"      Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 2001; 104:3158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/3\">",
"      Walker DM, Walker JM, Pugsley WB, et al. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol 1995; 27:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/4\">",
"      Ikonomidis JS, Shirai T, Weisel RD, et al. Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C. Am J Physiol 1997; 272:H1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/5\">",
"      Speechly-Dick ME, Grover GJ, Yellon DM. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995; 77:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/6\">",
"      Cleveland JC Jr, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997; 96:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/7\">",
"      Bogaty P, Poirier P, Boyer L, et al. What induces the warm-up ischemia/angina phenomenon: exercise or myocardial ischemia? Circulation 2003; 107:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/8\">",
"      Williams DO, Bass TA, Gewirtz H, Most AS. Adaptation to the stress of tachycardia in patients with coronary artery disease: insight into the mechanism of the warm-up phenomenon. Circulation 1985; 71:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/9\">",
"      Okazaki Y, Kodama K, Sato H, et al. Attenuation of increased regional myocardial oxygen consumption during exercise as a major cause of warm-up phenomenon. J Am Coll Cardiol 1993; 21:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/10\">",
"      Maybaum S, Ilan M, Mogilevsky J, Tzivoni D. Improvement in ischemic parameters during repeated exercise testing: a possible model for myocardial preconditioning. Am J Cardiol 1996; 78:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/11\">",
"      Correa SD, Schaefer S. Blockade of K(ATP) channels with glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol 1997; 79:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/12\">",
"      Bogaty P, Kingma JG Jr, Robitaille NM, et al. Attenuation of myocardial ischemia with repeated exercise in subjects with chronic stable angina: relation to myocardial contractility, intensity of exercise and the adenosine triphosphate-sensitive potassium channel. J Am Coll Cardiol 1998; 32:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/13\">",
"      Kelion AD, Webb TP, Gardner MA, et al. The warm-up effect protects against ischemic left ventricular dysfunction in patients with angina. J Am Coll Cardiol 2001; 37:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/14\">",
"      Lambiase PD, Edwards RJ, Cusack MR, et al. Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol 2003; 41:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/15\">",
"      Lupi A, Lanza GA, Lucente M, et al. The \"warm-up\" phenomenon occurs in patients with chronic stable angina but not in patients with syndrome X. Am J Cardiol 1998; 81:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/16\">",
"      Solomon SD, Anavekar NS, Greaves S, et al. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. J Am Coll Cardiol 2004; 43:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/17\">",
"      Ishihara M, Inoue I, Kawagoe T, et al. Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarction. J Am Coll Cardiol 2001; 38:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/18\">",
"      Abete P, Ferrara N, Cacciatore F, et al. Angina-induced protection against myocardial infarction in adult and elderly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 1997; 30:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/19\">",
"      Ishihara M, Sato H, Tateishi H, et al. Beneficial effect of prodromal angina pectoris is lost in elderly patients with acute myocardial infarction. Am Heart J 2000; 139:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/20\">",
"      Abete P, Ferrara N, Cacciatore F, et al. High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients. J Am Coll Cardiol 2001; 38:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/21\">",
"      Anzai T, Yoshikawa T, Asakura Y, et al. Preinfarction angina as a major predictor of left ventricular function and long-term prognosis after a first Q wave myocardial infarction. J Am Coll Cardiol 1995; 26:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/22\">",
"      Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995; 91:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/23\">",
"      Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation 1995; 91:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/24\">",
"      Iglesias-Garriz I, Corral F, Rodr&iacute;guez MA, et al. Pre-infarction angina elicits greater myocardial viability on reperfusion after myocardial infarction: a dobutamine stress echocardiographic study. J Am Coll Cardiol 2001; 37:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/25\">",
"      Iwasaka T, Nakamura S, Karakawa M, et al. Cardioprotective effect of unstable angina prior to acute anterior myocardial infarction. Chest 1994; 105:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/26\">",
"      Napoli C, Liguori A, Chiariello M, et al. New-onset angina preceding acute myocardial infarction is associated with improved contractile recovery after thrombolysis. Eur Heart J 1998; 19:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/27\">",
"      Noda T, Minatoguchi S, Fujii K, et al. Evidence for the delayed effect in human ischemic preconditioning: prospective multicenter study for preconditioning in acute myocardial infarction. J Am Coll Cardiol 1999; 34:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/28\">",
"      Tamura K, Tsuji H, Nishiue T, et al. Association of preceding angina with in-hospital life-threatening ventricular tachyarrhythmias and late potentials in patients with a first acute myocardial infarction. Am Heart J 1997; 133:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/29\">",
"      Gheeraert PJ, Henriques JP, De Buyzere ML, et al. Preinfarction angina protects against out-of-hospital ventricular fibrillation in patients with acute occlusion of the left coronary artery. J Am Coll Cardiol 2001; 38:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/30\">",
"      Shiraki H, Yoshikawa T, Anzai T, et al. Association between preinfarction angina and a lower risk of right ventricular infarction. N Engl J Med 1998; 338:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/31\">",
"      Kobayashi Y, Miyazaki S, Itoh A, et al. Previous angina reduces in-hospital death in patients with acute myocardial infarction. Am J Cardiol 1998; 81:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/32\">",
"      Kloner RA, Shook T, Antman EM, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation 1998; 97:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/33\">",
"      Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol 1997; 30:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/34\">",
"      Andreotti F, Pasceri V, Hackett DR, et al. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med 1996; 334:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/35\">",
"      Przyklenk K, Whittaker P. Brief antecedent ischemia enhances recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism. Circulation 2000; 102:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/36\">",
"      Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine. Circulation 1998; 97:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/37\">",
"      Pasceri V, Lanza GA, Patti G, et al. Preconditioning by transient myocardial ischemia confers protection against ischemia-induced ventricular arrhythmias in variant angina. Circulation 1996; 94:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/38\">",
"      Deutsch E, Berger M, Kussmaul WG, et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features. Circulation 1990; 82:2044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/39\">",
"      Cribier A, Korsatz L, Koning R, et al. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol 1992; 20:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/40\">",
"      Eltchaninoff H, Cribier A, Tron C, et al. Adaptation to myocardial ischemia during coronary angioplasty demonstrated by clinical, electrocardiographic, echocardiographic, and metabolic parameters. Am Heart J 1997; 133:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/41\">",
"      Okishige K, Yamashita K, Yoshinaga H, et al. Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty. J Am Coll Cardiol 1996; 28:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/42\">",
"      Airaksinen KE, Huikuri HV. Antiarrhythmic effect of repeated coronary occlusion during balloon angioplasty. J Am Coll Cardiol 1997; 29:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/43\">",
"      Lindhardt TB, Kelbaek H, Madsen JK, et al. Continuous monitoring of global left ventricular ejection fraction during percutaneous transluminal coronary angioplasty. Am J Cardiol 1998; 81:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/44\">",
"      Laskey WK. Beneficial impact of preconditioning during PTCA on creatine kinase release. Circulation 1999; 99:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/45\">",
"      Lee TM, Su SF, Chou TF, et al. Loss of preconditioning by attenuated activation of myocardial ATP-sensitive potassium channels in elderly patients undergoing coronary angioplasty. Circulation 2002; 105:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/46\">",
"      Billinger M, Fleisch M, Eberli FR, et al. Is the development of myocardial tolerance to repeated ischemia in humans due to preconditioning or to collateral recruitment? J Am Coll Cardiol 1999; 33:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/47\">",
"      Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/48\">",
"      Tomai F, Crea F, Gaspardone A, et al. Effects of A1 adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty. Eur Heart J 1996; 17:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/49\">",
"      Leesar MA, Stoddard M, Ahmed M, et al. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997; 95:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/50\">",
"      Leesar MA, Stoddard MF, Manchikalapudi S, Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 1999; 34:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/51\">",
"      Tomai F, Crea F, Gaspardone A, et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 1999; 33:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/52\">",
"      Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/53\">",
"      Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990; 66:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/54\">",
"      Jenkins DP, Pugsley WB, Alkhulaifi AM, et al. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart 1997; 77:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/55\">",
"      Teoh LK, Grant R, Hulf JA, et al. The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc Res 2002; 53:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/56\">",
"      Teoh LK, Grant R, Hulf JA, et al. A comparison between ischemic preconditioning, intermittent cross-clamp fibrillation and cold crystalloid cardioplegia for myocardial protection during coronary artery bypass graft surgery. Cardiovasc Surg 2002; 10:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/57\">",
"      Kaukoranta PK, Lepoj&auml;rvi MP, Ylitalo KV, et al. Normothermic retrograde blood cardioplegia with or without preceding ischemic preconditioning. Ann Thorac Surg 1997; 63:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/58\">",
"      Bell SP, Sack MN, Patel A, et al. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 2000; 36:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/59\">",
"      Belhomme D, Peynet J, Louzy M, et al. Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1999; 100:II340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/60\">",
"      Burns PG, Krukenkamp IB, Caldarone CA, et al. Does cardiopulmonary bypass alone elicit myoprotective preconditioning? Circulation 1995; 92:II447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/61\">",
"      Wei M, Wang X, Kuukasj&auml;rvi P, et al. Bradykinin preconditioning in coronary artery bypass grafting. Ann Thorac Surg 2004; 78:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/62\">",
"      Leesar MA, Stoddard MF, Dawn B, et al. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation 2001; 103:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/63\">",
"      Hill M, Takano H, Tang XL, et al. Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance. Circulation 2001; 104:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/64\">",
"      Jneid H, Chandra M, Alshaher M, et al. Delayed preconditioning-mimetic actions of nitroglycerin in patients undergoing exercise tolerance tests. Circulation 2005; 111:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/65\">",
"      Tiefenbrunn AJ, Sobel BE. Timing of coronary recanalization. Paradigms, paradoxes, and pertinence. Circulation 1992; 85:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/66\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/67\">",
"      Cohen MV, Yang XM, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. Circ Res 1994; 74:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/68\">",
"      Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998; 31:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/69\">",
"      Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization. Eur Heart J 1999; 20:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/70\">",
"      Lim R, Laskey WK. Ischemic preconditioning in unstable coronary syndromes: evidence for time dependence. J Am Coll Cardiol 1997; 30:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/71\">",
"      Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/72\">",
"      Shinmura K, Kodani E, Xuan YT, et al. Effect of aspirin on late preconditioning against myocardial stunning in conscious rabbits. J Am Coll Cardiol 2003; 41:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/73\">",
"      IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/74\">",
"      Walsh SR, Tang TY, Kullar P, et al. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg 2008; 34:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/75\">",
"      Illes RW, Swoyer KD. Prospective, randomized clinical study of ischemic preconditioning as an adjunct to intermittent cold blood cardioplegia. Ann Thorac Surg 1998; 65:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/76\">",
"      Malkowski MJ, Kramer CM, Parvizi ST, et al. Transient ischemia does not limit subsequent ischemic regional dysfunction in humans: a transesophageal echocardiographic study during minimally invasive coronary artery bypass surgery. J Am Coll Cardiol 1998; 31:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/77\">",
"      Przyklenk K, Bauer B, Ovize M, et al. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993; 87:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/78\">",
"      Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 2008; 79:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/79\">",
"      Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997; 96:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/80\">",
"      Kharbanda RK, Mortensen UM, White PA, et al. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation 2002; 106:2881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/81\">",
"      Cheung MM, Kharbanda RK, Konstantinov IE, et al. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 2006; 47:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/82\">",
"      Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007; 370:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/83\">",
"      Ali ZA, Callaghan CJ, Lim E, et al. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation 2007; 116:I98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/84\">",
"      Hoole SP, Heck PM, Sharples L, et al. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation 2009; 119:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39529/abstract/85\">",
"      B&oslash;tker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010; 375:727.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1489 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39529=[""].join("\n");
var outline_f38_38_39529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21540950\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISCHEMIC PRECONDITIONING IN HUMAN MYOCARDIUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      In vitro studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Warm-up angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preinfarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Variant angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Role of nitroglycerin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THERAPEUTIC APPLICATIONS OF PRECONDITIONING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Stable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Remote ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ISCHEMIC POSTCONDITIONING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21540950\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1489\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1489|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/36/35406\" title=\"figure 1\">",
"      Outcome MI and prior angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/5/17501\" title=\"figure 2\">",
"      Prior angina influences outcome after anterior MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/18/31021\" title=\"figure 3\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/27/19902\" title=\"figure 4\">",
"      Effect precondition time I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/38/26222\" title=\"figure 5\">",
"      Effect precondition time II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23066?source=related_link\">",
"      Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17705?source=related_link\">",
"      Cardiac rehabilitation: Exercise training and secondary prevention of coronary heart disease in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/25/19864?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/1/8216?source=related_link\">",
"      Coronary collateral circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35226?source=related_link\">",
"      Early noncardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/15/6394?source=related_link\">",
"      Ischemic reperfusion injury of the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39513?source=related_link\">",
"      New therapies for angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29257?source=related_link\">",
"      Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_38_39530="Troponins and creatine kinase as biomarkers of cardiac injury";
var content_f38_38_39530=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Troponins and creatine kinase as biomarkers of cardiac injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39530/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39530/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39530/contributors\">",
"     David A Morrow, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39530/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39530/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/38/39530/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/38/39530/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/38/39530/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac injury is defined as the disruption of normal cardiac myocyte membrane integrity resulting in the loss into the extracellular space (including blood) of intracellular constituents including detectable levels of a variety of biologically active cytosolic and structural proteins such as troponin, creatine kinase, myoglobin, heart-type fatty acid binding protein, and lactate dehydrogenase. Injury is usually considered irreversible (cell death), but definitive proof that cell death is an inevitable consequence of the process is not available. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Ischemia and enzyme elevations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Causes of cardiac injury include trauma, toxins, and viral infection, but ischemia or infarction consequent to an imbalance between the supply and demand of oxygen (and nutrients) is the most common cause.",
"   </p>",
"   <p>",
"    When a sufficient number of myocytes have died (myocyte necrosis) or lost function, acute clinical disease is apparent; examples include myocardial infarction (MI) or myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biochemical characteristics and utility of troponins and creatine kinase MB fraction (CK-MB) for the diagnosis of cardiac injury and acute myocardial infarction (MI) will be reviewed here. Other biomarkers of cardiac injury and disease states, other than an AMI, in which elevation of biomarkers are seen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28101?source=see_link\">",
"     \"Biomarkers of cardiac injury other than troponins and creatine kinase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=see_link\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ISCHEMIA AND ENZYME ELEVATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is considerable debate about whether biomarkers such as troponins or CK-MB are released with reversible as well as irreversible injury. If this phenomenon occurs, it should be seen with all cardiac biomarkers, and it would not be possible biochemically to distinguish reversible from irreversible injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those in favor of the hypothesis that cardiac biomarker elevations occur with reversible injury suggest that the minor elevations seen after triathlons",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marathons in some individuals and with severe pulmonary embolism reflect reversible injury since they tend to be transient and do not have the persistence seen with an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The development of more highly sensitive assays may allow for a better evaluation of this issue in the future since increases from normal values may persist but not be detected without highly sensitive assays. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=see_link&amp;anchor=H17#H17\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\", section on 'Myocardial strain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older studies (using less-sensitive tests) that evaluated patients with ischemia during stress testing did not show elevations in troponins or other biomarkers and thus did not support the hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/5\">",
"     5",
"    </a>",
"    ]. However, a report from the PROMPT-TIMI 35 study, which evaluated troponin release after stress testing using an ultrasensitive precommercial troponin (I) assay, does support the above hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/6\">",
"     6",
"    </a>",
"    ]. In this study of 120 patients referred for evaluation of possible myocardial ischemia, significant changes in circulating troponin were detected only in the 70 patients with transient stress-test induced myocardial ischemia documented on myocardial perfusion imaging. The consistency of the results was impressive, but the magnitude of the changes was small (mean = 0.002",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    meaning this approach cannot be used in individual patients without extremely high precision assays. Whether the increases reflect release due to ischemia or minor amounts of damage is unclear. A similar study using another high sensitivity precommercial assay for cTnT could not replicate these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study using pacing and coronary sinus sampling with an hs-cTnT assay also found elevations both in the coronary sinus and systemically with and without elevations in lactate in the coronary sinus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/8\">",
"     8",
"    </a>",
"    ]. These findings could be interpreted as suggesting that cTn is released with cardiac stress and thus due to reversible injury. Alternatively, elevations could represent irreversible myocyte injury since it is now clear that reparative mechanisms exist within the heart. However, from the clinical perspective, this issue might be less critical. Elevations of cTn in most situations, save short term after extreme exertion, are associated with adverse consequences regardless of their mechanism of release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TROPONINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac troponin I (cTnI) and T (cTnT) are cardiac regulatory proteins that control the calcium-mediated interaction of actin and myosin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/9\">",
"     9",
"    </a>",
"    ]. Both have cytosolic or early releasable and structural pools, with most existing in the structural pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=see_link&amp;anchor=H5#H5\">",
"     \"Excitation-contraction coupling in myocardium\", section on 'Role of tropomyosin and troponins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These proteins are products of specific genes and therefore have the potential to be unique for the heart. Studies performed with cTnI have failed to find any cTnI outside of the heart at any stage of neonatal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In contrast, cTnT is expressed to a minor extent in skeletal muscle. However, the present cTnT assay was not thought to detect these forms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/14\">",
"     14",
"    </a>",
"    ]. Data indicate that there are at least some patients with skeletal muscle disease who have proteins that are detected by the antibodies in the cTnT and hs-cTnT assay. This implies that skeletal muscle can, in some patients, be the source for elevations of cTnT detected in the blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/15\">",
"     15",
"    </a>",
"    ]. Defining the frequency of this phenomenon will require additional study. Thus, in most clinical settings, its specificity should be comparable to that of cTnI.",
"   </p>",
"   <p>",
"    It is thought that early troponin release during MI comes from what has been termed the cytosolic pool, which is of a magnitude that is similar to the amount of CK-MB in that pool. In reality, a better name for this pool might be the early releasable pool, since its cellular localization is not proven. Subsequent release is prolonged with degradation of the actin and myosin filaments in the area of damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Variations in assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cTnI and cTnT are specific markers for myocardial damage, there are variations in the sensitivity and specificity of various immunoassays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This is related to a lack of standardization, the presence of modified cTnI and cTnT in the serum, and variations in antibody cross-reactivities to the various detectable forms of cTnI that result from its degradation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/14,18-22\">",
"     14,18-22",
"    </a>",
"    ]. Point-of-care tests are usually less sensitive than laboratory-based tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Newer assays, labeled 'high sensitivity' or &lsquo;highly sensitive&rsquo; assays are being developed. However, there has been substantial confusion in the literature concerning what assays should be defined as &lsquo;high sensitivity&rsquo;. (See",
"    <a class=\"local\" href=\"#H2606156726\">",
"     'High sensitivity assays'",
"    </a>",
"    below.) In the absence of such a specific designation, the assays referred to are contemporary assays and not hs-cTn assays.",
"   </p>",
"   <p>",
"    Many groups have called for standardization of assays and prospective criteria for their analytic characterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/1,23-26\">",
"     1,23-26",
"    </a>",
"    ]. The joint 2012 European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/World",
"    </span>",
"    Health Federation definition of myocardial infarction endorses the use of troponin as the marker of choice overall and for each subcategory of AMI. It also states that laboratories should utilize a cutoff value of the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile of a normal reference population to define the presence of cardiac injury. Ideally this value should be measurable with a coefficient of variation (CV) of 10 percent or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/23\">",
"     23",
"    </a>",
"    ]. However, the guidelines do not suggest raising the value above the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value if this metric is not met and levels of imprecision between 10 and 20 percent do not make an assay unusable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/27\">",
"     27",
"    </a>",
"    ]. Since cTnT and cTnI levels are undetectable in most normal subjects, the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile is very low (eg, 0.01 to 0.5",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"    However, most assays are imprecise at this low level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/16\">",
"     16",
"    </a>",
"    ]. This limitation diminishes the sensitivity of the assays to detect changes with serial samples but does not significantly increase the rate of analytical false positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/28\">",
"     28",
"    </a>",
"    ]. Several contemporary (sensitive) assays are now close to or at that level of precision at the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value. Most contemporary (sensitive) assays are still not capable of measuring cTn in most normal subjects and thus determining a true 99 percent value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since all assays are unique, one cannot extrapolate a value from one assay to another. It is important for clinicians to be familiar with the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value and the level of 10 percent CV for the assay used in their clinical practice and to be aware that these reference limits do not apply to results from other clinical providers unless they are using the same assay. Many experts are urging that whole numbers be reported to avoid confusion since as assays become more sensitive, the number of zeros increases and the possibility of an error with one being left out or being misinterpreted is substantial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Normal range",
"    </span>",
"    &nbsp;&mdash;&nbsp;Young, healthy individuals without pathologic myocardial cell stress or damage are expected to have little or no measurable troponin in their blood with any assay and with most assays presently in use this is the case. As troponin assays become more sensitive, however, it appears that healthy individuals do have tiny but detectable levels of troponin. Thus, defining the normal range is made difficult by our incomplete understanding of what a &ldquo;normal&rdquo; troponin really is.",
"   </p>",
"   <p>",
"    With contemporary assays, individuals with increased values above the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL are at increased cardiovascular risk. Some values even slightly below the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value seem to suggest risk, but contemporary assays are not capable of defining these values very well due to marked imprecision. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Elevations in the general population'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This issue has been addressed in studies that have compared younger to older individuals with values in the normal range; the mean for the two groups differed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/30\">",
"     30",
"    </a>",
"    ]. To determine if this was a normal finding related to age or related to a comorbidity, they examined a cohort of older patients during long-term follow-up. Patients with values between the values of the younger and older group had an increased frequency of adverse events. Mortality was increased by 50 percent in those without a history of cardiovascular disease and by more than twofold in those with such a history. The importance of values in this range has been confirmed in two acute studies, one in chest pain patients and one in ED patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been shown that having a detectable level of troponin defines a group of stable patients likely to have either significant coronary artery disease or elevated filling pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Elevations in the general population",
"    </span>",
"    &nbsp;&mdash;&nbsp;A report of 3557 participants in the population-based Dallas Heart Study evaluated the prevalence of cTnT elevations in the general population using contemporary (sensitive) assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/34\">",
"     34",
"    </a>",
"    ]. Values &ge;0.01",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     (mcg/L),",
"    </span>",
"    which was the lower limit of detection, were seen in 0.7 percent. Four major predictors of detectable cTnT were diabetes mellitus, left ventricular hypertrophy, chronic kidney disease, and heart failure.",
"   </p>",
"   <p>",
"    These values are of prognostic importance. In a study of 957 healthy elderly patients in which 4 percent were found to have elevated detectable level of cTnT (&ge;0.01",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    there was an approximate twofold increase in cardiovascular mortality in this group, confirming the importance of these elevations clinically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/35\">",
"     35",
"    </a>",
"    ]. In a study of 989 individuals with putatively stable CAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/36\">",
"     36",
"    </a>",
"    ], 6.2 percent had elevations of cTnT above the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value. Of these patients, 58.6 percent had a cardiovascular event during follow-up, compared to 22.5 percent in the group without elevations. However, this prognostic relationship was not found to be independent when echo parameters and a natriuretic peptide were added to the model. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis of primary MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of an acute myocardial infarction (AMI) has traditionally relied upon the combination of chest pain, electrocardiographic (ECG) manifestations, and elevations in serum or plasma biomarkers of cardiac injury, or pathologic findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest symptoms are frequently atypical or absent and ECG abnormalities may be nonspecific or absent. As a result, the diagnosis of an AMI has increasingly depended upon evaluation of the rise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fall of blood biomarkers. Troponins are preferred to CK-MB due to their greater specificity and sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/23,37,38\">",
"     23,37,38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Why troponin is preferred'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The criteria used to define MI differ somewhat depending on the particular clinical circumstance of the patient: those suspected of an AMI based on their presentation; those undergoing revascularization with either coronary artery bypass graft surgery or percutaneous intervention; or those who have sustained sudden unexpected cardiac death.",
"   </p>",
"   <p>",
"    Several points are important for the understanding of how to use these criteria to diagnose an AMI in different clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile of the normal range of values should be the cutoff value for both troponin and CK-MB. With contemporary assays, these values are still far from the normal range.",
"     </li>",
"     <li>",
"      A rise",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fall should be observed. The ability to define how much of a change is significant requires a fixed period of time (usually six hours) and information concerning the variability of the measurements. In general, measurements are considered to be different if the values are more than three standard deviations of the variability around them. We believe that laboratories should report when significant changes have occurred over a fixed time period since the appropriate metrics will vary depending on the assay being used. Some assays seem to perform reasonably with a 20 percent change [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/39\">",
"       39",
"      </a>",
"      ], some with a 30 percent change [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/40\">",
"       40",
"      </a>",
"      ], and some with the need for even greater change.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria will identify more patients with AMI than previous criteria as troponin assays continue to become more sensitive. Consistent use of the same criteria is urged to improve the consistency of diagnosis.",
"   </p>",
"   <p>",
"    Cardiac troponin concentrations usually begin to rise two to three hours after the onset of AMI. By two to three hours after presentation, up to 80 percent of patients with AMI will have troponin elevations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/39\">",
"     39",
"    </a>",
"    ]. \"Rapidly appearing markers,\" such as myoglobin and CK isoforms, appear to provide little additional information when used together with a sensitive assay for troponin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/41\">",
"     41",
"    </a>",
"    ]. Recent cocaine use, which can elevate CK-MB, does not increase cTnI unless myocardial damage is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, there has been considerable reluctance to use the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL value clinically because of elevations that were challenging for clinicians to explain. Recent studies have again confirmed the early diagnostic and therapeutic value of using the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL for cTn. In two diagnostic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] that compared the results of newer, more sensitive assays (using the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value) to those of less or equally sensitive assays being used in the community for which cutoff values higher than the 99 percent value were being used.",
"   </p>",
"   <p>",
"    The strategy of using these contemporary assays at the recommended cutoff value detected many more patients earlier than if one used the same assays with higher cutoff values or less sensitive assays. In these studies, more than 90 percent of patients had elevated values in their first sample. This finding reflects in part the fact that many patients with non-ST elevation MI (NSTEMI) present late after the onset of pain, but the findings were similar in those whose putative onset was early (within three or four hours). Some of the additional reasons for such a high initial percentage are discussed below. Since most of the assays used in these studies are already in use, the major finding of these reports was to reaffirm the need to use the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value for rapid diagnosis and to optimally identify patients with AMI who present with chest discomfort. These studies also reinforced the lack of benefit of so-called early rising markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that in these studies the pretest probability of disease even using the less sensitive local approach was 36 to 46 percent in these European studies, which is much higher than usual, especially in emergency departments in the United States. This will make all assays appear to perform better. In addition, these studies used a less sensitive standard as their gold standard, again inflating the accuracy of their approach. Had the more accurate assays been used to probe the percentage of early diagnoses, the number would have been lower. Finally, for the most part they considered any elevation indicative of a positive diagnosis rather than looking for a rise",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fall in values and with the exception of one analysis, alternative diagnoses for the elevated troponin values were not explored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/45\">",
"     45",
"    </a>",
"    ]. These approaches enhance the sensitivity of the approach and obfuscate what could be an important issue with it: the idea that with greater sensitivity, a greater percentage of elevations are likely to be chronic and due to other cardiac comorbidities and not acute ischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic importance of using sensitive thresholds in the evaluation of patients with ACS was highlighted in a study of patients with suspected acute coronary syndrome (ACS). The management and outcomes of 1038 individuals evaluated with a sensitive troponin I assay in 2008 using a high cutoff value were compared to 1054 individuals evaluated with the same assay in 2009 using the 10 percent coefficient of variation (CV) cutoff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/46\">",
"     46",
"    </a>",
"    ]. Managing physicians used differing thresholds for the detection of myocardial necrosis in the two groups: 0.20",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the former and 0.05",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in the latter. Each group was stratified into three subgroups (&lt;0.05, 0.05 to 0.19, and &ge;0.20",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    The primary outcome was the combination of recurrent myocardial infarction and death at one year. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rates of the use of secondary preventative interventions, such as statins and dual antiplatelet therapy at discharge, in the subgroup of patients with plasma troponin concentrations of 0.05 to 0.19",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      improved significantly comparing the 2008 to 2009 cohorts, while the use of these interventions did not change significantly in the other subgroups.",
"     </li>",
"     <li>",
"      In 2008, the primary outcome occurred in 39 percent of patients with plasma troponin concentrations of 0.05 to 0.19",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      compared with 7 and 24 percent of those with troponin concentrations of &lt;0.05",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or &ge;0.20",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      In 2009, the primary outcome occurred significantly less frequently (21 percent) in patients with plasma troponin concentrations of 0.05 to 0.19",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      while there was no significant change in the other two subgroups between the two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As acknowledged by the authors, these results might have been still better had the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL value been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the delay in biomarker elevations, reperfusion therapy in patients who have a suspected acute ST elevation MI should not await the results of cardiac biomarkers. This approach was recommended by the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force, and was not changed in the 2007",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/38,48\">",
"     38,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients without diagnostic ST segment elevation, rapid intervention is less critical. Serial biomarker testing can be performed after four to six or more hours if the initial values are indeterminate, the ECG remains nondiagnostic, and clinical suspicion remains high. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients who present with chest pain without ischemic changes on the ECG, an elevated troponin is associated with significant increases in the incidence of both coronary artery disease in the subset of patients who underwent angiography (90 versus 23 percent in the absence of troponin elevations) and adverse cardiac events over the next year (33 versus 13 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/49\">",
"     49",
"    </a>",
"    ]. This study used a cutoff higher than the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile. It is likely that the differences would have been greater had the recommended cutoff been used. However, it should also be appreciated that any cardiac injury can induce elevations of troponin. It is also clear that with the use of reasonable assays for cTn, aborted AMI (those without any elevations in biomarkers) no longer exist. However, the smaller the amount of damage, the better the prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are multiple potential proximal causes of MI. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link&amp;anchor=H4#H4\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Acute MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is now clear from several series that patients with AMI need not always have fixed coronary artery disease. This assumption has been responsible for concerns that cTn values are &ldquo;falsely positive.&rdquo; Up to 30 percent of patients with unstable coronary artery disease may not have a culprit lesion but often respond to acetylcholine with recapitulation of their chest discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/51\">",
"     51",
"    </a>",
"    ]. These patients have an excellent long-term prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/52\">",
"     52",
"    </a>",
"    ]. Included in this group most likely are the patients reported in several series who have elevated cTn values, normal coronary arteries but magnetic resonance imaging evidence of AMI with delayed subendocardial hyperenhancement. Of interest, most of these patients are women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. These patients would be designated as type 2 AMIs by the global task force definition of AMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link&amp;anchor=H4#H4\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Acute MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, patients with fixed coronary artery disease and supply-demand abnormalities, such as post-operative patients, fit into this category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/56\">",
"     56",
"    </a>",
"    ]. It is thought that these patients include mostly so-called type 2 AMIs such as those identified above and thus are less in need of aggressive intervention than others. Unfortunately, these distinctions are impossible to make based on the cTn data and thus must be made clinically. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Late diagnosis and reinfarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in cTnT and cTnI after an AMI persist for up to 10 days, thus permitting late diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Troponins can also be used for detecting reinfarction. This was illustrated in a series of nine patients in whom re-elevations in cTnI were prompt and permitted the diagnosis of reinfarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/59\">",
"     59",
"    </a>",
"    ]. As a result, CK-MB is no longer required even though it returns to baseline levels earlier.",
"   </p>",
"   <p>",
"    According to the 2012 Joint European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/World",
"    </span>",
"    Health Federation Task Force for the Universal definition of Myocardial Infarction, reinfarction is used for an acute Mi that occurs within 28 days of an incident or recurrent MI. If reinfarction is suspected, an immediate measurement of cardiac troponin should be made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/60\">",
"     60",
"    </a>",
"    ]. A second sample is obtained three to six hours later and recurrent infarction is present if there is a &ge;20 percent increase in the second sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis most apt to mimic AMI both in terms of clinical presentation and cTn results is acute myocarditis. Both syndromes can present with ST segment elevation and substantial elevations in cTn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/61\">",
"     61",
"    </a>",
"    ]. In a series of 60 patients who presented with possible AMI but had normal coronary arteries, 30 had MRI features of acute myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/62\">",
"     62",
"    </a>",
"    ]. Thus, this should be a consideration in patients who present in this manner and have normal coronary arteries. One possible indication for CMR would be to determine the source of myocardial damage in a patient with elevated troponin levels but without obstructive coronary disease at invasive coronary angiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Apical ballooning should also be considered, but in general, elevations of cTn are more modest in this condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=see_link&amp;anchor=H7#H7\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both cTnI and cTnT provide improved specificity compared to the other marker proteins for the detection of myocardial injury, but elevations do not necessarily imply that the cause is ischemic heart disease. Troponin elevations occur in a variety of clinical conditions, including disorders that are in the differential diagnosis of acute infarction such as a moderate to severe pulmonary embolism with acute right heart overload, heart failure, and myocarditis. The troponin elevations are more often modest in these disorders and, among patients with pulmonary embolism, usually resolve within 40 hours in contrast to the more prolonged elevation with acute myocardial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/4\">",
"     4",
"    </a>",
"    ]. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=see_link\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of acute pulmonary embolism\", section on 'Troponin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Troponin elevations are also indicative of myocardial injury in patients who are critically ill and are associated with an adverse prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=see_link&amp;anchor=H8#H8\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\", section on 'Critical illness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Troponin release can be induced by trauma, as occurs during cardiopulmonary resuscitation, electrical cardioversion, or implantable cardioverter defibrillator (ICD) firings. In one study of 38 patients undergoing elective cardioversion using a median cumulative energy of 300 J, for example, three patients had minimal elevations of cTnI (0.8 to 1.5",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    suggestive of subtle myocardial injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/64\">",
"     64",
"    </a>",
"    ]. Substantial troponin elevations suggest the presence of myocardial injury from causes unrelated to direct current cardioversion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150151846\">",
"    <span class=\"h2\">",
"     Infarct size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians use peak values of biomarkers to provide a rough estimate of infarct size. Recent data using both scintigraphy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/65,66\">",
"     65,66",
"    </a>",
"    ] and MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/67\">",
"     67",
"    </a>",
"    ] suggest that peak cTnT values or the 72 to 96 hour values correlate with infarct size determined from imaging approaches. The slope of the relationship is different if one uses the 24-hour, 48-hour, or peak value versus the 72 to 96 hour value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/68\">",
"     68",
"    </a>",
"    ] and, as with CK-MB, the correlation is less robust with NSTEMI than with STEMI. In addition, the slope of the relationship is different with and without reperfusion. Nonetheless, correlation ranges are good (from 0.8 to 0.93) in these studies and are better than the correlations reported for CK-MB. Similar data are available for cTnI as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prognosis after MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognostic value of elevated troponins has been demonstrated in patients with ST segment elevation MI (STEMI) and non-ST elevation MI (NSTEMI). Both cTnI and cTnT appear to be equivalent for this purpose and any detectable elevation at the time of presentation is of significance (",
"    <a class=\"graphic graphic_figure graphicRef57088 \" href=\"mobipreview.htm?15/44/16078\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. The optimal cutoff value is the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of findings in acute STEMI is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The GUSTO-III trial evaluated 12,666 patients with an STEMI who received fibrinolytic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/74\">",
"       74",
"      </a>",
"      ]. An elevated cTnT at the time of presentation was an independent predictor of mortality at 30 days in a multivariate regression analysis (15.7 versus 6.2 percent for a negative cTnT). This is likely at least in part because patients with elevated values present later.",
"     </li>",
"     <li>",
"      The admission troponin concentration has prognostic value in patients with an STEMI who undergo early PCI. This was illustrated in a report of 140 patients undergoing PCI usually with stenting. Those with admission cTnT &ge;0.1",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      were more likely to have persistently reduced blood flow in the infarct-related artery (TIMI flow grade less than 3) after the procedure (25 versus 8 percent for negative cTnT), a higher incidence of no-reflow, and a higher mortality at both 30 days and nine months (12.5 versus 4 and 14 versus 4 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/75\">",
"       75",
"      </a>",
"      ]. This is likely at least in part because patients with elevated values present later.",
"     </li>",
"     <li>",
"      A pooled analysis of 21 studies involving 18,982 patients with an acute coronary syndrome found that an elevated serum cTnI or cTnT was associated with an increased risk of cardiac death or reinfarction at 30 days (odds ratio 3.44, 95% CI 2.94-4.03) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/76\">",
"       76",
"      </a>",
"      ]. Elevated troponins on admission were also predictive of long-term outcome (five months to three years) in those with a STEMI (OR 3.11).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Non-ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevation in troponin is associated with an adverse early and long-term prognosis in men and women with a non-ST elevation acute coronary syndrome (NSTEMI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/71,76-85\">",
"     71,76-85",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of seven clinical trials and nineteen cohort studies of patients with NSTEMI, 5360 patients had a cTnT measurement and 6603 had a cTnI measurement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/71\">",
"       71",
"      </a>",
"      ]. The mortality rate was higher for patients with either an elevated cTnT (6.0 versus 1.5 percent at 28 weeks) or an elevated cTnI (5.5 versus 1.7 percent at 10 weeks).",
"     </li>",
"     <li>",
"      Similar findings were noted in a second meta-analysis of 21 studies: 3579 patients with NSTEMI had 30-day follow-up, and 2227 had long-term follow-up (five months to three years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/76\">",
"       76",
"      </a>",
"      ]. Patients with an elevated cTnT or cTnI had a significantly higher cardiac mortality rate in both the short term (5.9 versus 1.3 percent) and long term (10.1 versus 4.0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of factors may contribute to the increase in mortality. In the noninvasive arm in the FRISC-II trial, any elevation in cTnT was associated with an increased likelihood of severe three vessel disease, an unstable plaque with thrombus and downstream microembolization, impairment of coronary flow, and reinfarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/82\">",
"     82",
"    </a>",
"    ]. A more pronounced troponin elevation was associated with a greater likelihood of persistent occlusion of the culprit vessel and a reduced left ventricular ejection fraction.",
"   </p>",
"   <p>",
"    Probably because of the higher risk, patients with an ACS and elevated troponins benefit more from an early invasive therapy than those who do not have elevated troponins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/86-88\">",
"     86-88",
"    </a>",
"    ] and from the use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/72\">",
"     72",
"    </a>",
"    ] and low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/77\">",
"     77",
"    </a>",
"    ], perhaps because troponin elevations are associated with complex lesion characteristics and thrombus formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/82,89\">",
"     82,89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29257?source=see_link&amp;anchor=H11#H11\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\", section on 'Gradation of risk'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H35#H35\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Serum troponins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Degree of troponin elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of elevation of cTnI or cTnT also has significant prognostic value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/78-80,84,90,91\">",
"     78-80,84,90,91",
"    </a>",
"    ]. This effect has been illustrated in a number of major trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the GUSTO IV ACS trial, over 7000 patients who did not undergo early revascularization were stratified by quartiles of cTnT (&le;0.01, 0.01 to 0.12, 0.12 to 0.47, and &gt;0.47) and by quartiles of CRP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/90\">",
"       90",
"      </a>",
"      ]. The 30-day mortality rate increased from 1.1 to 7.4 percent from the first to fourth quartiles of cTnT. There was also a significant increase in the 30-day rate of MI from the first to second quartiles of cTnT (2.5 versus 6.7 percent), but no further increase between the upper three quartiles. CRP and troponin T had independent and complementary prognostic significance; the mortality rate at 30 days ranged from 0.3 to 9.1 percent for patients in the lowest to highest quartile of both markers.",
"     </li>",
"     <li>",
"      A similar correlation of the degree of troponin elevation with mortality was seen in the TIMI IIIB trial (",
"      <a class=\"graphic graphic_figure graphicRef69927 \" href=\"mobipreview.htm?34/48/35597\">",
"       figure 2",
"      </a>",
"      ), the GUSTO IIa trial (",
"      <a class=\"graphic graphic_figure graphicRef79900 \" href=\"mobipreview.htm?23/35/24125\">",
"       figure 3",
"      </a>",
"      ), and the FRISC study (",
"      <a class=\"graphic graphic_figure graphicRef54597 \" href=\"mobipreview.htm?8/42/8879\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/78-80,84\">",
"       78-80,84",
"      </a>",
"      ]. The correlation with in-hospital and long-term mortality has also been noted in patients treated with an early invasive strategy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimal use for prognosis requires more than an initial sample. The GUSTO IIa trial obtained baseline, peak, and late (8 and 16 hour) cTnT measurements in 734 patients with an acute coronary syndrome. Mortality at 30 days was 10 percent in those with an elevated cTnT (&gt;0.1",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    at baseline, 5 percent with a late elevation of cTnT, and 0 percent in patients who never developed a positive test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/93\">",
"     93",
"    </a>",
"    ]. After adjustment for baseline characteristics, any elevated cTnT value predicted 30-day and one-year mortality, and the 8 and 16 hour values added strength to the baseline value (",
"    <a class=\"graphic graphic_figure graphicRef62648 \" href=\"mobipreview.htm?34/26/35245\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with marked troponin elevations (eg, highest tertile) have presented later, have visible thrombus on angiography and a lower rate of TIMI 3 flow, depressed left ventricular function, and abnormal Q waves on the ECG compared to those in the second tertile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/82,94\">",
"     82,94",
"    </a>",
"    ]. These patients are less likely to have recurrent MI at one year than those in the lower tertiles, perhaps because they were more likely to have total coronary occlusion and completed infarctions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2606156726\">",
"    <span class=\"h2\">",
"     High sensitivity assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several high sensitivity (hs) assays that have been or are being developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/95-103\">",
"     95-103",
"    </a>",
"    ]. A proposed optimal criterion for calling an assay hs is the number of normal subjects it is capable of detecting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/104\">",
"     104",
"    </a>",
"    ]. Most contemporary (sensitive, but not high sensitive) assays detect very few normal subjects, whereas some of these hs assays detect nearly 100 percent depending on the population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/95-102\">",
"     95-102",
"    </a>",
"    ]. Part of the problem in this area is that companies do studies under ideal circumstances. For example, the hscTnT assay was reported to detect roughly 80 percent of normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/99\">",
"     99",
"    </a>",
"    ]. However, in a study of based on a population including abnormals where one might anticipate fewer undetectable values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/105\">",
"     105",
"    </a>",
"    ], only 25 percent of the population had detectable values. This likely reflects differences in populations, the age of the samples, and the specific equipment used for the analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/106\">",
"     106",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2606156734\">",
"    <span class=\"h3\">",
"     Analytical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only the hscTnT assay has been released for use and it has not yet been approved for use in the US. Its analytical characteristics include a 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value of 13.5",
"    <span class=\"nowrap\">",
"     ng/L",
"    </span>",
"    (0.0135",
"    <span class=\"nowrap\">",
"     ug/L)",
"    </span>",
"    and a 10 percent CV value of 13.0",
"    <span class=\"nowrap\">",
"     ng/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/99\">",
"     99",
"    </a>",
"    ]. Thus, a value above 14",
"    <span class=\"nowrap\">",
"     ng/L",
"    </span>",
"    (0.014",
"    <span class=\"nowrap\">",
"     ug/L)",
"    </span>",
"    is considered abnormal. In at least two studies, however, the performance of this assay has not been superior to conventional assays used at the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/43,107\">",
"     43,107",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    It should be noted that hs assays are potentially far more prone than sensitive assays to analytical problems because small differences can be of such importance. For example, even mild degrees of hemolysis reduce hscTnT values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/108\">",
"     108",
"    </a>",
"    ] and differences in the type of sample (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    compared to serum or EDTA) can also make a difference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, with the hscTnT assay, it should be noted that the potential for elevations due to skeletal muscle disease will be greater with this hs assay than with the present generation assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/15\">",
"     15",
"    </a>",
"    ]. Finally, with two of the hs assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/99,109\">",
"     99,109",
"    </a>",
"    ] but not a third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/98\">",
"     98",
"    </a>",
"    ], men and women have different 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile values",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2606156742\">",
"    <span class=\"h3\">",
"     Clinical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer assays are as much as 10 times more sensitive than most so-called &lsquo;sensitive&rsquo; assays and they have partially clarified some of the issues raised regarding &lsquo;normal range&rsquo; (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Normal range'",
"    </a>",
"    above). With these assays, most individuals, even those without apparent myocardial disease (&ldquo;normals&rdquo;), have detectable values for cTn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/95,96,99\">",
"     95,96,99",
"    </a>",
"    ]. The etiology of these minor amounts of protein is unclear and this is an area under active investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/8,110\">",
"     8,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using these highly sensitive assays, values that are elevated above the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL define a high-risk group regardless of the type of underlying cardiovascular disease. Even within the normal range of these highly sensitive assays, it appears that the higher the value, the greater the risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/100,105,111-113\">",
"     100,105,111-113",
"    </a>",
"    ]. This suggests that each individual has",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own normal baseline and that elevations above that baseline occur as cardiac disease ensues and thus defines increased risk.",
"   </p>",
"   <p>",
"    These newer assays have tremendous potential for clinical medicine. For instance, they are likely to increase the rapidity and accuracy of diagnosis of acute coronary syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/96,97,101,102,114\">",
"     96,97,101,102,114",
"    </a>",
"    ] or to identify patients at high risk of events with cardiovascular disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential benefit from the use of highly sensitive assays was evaluated in a study of 413 patients who presented to emergency departments in Germany with symptoms suggestive of an acute coronary syndrome and were ultimately diagnosed with acute myocardial infarction using the recommended universal definition (evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia and clinical manifestations of ischemia, including symptoms, characteristic changes in the electrocardiogram, or imaging evidence of ischemia or infarction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link&amp;anchor=H4#H4\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Acute MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this study, the diagnosis of myocardial necrosis was established by at least one troponin measurement above the 10 percent imprecision cutoff of the hospital-specific troponin assay, together with an increasing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreasing pattern of at least 20 percent within six hours after admission. The diagnostic performance of two protocol-specified troponin assays (different from the hospital-specific assays) was evaluated. These two assays were measured on admission and after three and six hours. One of these assays was a novel hsTnI (level of detection = 3.4",
"    <span class=\"nowrap\">",
"     pg/mL;",
"    </span>",
"    99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL = 24",
"    <span class=\"nowrap\">",
"     pg/mL;",
"    </span>",
"    diagnostic threshold for MI = 30",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    The other is a standard available assay from Abbott (the level of detection = 10",
"    <span class=\"nowrap\">",
"     pg/mL;",
"    </span>",
"    99",
"    <sup>",
"     th",
"    </sup>",
"    percentile URL = 280",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    diagnostic threshold for MI = 300",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The area under the receiver operating characteristic (ROC) curves was high for both tests on admission (0.96 and 0.92, respectively). The ROC curves were similar except at the lower concentrations of troponin I, which were detectable only with the highly sensitive assay. This difference was most apparent when the onset of chest pain was less than two hours.",
"     </li>",
"     <li>",
"      At admission, hsTnI had a sensitivity of 82.3 percent and a negative predictive value of 94.7 percent (for ruling out MI). Comparable values for cTnI were 79.4 and 94.0 percent.",
"     </li>",
"     <li>",
"      At three hours, the sensitivity was 98.2 and the negative predictive value was 99.4 percent for both assays.",
"     </li>",
"     <li>",
"      Combining the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile cutoff at admission with the serial change in troponin concentration within three hours, the positive predictive value (for ruling in MI) for hsTnI increased from 75.1 to 95.8 and for cTnI from 80.9 to 96.1 percent.",
"     </li>",
"     <li>",
"      Optimal specificity for the diagnosis of AMI was achieved using a percentage change of 250 percent but at the cost of a substantial reduction in sensitivity. A 50 percent change optimized the diagnosis of AMI in late presenters at a similar cost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data indicate that hs assays will facilitate the diagnosis of presently defined AMIs, but important issues remain unresolved, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The gold standard applied in this and other studies is based on older, less sensitive assays. Performance characteristics comparing hs assays are unknown and will likely influence the optimal delta change value.",
"     </li>",
"     <li>",
"      The hs assay used in the study and others have sex-based differences in the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile. It remains uncertain whether sex-specific cut points need to be established for hs assays.",
"     </li>",
"     <li>",
"      Optimal thresholds for change values are not yet defined:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      a) There is a clear trade-off between sensitivity and specificity that clinicians must recognize.",
"     </li>",
"     <li>",
"      b) There are differences among the hs assays studied and this precludes establishing consistent criteria for use with all assays.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Furthermore, they may be of value in patients with stable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/101,112\">",
"     101,112",
"    </a>",
"    ] and eventually for more chronic screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/29\">",
"     29",
"    </a>",
"    ], including during stress testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] and in patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/100\">",
"     100",
"    </a>",
"    ]. For example, in a study of 3546 of participants in the Dallas heart study who were evaluated using a highly sensitive assay hscTnT assay, the lower limit of detection was 0.005",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile value in these apparently healthy individuals was &ge;0.014",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Troponin was detectable in 25.0 percent, and 2.0 percent had elevations above the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/105\">",
"     105",
"    </a>",
"    ]. Among those with elevations above the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile, the vast majority had detectable cardiovascular comorbidities.",
"   </p>",
"   <p>",
"    However, the use of more sensitive assays may lead to situations in which the cause of the elevations is not apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/99,102\">",
"     99,102",
"    </a>",
"    ]. Although these elevations are likely to be related to cardiovascular abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/101\">",
"     101",
"    </a>",
"    ], it is unclear at present how clinicians should respond to such elevations other than to exclude an acute process with the use of serial measurements to see if a changing pattern is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/29,102,115\">",
"     29,102,115",
"    </a>",
"    ]. In addition, subsetting patients before receiving the results of testing in a Bayesian manner may help improve the ability to manage these patients rather than allowing the lab test to override clinical judgment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic implications of elevations of cTn have been evaluated in multiple studies of which the following three are representative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 2010 report of 3546 individuals (discussed above) who were evaluated with a highly sensitive assay, elevation of cTnT was significantly associated with all-cause mortality in the highest cTnT category (adjusted hazard ratio 2.8, 95% CI 1.4-5.2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/105\">",
"       105",
"      </a>",
"      ]. In addition, there were differences in the normal values found in men and women and as opposed to 0.7 percent of the population having an elevated value. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In a study of adults aged 65 years or older without prior heart failure (HF), high sensitivity cTnT was measured at baseline (n = 4221) and two- to three-year follow-up (n = 2918) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/113\">",
"       113",
"      </a>",
"      ]. cTnT was detectable (&ge;3.00",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      in 66 percent at baseline. During a median follow-up of nearly 12 years, there was a significantly increased risk of HF and cardiovascular death in those with detectable levels at baseline, compared to those without. Among individuals with initially detectable cTnT, a subsequent increase of more than 50 percent was associated with a greater risk for HF and cardiovascular death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations demonstrate that troponin elevations can be due to structural heart disease in the absence of any acute process and thus have prognostic value. As assays become more sensitive as discussed above, this percentage will likely increase and the need to observe a rising pattern to distinguish acute from chronic elevations will become more important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is still considerable controversy about how to use these assays to detect acute events such as AMI. In many patients with AMI, large changes in cTn occur over time and the diagnosis is easy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/117\">",
"     117",
"    </a>",
"    ]. However, especially with hs-cTn assays, the number of more subtle cases will increase. These challenges revolve around a couple of issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile URL is different for different groups. In some assays, this can be gender related and in some it is related to underlying co-morbidities such as age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/118\">",
"       118",
"      </a>",
"      ] or diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/119\">",
"       119",
"      </a>",
"      ]. Thus, whereas some clinicians in the past have used an abnormal value in many situations as synonymous with acute disease, such a strategy will misclassify even more patients with hs-cTn assays.",
"     </li>",
"     <li>",
"      Because of the large number of minor elevations associated with chronic disease, whether detected or undetected, the ability to define a rising or falling pattern has become even more important. However, the optimal criterion for a meaningful change has not yet been defined. Several approaches have been advocated, each of which increases specificity at the cost of reducing sensitivity. Because most studies are predicated on the use of older cTn assays as the gold standard, cases of MI detectable only with hs assays are not included [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/43,107\">",
"       43,107",
"      </a>",
"      ], whereas patients who have CAD are often included as having AMI if a baseline elevation of hs-cTn is found even if a rise is not found. Therefore, even the approaches proposed to date may not be optimal:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Biological variation: This approach is based on conjoint biological and analytic variability that can only be derived in normal subjects. This metric defines the extent to which variation alone can explain a given rise",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fall of values. The key metric is the reference change value (RCV). The RCV has varied, depending upon the assay, from 42 to 86 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/106,120,121\">",
"       106,120,121",
"      </a>",
"      ] and is unique not only to each individual assay but even with the same reagents, to differing pieces of equipment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/106\">",
"       106",
"      </a>",
"      ]. Some experts have advocated these values be used to define when a rising and falling pattern is present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/122\">",
"       122",
"      </a>",
"      ]. To date, there are no published clinical data supporting this approach.",
"     </li>",
"     <li>",
"      Percentage change: The use of a percentage criteria can be based on biological variation or some other derived metric. Notably, some of the percentages proposed for clinical use are much lower than biological change. In addition, at low values a large percentage change may be reasonable but at higher values, it may not be nearly as successful. In addition, it is likely from the theory of biological variation that the further a value is from the RCV, the more cases due to variability alone (true false positives) will be included.",
"     </li>",
"     <li>",
"      Absolute change: A recent paper using the hs-cTnT assay has suggested that the use of a value of 7 to 9 ng over a one to two hour period optimizes sensitivity for detection of acute changes and thus AMI. These data require confirmation and depending on the baseline value, will often be below biological variation, so will by definition likely (depending on the percent change) include some individuals whose change is due to variability alone. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the limitations to each of these approaches to clinical application of hs-cTn assays, careful individualization of patients based on clinical grounds is mandatory. It also should be appreciated that some patients who do not manifest change could be late after AMI and that may only be apparent by seeing a falling in values over time. Finally, some patients with putative unstable angina will have elevated hs-cTn values that do not change but are likely due to structural heart disease. This group could be confusing to clinicians. Finally, it is likely that the relative percentage of Type 2 AMIs will increase with use of increasingly sensitive cTn assays. Such patients with Type 2 (demand-related) MI are not likely to benefit from the aggressive anti-thrombotic therapy that prior studies have documented to be of benefit in patients with predominantly Type 1 (acute atherothrombotic) non-STEMI. The clinical implication is that until more data are available, clinicians may need to individualize the care of these patients.",
"   </p>",
"   <p>",
"    Based on the concerns stated above, we would suggest that additional data are needed before advocating the routine use of high sensitive troponin assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CREATINE KINASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The enzyme creatinine kinase (formerly referred to as creatinine phosphokinase) exists as isoenzymes, which are dimers of M and B chains and exist in three combinations: MM, MB, and BB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/123\">",
"     123",
"    </a>",
"    ]. These isoenzymes reside in the cytosol and facilitate the egress of high-energy phosphates into and out of mitochondria. Their diagnostic use has become markedly diminished over time but they are included here predominantly for those areas of the world where cardiac troponin assays are not yet in exclusive use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     CK basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatine Kinase (CK) isoenzyme activity is distributed in many tissues, including skeletal muscle, but there is more of the CK-MB fraction in the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/124\">",
"     124",
"    </a>",
"    ]. Most muscles have more CK per gram than heart tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. Thus, skeletal muscle breakdown can lead to absolute increases in CK-MB in the plasma. In addition, in response to organ damage, including vigorous exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/127\">",
"     127",
"    </a>",
"    ], there is regeneration of skeletal muscle fibers and re-expression of proteins that existed during ontogeny, resulting in increased production of B chain CK protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/126,128,129\">",
"     126,128,129",
"    </a>",
"    ]. A large percentage of the CK that is released is degraded locally or in lymph [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/130\">",
"     130",
"    </a>",
"    ]. Reperfusion truncates this process and increases the rapidity and magnitude of egress of CK into plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Total CK measurements for the detection of cardiac damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in total serum CK lack specificity for cardiac damage, which improves with measurement of the MB fraction. The normal range of CK also varies considerably; a twofold or greater increase in the CK concentration is required for diagnosis. This criterion can be problematic in older individuals who, because of their lower muscle mass, may have low baseline serum total CK and, during MI, may have elevated serum CK-MB with values of total CK that rise but remain within the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/132-134\">",
"     132-134",
"    </a>",
"    ]. For these reasons, total CK has not been used in the diagnosis of myocardial damage for years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     CK-MB fraction for diagnosis of AMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cardiac troponin is available, CK-MB should not be used for the diagnosis of acute myocardial infarction. If it is the only assay available, it can be used but is far less sensitive and specific. Assays for CK-MB can be performed easily and rapidly.",
"   </p>",
"   <p>",
"    Most assays measure CK-MB mass, which is more sensitive than activity assays. In addition, mass assays avoid, for the most part, detection of macrokinases (CK linked to IgG and dimers of mitochondrial CK) that can confound diagnosis with activity assays. The presence of macrokinases should be considered, as one possibility, when CK-MB is a very high percentage (&gt;20 percent) of total CK [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/9\">",
"     9",
"    </a>",
"    ]. However, patients with chronic skeletal muscle disease often have falsely positive CK-MB results when percentage criteria are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/129,135-137\">",
"     129,135-137",
"    </a>",
"    ]. The proportion of CK that is CK-MB can be as high as 50 percent with chronic skeletal muscle injury, such as",
"    <span class=\"nowrap\">",
"     dermatomyositis/polymyositis,",
"    </span>",
"    due to increased production of B chain CK protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/126,129,135\">",
"     126,129,135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Specificity and sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;CK-MB has high specificity for cardiac tissue and was the preferred marker of cardiac injury for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/9\">",
"     9",
"    </a>",
"    ]. CK-MB typically begins to rise four to six hours after the onset of infarction but is not elevated in all patients until about 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/138,139\">",
"     138,139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An elevated CK-MB is relatively specific for myocardial injury, particularly in patients with ischemic symptoms when skeletal muscle damage is not present. Elevations return to baseline within 36 to 48 hours, in contrast to elevations in troponin, which can persist for as long as 10 to 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/140\">",
"     140",
"    </a>",
"    ]. This means that CK-MB, unlike troponins, cannot be used for the late diagnosis of an acute MI but can be used to suggest infarct extension if levels rise again after declining. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gender specific values are essential for diagnostic use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/17\">",
"     17",
"    </a>",
"    ]. CK-MB typically begins to rise four to six hours after the onset of infarction but is not elevated in all patients until about 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/138,139\">",
"     138,139",
"    </a>",
"    ]. It is now clear that cTn rises far more rapidly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/41\">",
"     41",
"    </a>",
"    ]. Elevations return to baseline within 36 to 48 hours, in contrast to elevations in troponin, which can persist for as long as 10 to 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/140\">",
"     140",
"    </a>",
"    ]. Because CK-MB can be released from skeletal muscle, its diagnostic use is impaired when skeletal muscle injury is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/42\">",
"     42",
"    </a>",
"    ]. Some have suggested using a ratio of CK-MB to total CK to improve specificity, but that approach markedly reduces the sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     CK-MB fraction for prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a relationship between infarct size, which can be estimated by CK-MB and prognosis. Peak values are less precise, but if adequate numbers of samples are obtained, they can provide a reasonable estimate. Comparisons with cTn suggest that cTn provides better estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/65-69\">",
"     65-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     CK and coronary reperfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time to peak CK levels and the slope of CK-MB release can be used to assess whether reperfusion has occurred after fibrinolysis and, when used in conjunction with clinical variables, can predict whether TIMI 0 or 1 and TIMI 2 or 3 grade flow is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/57\">",
"     57",
"    </a>",
"    ]. However, CK-MB criteria cannot identify the presence of TIMI 3 flow, which is the only level of perfusion associated with improved survival after fibrinolysis and this approach is not necessary at all with primary PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Reinfarction and late diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since CK levels return to baseline 36 to 48 hours after infarction, resampling can be used to detect reinfarction, and because cTn does not normalize that rapidly, it was initially suggested that CK-MB might be of value in this area. It is now clear that cTn increases rapidly, albeit from an abnormal baseline in patients with reinfarction. Therefore, the use of cTn has been recommended for all AMI diagnosis, including reinfarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     WHY TROPONIN IS PREFERRED",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their increased sensitivity and specificity compared with CK-MB and other markers, troponins are preferred for the diagnosis of MI. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Diagnosis of primary MI'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The basis for the consistent observation that troponin is more sensitive than CK-MB relates to the fact that more troponin is found in the heart per gram of myocardium and that a greater percentage depleted from the heart by cardiac injury arrives in the blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to specificity, troponin elevations are almost always specific for cardiac injury, except for the infrequent analytical false positives caused by fibrin interference",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cross-reacting antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/37\">",
"     37",
"    </a>",
"    ]. As mentioned above, CK-MB is not specific for cardiac injury, as a small amount is found in skeletal muscle. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'CK basics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is difficult today to find any situation in which CK-MB adds anything other than cost to the clinical utility of cTn if that marker is used properly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of well-done studies have shown that troponin measurements have enhanced prognostic value compared to CK-MB measurements in patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/76,141-143\">",
"     76,141-143",
"    </a>",
"    ]. This was illustrated in a review of almost 30,000 such patients from the multicenter CRUSADE initiative in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/141\">",
"     141",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The results were discordant in 28 percent of patients. Troponin was more sensitive, as 18 percent had elevated troponin but normal CK-MB values. In addition, 10 percent had false positive CK-MB elevations, as defined by normal troponin values.",
"     </li>",
"     <li>",
"      Compared to patients who were negative for both biomarkers, in-hospital mortality was not increased in patients who were troponin-negative and CK-MB-positive (ie, false positives; 3.0 versus 2.7 percent, adjusted odds ratio 1.02, 95 percent CI 0.75-1.38)",
"     </li>",
"     <li>",
"      Compared to patients who were negative for both biomarkers, there was a nonsignificant trend toward increased mortality in patients who were",
"      <span class=\"nowrap\">",
"       troponin-positive/CK-MB-negative",
"      </span>",
"      (4.5 versus 2.7 percent, adjusted odds ratio 1.15, 95 percent CI 0.86-1.54) and a significant increase in mortality in patients who were positive for both biomarkers (5.9 versus 2.7 percent, adjusted odds ratio 1.53, 95 percent CI 1.18-1.98).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences in outcomes could not be explained by differences in therapy since the two discordant groups were treated similarly with antithrombotic agents and percutaneous coronary intervention (PCI). Thus, an isolated CK-MB elevation has limited prognostic value in patients with a non-ST elevation ACS, while an isolated troponin elevation was associated with increased risk.",
"   </p>",
"   <p>",
"    Similar findings have been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/76,142,143\">",
"     76,142,143",
"    </a>",
"    ]. In a report of over 10,000 patients with an ACS from the multicenter GRACE registry, 1110 (10.4 percent) were",
"    <span class=\"nowrap\">",
"     troponin-positive/CK-MB-negative",
"    </span>",
"    and 822 (7.7 percent) were",
"    <span class=\"nowrap\">",
"     troponin-negative/CK-MB-positive",
"    </span>",
"    (false positives) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/143\">",
"     143",
"    </a>",
"    ]. In-hospital mortality was highest when both troponin and CK-MB were positive (7.7 percent), intermediate in",
"    <span class=\"nowrap\">",
"     troponin-positive/CK-MB-negative",
"    </span>",
"    patients (3.9 percent), and lowest in patients in whom both markers were negative and those who were",
"    <span class=\"nowrap\">",
"     troponin-negative/CK-MB-positive",
"    </span>",
"    (1.7 and 2.3 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     BIOMARKERS AFTER REVASCULARIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     After PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been considerable controversy over the prognosis of elevated cardiac biomarkers after percutaneous coronary intervention (PCI). This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link&amp;anchor=H5#H5\">",
"     \"Periprocedural myocardial infarction following percutaneous coronary intervention\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     After CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative MI after CABG is defined as increases in biomarkers greater than 10 times the 99",
"    <sup>",
"     th",
"    </sup>",
"    percentile upper reference limit (URL) plus either new pathological Q waves or LBBB on the postoperative ECG, or angiographically documented new graft or native coronary occlusion, or imaging evidence of new loss of viable myocardium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link&amp;anchor=H107850186#H107850186\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'After revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MI in this setting occurs in 4 to 5 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=see_link&amp;anchor=H3#H3\">",
"     \"Early cardiac complications of coronary artery bypass graft surgery\", section on 'Perioperative MI'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevations in CK-MB are much more common than Q waves, occurring in 62 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/144-146\">",
"     144-146",
"    </a>",
"    ]. This dissociation from Q waves suggests that most of the damage that occurs during CABG is subendocardial and thus is a routine sequela of the procedure rather than a coronary artery problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/147\">",
"     147",
"    </a>",
"    ]. Only marked CK-MB elevations (5 to 10 times the upper limit of normal) are associated with transmural infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/147\">",
"     147",
"    </a>",
"    ] and increased long-term mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated troponin may be a more specific and sensitive marker than CK-MB of a new MI after CABG, and may be more predictive of early complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnostic value of troponin elevations was illustrated in a study of 590 patients in whom a cTnT concentration &gt;3.4",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      24 hours after CABG correlated best with a perioperative MI as defined by new Q waves on the ECG and CK-MB &gt;100",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      within 48 hours after surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/148\">",
"       148",
"      </a>",
"      ]. The sensitivity and specificity, and positive and negative predictive values were 90 and 94 percent.",
"     </li>",
"     <li>",
"      The prognostic value of troponin elevations was addressed in a report of 224 patients in whom cTnT and CK-MB were measured every eight hours after cardiac surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/146\">",
"       146",
"      </a>",
"      ]. In a multivariable analysis, serum troponin T concentrations &ge;1.58",
"      <span class=\"nowrap\">",
"       mcg/L",
"      </span>",
"      (which represented the upper quintile) were the strongest predictor of postoperative death or shock immediately postoperatively or at 18 to 24 hours. CK-MB did not have independent short-term prognostic importance when troponin T was measured. Long-term data were not provided.",
"     </li>",
"     <li>",
"      A recent investigation of 1365 patients supports this contention for cTnI as well. Measurements were taken 2 and 24 hours after surgery. After multivariate correction, cTnI levels were predictive of both 30-day and one-year mortality and there was a gradation of risk with those with the highest values manifesting the greatest risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it should be appreciated that all elevations of troponin after CABG are not indicative of a vascular event. The process of cardiopulmonary bypass itself, issues related to cardiac preservation, and mechanical injury can all contribute. Recent CMRI data suggest that until troponin (or CKMB) values are very elevated, most of the damage is subendocardial and often apical, suggesting a nonvascular etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/147\">",
"     147",
"    </a>",
"    ]. Even when marked elevations occur, only 67 of 118 patients have a primary graft occlusion, emphasizing the need to consider the etiology of biomarker elevations and not considering all elevations due to vascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/38/39530/abstract/150\">",
"     150",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For infarction after cardiac surgical procedures, a fivefold increase from baseline in biomarkers is recommended along with ancillary criteria such as new Q waves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     BIOMARKERS AFTER NONCARDIAC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Troponins are ideal for diagnosing perioperative MI after noncardiac (mostly vascular) surgery. The same cutoff levels used to diagnose an acute MI should be used to detect perioperative injury in such patients. The discussion of the significance of a postoperative troponin elevation is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=see_link\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     USE IN RENAL FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues relating to the clinical use of cardiac troponins and CK-MB in patients with renal failure are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"     \"Serum cardiac enzymes in patients with renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of serum biomarkers is a key component in the diagnosis of irreversible myocardial cell death (as occurs with myocardial infarction) or possibly reversible cell injury. Troponins and creatine kinase (CK) MB are the two biomarkers which have the greatest utility for this purpose. They are also superior to other biomarkers for assessing prognosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28101?source=see_link\">",
"     \"Biomarkers of cardiac injury other than troponins and creatine kinase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following points summarize the proper use of these biomarkers for diagnosis and prognosis of acute myocardial infarction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Troponin values within the normal range (using current methodologies) likely come from a mixture of truly normal individuals with detectable values and some with comorbidities reflected by low but detectable values. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Normal range'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Troponin elevations (above the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile) can be due to structural heart disease in the absence of any acute process. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Elevations in the general population'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of an acute myocardial infarction depends on observation of a rise",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fall of blood biomarkers, particularly troponins, with at least one value above the 99",
"      <sup>",
"       th",
"      </sup>",
"      percentile, in addition to clinical information or electrocardiographic changes. The more sensitive the assay, the more important it is to determine a change for confirmation. This need is particularly important with highly sensitive assays. (See",
"      <a class=\"local\" href=\"#H2606156726\">",
"       'High sensitivity assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using cardiac troponins in preference to CK-MB for diagnostic and prognostic purposes; it is unnecessary to obtain both values. Cardiac troponins I and T are equally useful. We do not recommend the routine use of high sensitive assays of troponin at the present time.",
"     </li>",
"     <li>",
"      The impact of a rise is serum biomarkers after PCI is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link&amp;anchor=H5#H5\">",
"       \"Periprocedural myocardial infarction following percutaneous coronary intervention\", section on 'Prognosis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For the diagnosis of myocardial infarction after coronary artery bypass graft surgery (CABG), a 10-fold increase from baseline in biomarkers along with ancillary criteria, such as new Q waves, is needed. Myocardial infarction after CABG is associated with an increase in mortality. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Biomarkers after revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a delay in the rise of biomarkers after an acute MI. In patients who have an acute STEMI, reperfusion therapy should not await the results of cardiac biomarkers. In patients without diagnostic ST segment elevation, serial biomarker testing is performed after four or more hours if the initial values are indeterminate, the ECG remains nondiagnostic, and clinical suspicion remains high. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis of primary MI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/1\">",
"      Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation 2000; 102:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/2\">",
"      Shave R, George KP, Atkinson G, et al. Exercise-induced cardiac troponin T release: a meta-analysis. Med Sci Sports Exerc 2007; 39:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/3\">",
"      Gupta S, de Lemos JA. Use and misuse of cardiac troponins in clinical practice. Prog Cardiovasc Dis 2007; 50:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/4\">",
"      M&uuml;ller-Bardorff M, Weidtmann B, Giannitsis E, et al. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002; 48:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/5\">",
"      Carlson RJ, Navone A, McConnell JP, et al. Effect of myocardial ischemia on cardiac troponin I and T. Am J Cardiol 2002; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/6\">",
"      Sabatine MS, Morrow DA, de Lemos JA, et al. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J 2009; 30:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/7\">",
"      Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. Clin Chem 2008; 54:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/8\">",
"      Turer AT, Addo TA, Martin JL, et al. Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol 2011; 57:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/9\">",
"      Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993; 88:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/10\">",
"      Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991; 67:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/11\">",
"      Adams JE 3rd, Schechtman KB, Landt Y, et al. Comparable detection of acute myocardial infarction by creatine kinase MB isoenzyme and cardiac troponin I. Clin Chem 1994; 40:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/12\">",
"      Adams JE 3rd, Bodor GS, D&aacute;vila-Rom&aacute;n VG, et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993; 88:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/13\">",
"      Bodor GS, Porterfield D, Voss EM, et al. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 41:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/14\">",
"      Ricchiuti V, Voss EM, Ney A, et al. Cardiac troponin T isoforms expressed in renal diseased skeletal muscle will not cause false-positive results by the second generation cardiac troponin T assay by Boehringer Mannheim. Clin Chem 1998; 44:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/15\">",
"      Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol 2011; 58:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/16\">",
"      Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004; 50:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/17\">",
"      Apple FS, Quist HE, Doyle PJ, et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/18\">",
"      Shi Q, Ling M, Zhang X, et al. Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays. Clin Chem 1999; 45:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/19\">",
"      Labugger R, Organ L, Collier C, et al. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000; 102:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/20\">",
"      Heeschen C, Goldmann BU, Langenbrink L, et al. Evaluation of a rapid whole blood ELISA for quantification of troponin I in patients with acute chest pain. Clin Chem 1999; 45:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/21\">",
"      Katrukha AG, Bereznikova AV, Esakova TV, et al. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem 1997; 43:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/22\">",
"      Wu AH, Feng YJ, Moore R, et al. Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization. Clin Chem 1998; 44:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/23\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/24\">",
"      Panteghini M, Gerhardt W, Apple FS, et al. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001; 39:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/25\">",
"      Lee TH, Thomas EJ, Ludwig LE, et al. Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery. Am J Cardiol 1996; 77:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/26\">",
"      Baum H, Braun S, Gerhardt W, et al. Multicenter evaluation of a second-generation assay for cardiac troponin T. Clin Chem 1997; 43:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/27\">",
"      Jaffe AS, Apple FS, Morrow DA, et al. Being rational about (im)precision: a statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the definition of myocardial infarction. Clin Chem 2010; 56:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/28\">",
"      Apple FS, Parvin CA, Buechler KF, et al. Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction. Clin Chem 2005; 51:2198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/29\">",
"      Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J 2008; 155:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/30\">",
"      Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006; 113:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/31\">",
"      Kavsak PA, Newman AM, Lustig V, et al. Long-term health outcomes associated with detectable troponin I concentrations. Clin Chem 2007; 53:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/32\">",
"      Waxman DA, Hecht S, Schappert J, Husk G. A model for troponin I as a quantitative predictor of in-hospital mortality. J Am Coll Cardiol 2006; 48:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/33\">",
"      Schulz O, Kirpal K, Stein J, et al. Importance of low concentrations of cardiac troponins. Clin Chem 2006; 52:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/34\">",
"      Wallace TW, Abdullah SM, Drazner MH, et al. Prevalence and determinants of troponin T elevation in the general population. Circulation 2006; 113:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/35\">",
"      Daniels LB, Laughlin GA, Clopton P, et al. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008; 52:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/36\">",
"      Hsieh BP, Rogers AM, Na B, et al. Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study. Am Heart J 2009; 158:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/37\">",
"      Saenger AK, Jaffe AS. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation 2008; 118:2200.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/39\">",
"      Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem 2006; 52:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/40\">",
"      Apple FS, Pearce LA, Smith SW, et al. Role of monitoring changes in sensitive cardiac troponin I assay results for early diagnosis of myocardial infarction and prediction of risk of adverse events. Clin Chem 2009; 55:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/41\">",
"      Eggers KM, Oldgren J, Nordenskj&ouml;ld A, Lindahl B. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J 2004; 148:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/42\">",
"      Hollander JE, Levitt MA, Young GP, et al. Effect of recent cocaine use on the specificity of cardiac markers for diagnosis of acute myocardial infarction. Am Heart J 1998; 135:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/43\">",
"      Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/44\">",
"      Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009; 361:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/45\">",
"      Jaffe AS, Apple FS. High-sensitivity cardiac troponin: hype, help, and reality. Clin Chem 2010; 56:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/46\">",
"      Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA 2011; 305:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/47\">",
"      Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ 2012; 344:e1533.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/49\">",
"      deFilippi CR, Tocchi M, Parmar RJ, et al. Cardiac troponin T in chest pain unit patients without ischemic electrocardiographic changes: angiographic correlates and long-term clinical outcomes. J Am Coll Cardiol 2000; 35:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/50\">",
"      Vasile VC, Babuin L, Ting HH, et al. Aborted myocardial infarction: is it real in the troponin era? Am Heart J 2009; 157:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/51\">",
"      Ong P, Athanasiadis A, Hill S, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol 2008; 52:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/52\">",
"      Ong P, Athanasiadis A, Borgulya G, et al. 3-year follow-up of patients with coronary artery spasm as cause of acute coronary syndrome: the CASPAR (coronary artery spasm in patients with acute coronary syndrome) study follow-up. J Am Coll Cardiol 2011; 57:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/53\">",
"      Martinez MW, Babuin L, Syed IS, et al. Myocardial infarction with normal coronary arteries: a role for MRI? Clin Chem 2007; 53:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/54\">",
"      Christiansen JP, Edwards C, Sinclair T, et al. Detection of myocardial scar by contrast-enhanced cardiac magnetic resonance imaging in patients with troponin-positive chest pain and minimal angiographic coronary artery disease. Am J Cardiol 2006; 97:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/55\">",
"      Dokainish H, Pillai M, Murphy SA, et al. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol 2005; 45:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/56\">",
"      Landesberg G, Beattie WS, Mosseri M, et al. Perioperative myocardial infarction. Circulation 2009; 119:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/57\">",
"      Ohman EM, Christenson RH, Califf RM, et al. Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. Am Heart J 1993; 126:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/58\">",
"      Christenson RH, Ohman EM, Topol EJ, et al. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. Circulation 1997; 96:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/59\">",
"      Apple FS, Murakami MM. Cardiac troponin and creatine kinase MB monitoring during in-hospital myocardial reinfarction. Clin Chem 2005; 51:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/60\">",
"      Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/61\">",
"      Franz WM, Remppis A, Kandolf R, et al. Serum troponin T: diagnostic marker for acute myocarditis. Clin Chem 1996; 42:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/62\">",
"      Villata G, Bollati M, Gambino A, et al. Comment on the 'pilot' GRACIA-2 randomized trial. Eur Heart J 2007; 28:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/63\">",
"      Babuin L, Vasile VC, Rio Perez JA, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit Care Med 2008; 36:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/64\">",
"      Allan JJ, Feld RD, Russell AA, et al. Cardiac troponin I levels are normal or minimally elevated after transthoracic cardioversion. J Am Coll Cardiol 1997; 30:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/65\">",
"      Licka M, Zimmermann R, Zehelein J, et al. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 2002; 87:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/66\">",
"      Panteghini M, Cuccia C, Bonetti G, et al. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 2002; 48:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/67\">",
"      Steen H, Giannitsis E, Futterer S, et al. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 2006; 48:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/68\">",
"      Giannitsis E, Steen H, Kurz K, et al. Cardiac magnetic resonance imaging study for quantification of infarct size comparing directly serial versus single time-point measurements of cardiac troponin T. J Am Coll Cardiol 2008; 51:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/69\">",
"      Vasile VC, Babuin L, Giannitsis E, et al. Relationship of MRI-determined infarct size and cTnI measurements in patients with ST-elevation myocardial infarction. Clin Chem 2008; 54:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/70\">",
"      Olatidoye AG, Wu AH, Feng YJ, Waters D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 1998; 81:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/71\">",
"      Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001; 38:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/72\">",
"      Heeschen C, Hamm CW, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/73\">",
"      James S, Armstrong P, Califf R, et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am J Med 2003; 115:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/74\">",
"      Ohman EM, Armstrong PW, White HD, et al. Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. Am J Cardiol 1999; 84:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/75\">",
"      Giannitsis E, M&uuml;ller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue perfusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 2001; 104:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/76\">",
"      Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000; 140:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/77\">",
"      Morrow DA, Antman EM, Tanasijevic M, et al. Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI-11B substudy. J Am Coll Cardiol 2000; 36:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/78\">",
"      Lindahl B, Venge P, Wallentin L. Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. Circulation 1996; 93:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/79\">",
"      Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/80\">",
"      Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996; 335:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/81\">",
"      Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 1997; 337:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/82\">",
"      Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/83\">",
"      Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 2000; 35:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/84\">",
"      Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/85\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/86\">",
"      Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/87\">",
"      Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2002; 40:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/88\">",
"      Diderholm E, Andr&eacute;n B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 2002; 143:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/89\">",
"      Heeschen C, van Den Brand MJ, Hamm CW, Simoons ML. Angiographic findings in patients with refractory unstable angina according to troponin T status. Circulation 1999; 100:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/90\">",
"      James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/91\">",
"      Kontos MC, Shah R, Fritz LM, et al. Implication of different cardiac troponin I levels for clinical outcomes and prognosis of acute chest pain patients. J Am Coll Cardiol 2004; 43:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/92\">",
"      Mueller C, Neumann FJ, Perruchoud AP, et al. Prognostic value of quantitative troponin T measurements in unstable angina/non-ST-segment elevation acute myocardial infarction treated early and predominantly with percutaneous coronary intervention. Am J Med 2004; 117:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/93\">",
"      Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation 1998; 98:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/94\">",
"      Antman EM. Troponin measurements in ischemic heart disease: more than just a black and white picture. J Am Coll Cardiol 2001; 38:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/95\">",
"      Wu AH, Fukushima N, Puskas R, et al. Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. Clin Chem 2006; 52:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/96\">",
"      Kavsak PA, MacRae AR, Yerna MJ, Jaffe AS. Analytic and clinical utility of a next-generation, highly sensitive cardiac troponin I assay for early detection of myocardial injury. Clin Chem 2009; 55:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/97\">",
"      Wilson SR, Sabatine MS, Braunwald E, et al. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J 2009; 158:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/98\">",
"      Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009; 54:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/99\">",
"      Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/100\">",
"      Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007; 116:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/101\">",
"      Januzzi JL Jr, Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation 2010; 121:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/102\">",
"      Diamond GA, Kaul S. How would the Reverend Bayes interpret high-sensitivity troponin? Circulation 2010; 121:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/103\">",
"      Korley FK and Jaffe AS. Preparing the United States for high-sensitivity cardiac troponin assays. J Am Coll Cardiol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/104\">",
"      Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 2009; 55:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/105\">",
"      de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/106\">",
"      Frankenstein L, Wu AH, Hallermayer K, et al. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem 2011; 57:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/107\">",
"      Aldous SJ, Florkowski CM, Crozier IG, et al. Comparison of high sensitivity and contemporary troponin assays for the early detection of acute myocardial infarction in the emergency department. Ann Clin Biochem 2011; 48:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/108\">",
"      Bais R. The effect of sample hemolysis on cardiac troponin I and T assays. Clin Chem 2010; 56:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/109\">",
"      Apple FS, Simpson PA, Murakami MM. Defining the serum 99th percentile in a normal reference population measured by a high-sensitivity cardiac troponin I assay. Clin Biochem 2010; 43:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/110\">",
"      Shave R, Baggish A, George K, et al. Exercise-induced cardiac troponin elevation: evidence, mechanisms, and implications. J Am Coll Cardiol 2010; 56:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/111\">",
"      Kavsak PA, Wang X, Ko DT, et al. Short- and long-term risk stratification using a next-generation, high-sensitivity research cardiac troponin I (hs-cTnI) assay in an emergency department chest pain population. Clin Chem 2009; 55:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/112\">",
"      Derdeyn CP. Moyamoya disease and moyamoya syndrome. N Engl J Med 2009; 361:97; author reply 98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/113\">",
"      deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010; 304:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/114\">",
"      Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 2011; 306:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/115\">",
"      Katus HA, Giannitsis E, Jaffe AS, Thygesen K. Higher sensitivity troponin assays: Quo vadis? Eur Heart J 2009; 30:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/116\">",
"      Jaffe AS. Chasing troponin: how low can you go if you can see the rise? J Am Coll Cardiol 2006; 48:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/117\">",
"      Giannitsis E, Becker M, Kurz K, et al. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem 2010; 56:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/118\">",
"      Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. Eur Heart J 2011; 32:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/119\">",
"      Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011; 123:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/120\">",
"      Wu AH, Lu QA, Todd J, et al. Short- and long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem 2009; 55:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/121\">",
"      Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010; 56:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/122\">",
"      White HD. Higher sensitivity troponin levels in the community: what do they mean and how will the diagnosis of myocardial infarction be made? Am Heart J 2010; 159:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/123\">",
"      Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 1985; 54:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/124\">",
"      Roberts R, Gowda KS, Ludbrook PA, Sobel BE. Specificity of elevated serum MB creatine phosphokinase activity in the diagnosis of acute myocardial infarction. Am J Cardiol 1975; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     Neumeier D. Tissue specific and subcellular distribution of creatine kinase isoenzymes. In: Creatine Kinase Isoenzymes, Lang H (Ed), Springer-Verlag, Berlin/Heidelberg 1981. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/126\">",
"      Trask RV, Billadello JJ. Tissue-specific distribution and developmental regulation of M and B creatine kinase mRNAs. Biochim Biophys Acta 1990; 1049:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/127\">",
"      Siegel AJ, Silverman LM, Evans WJ. Elevated skeletal muscle creatine kinase MB isoenzyme levels in marathon runners. JAMA 1983; 250:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/128\">",
"      Fontanet HL, Trask RV, Haas RC, et al. Regulation of expression of M, B, and mitochondrial creatine kinase mRNAs in the left ventricle after pressure overload in rats. Circ Res 1991; 68:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/129\">",
"      Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin Pathol 1991; 95:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/130\">",
"      Clark GL, Robison AK, Gnepp DR, et al. Effects of lymphatic transport of enzyme on plasma creatine kinase time-activity curves after myocardial infarction in dogs. Circ Res 1978; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/131\">",
"      Vatner SF, Baig H, Manders WT, Maroko PR. Effects of coronary artery reperfusion on myocardial infarct size calculated from creatine kinase. J Clin Invest 1978; 61:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/132\">",
"      Dillon MC, Calbreath DF, Dixon AM, et al. Diagnostic problem in acute myocardial infarction: CK-MB in the absence of abnormally elevated total creatine kinase levels. Arch Intern Med 1982; 142:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/133\">",
"      Heller GV, Blaustein AS, Wei JY. Implications of increased myocardial isoenzyme level in the presence of normal serum creatine kinase activity. Am J Cardiol 1983; 51:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/134\">",
"      Yusuf S, Collins R, Lin L, et al. Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. Am J Cardiol 1987; 59:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/135\">",
"      Larca LJ, Coppola JT, Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a noncardiac source. Ann Intern Med 1981; 94:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/136\">",
"      Lenke LG, Bridwell KH, Jaffe AS. Increase in creatine kinase MB isoenzyme levels after spinal surgery. J Spinal Disord 1994; 7:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/137\">",
"      Badsha H, Gunes B, Grossman J, Brahn E. Troponin I Assessment of Cardiac Involvement in Patients With Connective Tissue Disease and an Elevated Creatine Kinase MB Isoform Report of Four Cases and Review of the Literature. J Clin Rheumatol 1997; 3:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/138\">",
"      Puleo PR, Guadagno PA, Roberts R, et al. Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB. Circulation 1990; 82:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/139\">",
"      Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med 1994; 331:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/140\">",
"      Jaffe AS, Landt Y, Parvin CA, et al. Comparative sensitivity of cardiac troponin I and lactate dehydrogenase isoenzymes for diagnosing acute myocardial infarction. Clin Chem 1996; 42:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/141\">",
"      Newby LK, Roe MT, Chen AY, et al. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol 2006; 47:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/142\">",
"      Rao SV, Ohman EM, Granger CB, et al. Prognostic value of isolated troponin elevation across the spectrum of chest pain syndromes. Am J Cardiol 2003; 91:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/143\">",
"      Goodman SG, Steg PG, Eagle KA, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006; 151:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/144\">",
"      Costa MA, Carere RG, Lichtenstein SV, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the arterial revascularization therapies study (ARTS). Circulation 2001; 104:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/145\">",
"      Brener SJ, Lytle BW, Schneider JP, et al. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. J Am Coll Cardiol 2002; 40:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/146\">",
"      Januzzi JL, Lewandrowski K, MacGillivray TE, et al. A comparison of cardiac troponin T and creatine kinase-MB for patient evaluation after cardiac surgery. J Am Coll Cardiol 2002; 39:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/147\">",
"      Steuer J, Bjerner T, Duvernoy O, et al. Visualisation and quantification of peri-operative myocardial infarction after coronary artery bypass surgery with contrast-enhanced magnetic resonance imaging. Eur Heart J 2004; 25:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/148\">",
"      Carrier M, Pellerin M, Perrault LP, et al. Troponin levels in patients with myocardial infarction after coronary artery bypass grafting. Ann Thorac Surg 2000; 69:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/149\">",
"      Croal BL, Hillis GS, Gibson PH, et al. Relationship between postoperative cardiac troponin I levels and outcome of cardiac surgery. Circulation 2006; 114:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/38/39530/abstract/150\">",
"      Thielmann M, Massoudy P, Jaeger BR, et al. Emergency re-revascularization with percutaneous coronary intervention, reoperation, or conservative treatment in patients with acute perioperative graft failure following coronary artery bypass surgery. Eur J Cardiothorac Surg 2006; 30:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39530=[""].join("\n");
var outline_f38_38_39530=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ISCHEMIA AND ENZYME ELEVATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TROPONINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Variations in assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Normal range",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Elevations in the general population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis of primary MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Late diagnosis and reinfarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150151846\">",
"      Infarct size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prognosis after MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Non-ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Degree of troponin elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2606156726\">",
"      High sensitivity assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2606156734\">",
"      - Analytical considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2606156742\">",
"      - Clinical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CREATINE KINASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CK basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Total CK measurements for the detection of cardiac damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CK-MB fraction for diagnosis of AMI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Specificity and sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CK-MB fraction for prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CK and coronary reperfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Reinfarction and late diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      WHY TROPONIN IS PREFERRED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      BIOMARKERS AFTER REVASCULARIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      After PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      After CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      BIOMARKERS AFTER NONCARDIAC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      USE IN RENAL FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/86\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/86|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/44/16078\" title=\"figure 1\">",
"      Troponin predicts outcome in unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/48/35597\" title=\"figure 2\">",
"      Troponin I in unstable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/35/24125\" title=\"figure 3\">",
"      Troponin T in acute ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/42/8879\" title=\"figure 4\">",
"      ST depression and troponins predict outcome in NSTACS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/26/35245\" title=\"figure 5\">",
"      Prognosis troponin T level",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/28/28101?source=related_link\">",
"      Biomarkers of cardiac injury other than troponins and creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/28/39368?source=related_link\">",
"      Early cardiac complications of coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10632?source=related_link\">",
"      Excitation-contraction coupling in myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=related_link\">",
"      Perioperative myocardial infarction after noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=related_link\">",
"      Periprocedural myocardial infarction following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29257?source=related_link\">",
"      Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_38_39531="Differential diagnosis of excess intestinal gas";
var content_f38_38_39531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of excess intestinal gas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Intestinal obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Adhesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Motility disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Scleroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pseudo-obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritable bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Malabsorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lactose intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fructose intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Celiac disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pancreatic insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infectious",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Small intestinal bacterial overgrowth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Giardiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Psychological",
"        <span class=\"sublist1_start\">",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anxiety (aerophagia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Dietary",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39531=[""].join("\n");
var outline_f38_38_39531=null;
var title_f38_38_39532="Treatment of odontogenic infections in adults";
var content_f38_38_39532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial regimens for odontogenic soft tissue infections in adults*",
"    <sup>",
"     &bull;",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical entity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common causative organisms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antimicrobial regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Odontogenic deep space infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Normal hosts",
"       </td>",
"       <td rowspan=\"5\">",
"        Viridans and other streptococci,",
"        <em>",
"         Peptostreptococcus",
"        </em>",
"        spp,",
"        <em>",
"         Bacteroides",
"        </em>",
"        spp, and other oral anaerobes",
"       </td>",
"       <td>",
"        Ampicillin-sulbactam 3 g IV every 6 hours",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Penicillin G 2-4 MU IV every 4-6 hours,",
"        <strong>",
"         PLUS",
"        </strong>",
"        either:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <p>",
"         Clindamycin 600 mg IV every 6-8 hours",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Metronidazole 500 mg IV or PO every 8 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        Cefoxitin 1-2 g IV every 4 hours",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotetan 2 g IV every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"6\">",
"        Immunocompromised hosts",
"       </td>",
"       <td rowspan=\"6\">",
"        Viridans and other streptococci,",
"        <em>",
"         Peptostreptococcus",
"        </em>",
"        spp,",
"        <em>",
"         Bacteroides",
"        </em>",
"        spp, and other oral anaerobes, facultative gram-negative bacilli (including",
"        <em>",
"         Pseudomonas aeruginosa",
"        </em>",
"        )",
"       </td>",
"       <td>",
"        Piperacillin-tazobactam 4.5 g IV every 6 hours",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipenem-cilastatin 500 mg IV every 6 hours",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem 1 g IV every 8 hours",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cefepime 1-2 g IV every 12 hours",
"        <strong>",
"         PLUS",
"        </strong>",
"        either:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <p>",
"         Clindamycin 600 mg IV every 6-8 hours",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Metronidazole 500 mg IV every 8 hours",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         OR",
"        </strong>",
"        Ciprofloxacin 400 mg IV every 12 hours",
"        <sup>",
"         &bull;",
"        </sup>",
"        <strong>",
"         PLUS",
"        </strong>",
"        <br/>",
"        metronidazole 500 mg IV every 8 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The doses recommended in this table are intended for patients with normal renal and hepatic function.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Local and institutional rates of antibiotic resistance should be considered before choosing an antibiotic regimen. This is particularly important for immunocompromised patients, since there are substantial rates of fluoroquinolone resistance among",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      and other gram-negative bacteria in some regions.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39532=[""].join("\n");
var outline_f38_38_39532=null;
var title_f38_38_39533="Contents: General surgery calculators";
var content_f38_38_39533=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       General surgery calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General surgery calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/19/14642\">",
"           Calculator: Clinical indicators for malignant hyperthermia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/54/16225\">",
"           Calculator: Mangled Extremity Severity Score (MESS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/36/40513\">",
"           Calculator: Pressure ulcer risk stratification (Braden score)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/0/34818\">",
"           Calculator: Venous clinical severity score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/62/27616\">",
"           Calculator: Venous segmental disease score for obstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/44/32448\">",
"           Calculator: Venous segmental disease score for reflux",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/63/13299\">",
"           Calculator: Villalta score for severity of post-thrombotic syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/41/2706\">",
"           Calculator: Ideal body weight (method of Devine) and dosing weight for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E658D24C17-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f38_38_39533=[""].join("\n");
var outline_f38_38_39533=null;
var title_f38_38_39534="Contents: Acid peptic disease";
var content_f38_38_39534=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Acid peptic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Acid peptic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Dyspepsia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/4/27720\">",
"           Approach to the patient with dyspepsia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/28/35272\">",
"           Functional dyspepsia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/22/30055\">",
"           Acute and chronic gastritis due to Helicobacter pylori",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/10/9384\">",
"           Acute hemorrhagic erosive gastropathy and chronic chemical gastropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/30/31205\">",
"           Classification and diagnosis of gastritis and gastropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/58/33702\">",
"           Granulomatous gastritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/58/2984\">",
"           Large gastric folds: Hyperplastic and nonhyperplastic gastropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/39/24185\">",
"           Metaplastic (chronic) atrophic gastritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gastroesophageal reflux disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/8/1161\">",
"           Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/46/9959\">",
"           Helicobacter pylori and gastroesophageal reflux disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/53/42840\">",
"           Medical management of gastroesophageal reflux disease in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/28/25034\">",
"           Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/38/13928\">",
"           Pathophysiology of reflux esophagitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/57/42905\">",
"           Surgical management of gastroesophageal reflux in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Helicobacter pylori",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/40/44679\">",
"           Association between Helicobacter pylori infection and duodenal ulcer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/36/2634\">",
"           Association between Helicobacter pylori infection and gastrointestinal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/16/43271\">",
"           Bacteriology and epidemiology of Helicobacter pylori infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/59/37817\">",
"           Indications and diagnostic tests for Helicobacter pylori infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/10/12455\">",
"           Management of duodenal ulcers in patients infected with Helicobacter pylori",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/44/4809\">",
"           Pathophysiology of and immune response to Helicobacter pylori infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/32/23049\">",
"           Treatment regimens for Helicobacter pylori",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Peptic ulcer disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/40/44679\">",
"           Association between Helicobacter pylori infection and duodenal ulcer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/8/10375\">",
"           COX-2 inhibitors and gastroduodenal toxicity ��������� major clinical trials",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/18/13609\">",
"           Clinical manifestations of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/21/24919\">",
"           Diagnosis of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/42/19113\">",
"           Epidemiology and etiology of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12664\">",
"           Major causes of upper gastrointestinal bleeding in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/10/12455\">",
"           Management of duodenal ulcers in patients infected with Helicobacter pylori",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/14/43240\">",
"           Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/49/17174\">",
"           Multiple endocrine neoplasia type 1: Definition and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/37/6745\">",
"           NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/31/38393\">",
"           NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/58/12197\">",
"           NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/20/26947\">",
"           NSAIDs (including aspirin): Treatment of gastroduodenal toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/28/25034\">",
"           Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/21/40282\">",
"           Overview of the complications of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/18/42281\">",
"           Overview of the natural history and treatment of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/15/24826\">",
"           Overview of the treatment of bleeding peptic ulcers",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/36/3658\">",
"           Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/47/13049\">",
"           Pharmacology of antiulcer medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/61/16345\">",
"           Refractory or recurrent peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/57/33688\">",
"           Role of surgery in the management of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/5/40025\">",
"           Surgical management of complications of peptic ulcer disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/0/19466\">",
"           Unusual causes of peptic ulcer disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Physiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/28/25034\">",
"           Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/30/29160\">",
"           Physiology of gastric acid secretion",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D4F38792D6-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f38_38_39534=[""].join("\n");
var outline_f38_38_39534=null;
var title_f38_38_39535="Radial head fracture dislocation";
var content_f38_38_39535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fracture-dislocation of the radial head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 239px; height: 438px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These radiographs show a radial head fracture with posterior ulnar dislocation (MCL rupture and coronoid fracture; Mason Type IV).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mark Slabaugh, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_38_39535=[""].join("\n");
var outline_f38_38_39535=null;
